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Ischemic heart disease is a leading cause of morbidity and mortality worldwide. After the onset 
of myocardial infarction, multiple pathologies develop and progress the disease towards heart 
failure. Pathologies such as ischemia, inflammation, cardiomyocyte death, ventricular 
remodeling and dilation, and interstitial fibrosis, develop and involve the signaling of many 
proteins. Therapeutic proteins can play important roles in limiting or countering pathological 
changes after infarction. However, they typically have low retention rate and short half-lives in 
vivo in their free form and can benefit from the advantages offered by controlled release 
systems to overcome their challenges. Protein-based therapies can be more effective when 
concerns such as spatiotemporal presentation, bioactivity, and retention are addressed. We 
tested the efficacy of controlled delivery of different combinations of cardiac-implicated 
proteins such as VEGF, HGF, PDGF, FGF-2, IL-10, TIMP-3, and SDF-1α. The controlled 
delivery of an optimal combination of proteins per their physiologic spatiotemporal cues to the 
infarcted myocardium holds great potential to repair and regenerate the damaged heart muscle. 
To address this issue, we developed a spatiotemporal delivery vehicle comprised of fibrin gel 
and heparin-based coacervates. Proteins that should be released relatively quickly are embedded 
in the fibrin gel, while proteins that should be released over a longer period are embedded in the 
coacervate and distributed in the same gel. This dissertation describes the process of developing 
the fibrin gel-coacervate composite for spatiotemporal delivery of therapeutic proteins and 
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demonstrates its potential in triggering a significant cardiac repair process. It explores the ability 
of the coacervate to co-release different proteins, the development of the fibrin gel-coacervate 
system to achieve sequential delivery of different proteins, and the optimization of protein 
combinations and doses, paving the way for a potential comprehensive strategy to treat 
myocardial infarction. 
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1.0  INTRODUCTION 
Note: Most of the introductory chapter was published as a review article in Biomaterials 
Journal. H.K. Awada, Y. Wang. 2016. “Towards Comprehensive Cardiac Repair and 
Regeneration after Myocardial Infarction: Aspects to Consider and Proteins to Deliver”. 
Biomaterials 82: 94-112. 
Cardiovascular diseases (CVD) can be very costly and burdensome to society economically, 
socially, and psychologically. CVD account for 32% of deaths in the United States (US). 
Myocardial infarction (MI), commonly known as heart attack, is a major CVD that is 
responsible for significant morbidity and mortality, causing an estimated 7.3 million deaths per 
year worldwide [1]. According to the American Heart Association, 720,000 Americans 
experience new and recurrent heart attacks each year. Approximately, 15% of those 
experiencing an MI in a given year die because of it. In 2010, the direct and indirect cost of 
heart disease was approximately $205 billion in the US [2].  
Heart transplantation is the most effective treatment for chronic heart failure (CHF) 
patients. However, this option is very limited due to the lack of heart donors, highly invasive 
and complex surgical procedures, and significant cost. Reperfusion methods of the blocked 
coronary artery through percutaneous coronary intervention (PCI), coronary bypass surgery, and 
anti-thrombotic therapy are considered the standard of care for MI patients. In addition, 
angiotensin-converting enzyme (ACE) inhibitors and β-blockers are commonly used in the 
clinic to prevent adverse cardiac remodeling. Although these treatment methods lead to 
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significant reductions in restenosis and improve lifestyles and long-term survival, the incidence 
of MI and heart-related mortality have not significantly changed [3, 4]. The conventional 
medical treatments have reached their practical limits and are not able to regenerate the 
damaged cardiac tissue and restore heart function. Also, not all patients are eligible for these 
kinds of interventions. Therefore, the development of alternative MI treatment therapies is 
paramount. 
MI occurs as a result of an occlusion in one of the two main coronary arteries branching 
into the heart walls. The occlusion is usually due to coronary atherosclerosis and thrombosis 
that lead to heart muscle damage and likely progression to heart failure (Figure 1). As a result 
of the ischemia, many changes occur at the molecular, cellular, and tissue levels of the 
myocardium. Hypoxia, death of cardiomyocytes, inflammation, ventricular dilation and adverse 
remodeling, tissue necrosis, interstitial fibrosis, and contractile dysfunction are some of the 
main features that may present themselves during progression from MI to CHF [5, 6]. The next 
subsections will present overviews on these different pathological aspects of MI and the 
therapeutic interventions that have been explored to counter them in the last 15 years. We focus 
on proteins as potential therapies to repair and regenerate damaged cardiac tissue. We also focus 
on the complexity of tissue regeneration and repair processes providing reasoning for more 
comprehensive therapies. Finally, we discuss the importance of using controlled release systems 
to overcome the limitations of protein therapy. 
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Figure 1. Myocardial Infarction (MI) causes severe damage and adverse remodeling in the left ventricle 
(LV) myocardium, leading over time to LV wall thinning and dilation and ultimately progressing to
contractile dysfunction and heart failure. 
1.1 PATHOLOGICAL ASPECTS OF MI AND CORRESPONDING THERAPEUTIC 
INTERVENTIONS 
Over the last 15 years, many experimental studies provided evidence of the adult heart’s limited 
potential to regenerate and repair, motivating tests of new therapies [7-10]. Many of these 
attempted to overcome the limitations imposed by the endogenous biological system in order to 
achieve healing rather than scarring of the heart after MI. The full elucidation of the 
mechanisms of MI pathologies can help design more effective therapies. Therapeutic strategies, 
therefore, should take into account the different aspects of MI pathologies, and find solutions 
for the most critical or the complete set of impairments using more comprehensive well-
designed approaches. In this subsection, we describe various pathological changes after MI and 
proteins that may reverse or counter these changes (Table 1).  
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Table 1. Therapeutic proteins of interest with cardiac functions. Certain proteins should be either promoted or 
antagonized after MI to induce proper cardiac repair and regeneration. 
 
Protein Acronym Main  cardiac functions  References 
Insulin-like growth 
factor-I 
IGF-I Anti-apoptotic; promote stem cell growth and 
differentiation 
[27], [79], [122], 
[129] 
Hypoxia-inducible 
factor-1α 
HIF-1α Trigger release of angiogenic GFs and nitric oxide [12], [16-18] 
Transforming  
growth factor-β 
TGF-β Upregulate fibroblast proliferation, migration, and 
differentiation; trigger myofibroblast activation 
[164], [166],  [168], 
[203] 
Sonic hedgehog Shh Induce cardiac morphogenesis; anti-apoptotic [20], [86] 
Fibroblast growth 
factor-1 
FGF-1 Initiation of angiogenesis; stimulate cardiomyocyte 
proliferation 
[18], [20], [108], 
[225] 
Fibroblast  growth 
factor-2 
FGF-2 Initiation of angiogenesis; upregulate proliferation, 
migration, and survival of endothelial cells; induce 
chemotaxis; anti-apoptotic 
[16-18], [20], [22], 
[88] 
Vascular endothelial  
growth factor-A 
VEGF-A Initiation of angiogenesis; upregulate proliferation, 
migration, and survival of  endothelial cells ; trigger 
nitric oxide release 
[16-20] 
Platelet-derived  
growth factor-BB 
PDGF-BB Upregulate proliferation and chemotaxis of pericytes; 
promote neovessel maturation; anti-apoptotic 
[17], [27], [38], [249] 
Angiopoietin-1 Ang-1 Promote stabilization of  endothelial cell-pericyte 
interactions and vessel maturation  
[37], [40] 
Angiopoietin-2 Ang-2 Promote destabilization of  endothelial cell-pericyte 
interactions and vessel extravasation 
[37], [40] 
Hepatocyte  growth 
factor 
HGF Angiogenic, anti-apoptotic; chemotactic on stem cells [29], [30], [122], 
[215] 
Granulocyte colony-
stimulating factor 
G-CSF Chemotactic for stem cells; anti-apoptotic; angiogenic [28], [80], [121] 
Stromal cell-derived 
factor-1α 
SDF-1α Chemotactic for stem cells; angiogenic [31], [32], [85], 
[117], [216] 
Erythropoietin EPO Chemotactic for stem cells; angiogenic; anti-apoptotic [81-84], [124], [213] 
Thymosin-β4 Thymosin-β4 Chemotactic for stem cells; angiogenic [27], [123] 
Neuregulin-1 NRG-1 Induce cardiomyocyte proliferation; anti-apoptotic [104-107] 
Matrix 
metalloproteinase-2 
MMP-2 Promote ECM degradation by catalyzing the proteolysis 
of ECM proteins 
[60], [131], [141] 
Matrix 
metalloproteinase-9 
MMP-9 Promote ECM degradation by catalyzing the proteolysis 
of ECM proteins 
[60], [131], [141] 
Tissue inhibitor of 
metalloproteinases-1 
TIMP-1 Inhibit MMP activity and ECM degradation; anti-
apoptotic 
[88], [148], [150] 
Tissue inhibitor of 
metalloproteinases-3 
TIMP-3 Inhibit MMP activity and ECM degradation; anti-
apoptotic; anti-inflammatory 
[88], [140], [147], 
[149], [150], [177] 
Interleukin-10 IL-10 Anti-inflammatory; anti-apoptotic [66], [67] 
Interleukin-1β IL-1β Pro-inflammatory; induce MMP activity [55], [139], [164] 
Interleukin-6 
 
IL-6 Pro-inflammatory; upregulate fibroblast proliferation; 
induce MMP activity 
[55], [164] 
Tumor necrosis 
factor-α 
TNF-α Pro-inflammatory; pro-apoptotic; trigger myofibroblast 
activation; induce MMP activity  
[55], [62], [63], [139] 
Monocyte 
chemoattractant 
protein-1 
MCP-1 Pro-inflammatory; angiogenic; chemoattractant [26], [61], [128] 
Relaxin Relaxin Vasodilatory; anti-fibrotic; angiogenic; anti-
inflammatory 
[53] 
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1.1.1 Heart ischemia  
1.1.1.1 Ischemic damage and importance of proper vasculature 
The heart vasculature ensures the metabolic and structural homeostases of the heart. Proper 
perfusion provided by blood vessels is crucial for the growth and survival of cardiomyocytes 
[11]. For instance, improved activation of hypoxia response pathways by stabilizing hypoxia 
inducible factor (HIF)1-α in endothelial cells (ECs) leads to increased cardiomyocyte survival, 
improved LV systolic function, and reduced scar size [12]. The deficiency of laminin-α4, an 
abundant extracellular matrix (ECM) protein in the basement membrane of myocardial blood 
vessels, leads to myocyte hypoxia and necrosis, and ultimately heart failure [13]. Moreover, the 
interaction between ECs and cardiomyocytes offers increased protection for the myocytes 
through nitric oxide (NO)-dependent mechanisms and regulate myocyte contractility after an 
ischemic insult [14, 15]. Inadequate perfusion of the heart muscle can contribute to an 
irreversible myocardial hibernation and decrease of contractile function [11]. Hence, therapeutic 
angiogenesis that aims to form new blood vessels from pre-existing ones might contribute to the 
repair of the infarcted myocardium [16]. 
1.1.1.2 Angiogenesis mechanisms and proangiogenic therapies 
The hypoxic conditions activate angiogenic growth factors (GFs) that cause pericytes to detach 
from bloods vessels, allowing the loosening of cell-cell junctions and the migration, 
proliferation, and differentiation of ECs. Differentiated endothelial tip and stalk cells elongate 
the sprouting neovessels and form vessel lumens. As two neovessels fuse, blood perfusion can 
be initiated. Maturation and stabilization follow through the recruitment of pericytes to wrap 
around the growing neovessels [17]. Angiogenesis is a complex, tightly regulated process that 
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requires the cooperation of different cells, GFs, ECM, and signaling molecules (Figure 2). 
Spatial and temporal cues are important to ensure an adequate angiogenic outcome. 
Vascular endothelial GF (VEGF) and basic fibroblast GF (FGF-2) are key initiators of 
angiogenesis. VEGF is an endothelial-specific factor that stimulates the proliferation, migration, 
and survival of ECs. It is upregulated in response to hypoxia by HIF1-α signaling more than any 
other angiogenic factor [17, 18]. Additionally, VEGF induces the production of NO, a critical 
vasodilator, and promotes vascular permeability [19]. VEGF-mediated angiogenesis 
demonstrated therapeutic benefit in many ischemic heart disease animal models [20, 21]. FGF-2 
induces proliferation and migration of ECs and smooth muscle cells (SMCs), induces ECs to 
physically organize into tube-like structures, and triggers angiogenesis [16, 18, 20]. 
Additionally, FGF-2 promotes survival of ECs, SMCs, and cardiomyocytes [22]. FGF-2 
upregulates the expression of VEGF and vice versa [23, 24]. Moreover, FGF-2 increases the 
expression of other proangiogenic molecules such as hepatocyte GF (HGF), monocyte 
chemoattractant protein-1 (MCP-1), and platelet-derived GF receptor (PDGFR) on vascular 
SMCs [25, 26]. Administration of FGF-2 at the infarcted myocardium improves 
revascularization and cardiac contractility and reduces infarct size [3, 20, 27]. Other proteins 
that also improve angiogenesis include FGF-1, HGF, granulocyte colony-stimulating factor (G-
CSF), sonic hedgehog (Shh), erythropoietin (EPO), and stromal cell-derived factor 1-alpha 
(SDF-1α) (Table 1) [18, 20, 27, 28]. For example, HGF induces proliferation and migration of 
ECs, acts in synergy with VEGF, and improves heart function after MI through angiogenesis 
[29, 30]. SDF-1α might contribute to angiogenesis not by direct actions on ECs, but by 
recruiting endothelial progenitor cells (EPCs) and inducing other angiogenic factors such as 
VEGF [31, 32]. Some single GF applications, namely VEGF and FGF-2, reached clinical trials, 
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but showed only modest to little benefit in inducing proper revascularization and treating MI 
patients [20, 33, 34]. Possible reasons behind the limited therapeutic benefit seen in patients 
include rapid diffusion, large doses, and short half-lives of bolus injections of GFs and the 
minor attention paid to the spatiotemporal and physiologic presence of different GFs during 
angiogenesis.  
1.1.1.3 Importance of temporal cues in therapeutic angiogenesis 
The involvement of many signals, GFs, ECM components, and different cell types in the 
process of angiogenesis suggests that relying on a single factor might not be enough (Figure 2). 
It has been shown that VEGF or FGF-2 alone can lead to the formation of aberrant and leaky 
vessels that might regress quickly [35, 36]. Angiopoietin (Ang)-2 destabilizes blood vessels by 
weakening the interactions between ECs and pericytes [37]. Platelet-derived GF (PDGF) and 
Ang-1 are involved in stabilizing neovessels. PDGF triggers the recruitment of SMCs that cover 
the newly formed vessels, thus improving their functionality and reducing the possibility of 
regression and leakiness [38]. VEGF was shown to be a negative regulator of PDGF that 
inhibits its signaling and recruitment of pericytes. VEGF activates its receptor VEGFR-2, which 
complexes with PDGFR-β to block its signal transduction [39]. In contrast to Ang-2, Ang-1 
strengthens the interactions between ECs and pericytes [37]. Approaches that sequentially 
delivered early angiogenic factors such as FGF-2, VEGF, and Ang-2 followed by late factors 
such as PDGF and Ang-1 demonstrate a more robust angiogenesis process and mature 
neovasculature than single factors [40-43]. Therefore, therapies that aim to form mature 
vasculature in ischemic tissues should take into account the proper time to administer GFs and 
limit any potential antagonism between different GFs (Figure 2).  
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Figure 2. Fate of angiogenesis induced by combination or single protein therapies. A combination therapy 
that employs proteins involved in triggering angiogenesis (i.e. VEGF, FGF-2) in combination with proteins 
involved in stabilizing new blood vessels by pericytes (i.e. PDGF, ANG1), is more likely to induce a robust 
angiogenesis process forming mature and stable vasculature. Single protein therapies might lead to a 
transient angiogenesis process with new blood vessels prone to regression due to lack of stability and 
maturity provided by pericytes. 
1.1.1.4 Role of vasodilation  
Nitric Oxide (NO) is a potent vasodilator that helps regulate blood vessel tone and cardiac 
function [44]. It has been shown that reduced endothelial NO after MI contributes to 
pathophysiology and heart failure [45]. It is involved in the tissue response to ischemia and 
improves angiogenesis through HIF1-α and VEGF-mediated mechanisms [16]. Loss of function 
models targeting nitric oxide synthase (NOS) enzymes can lead to pathological consequences 
for vascular function [46, 47]. Mice lacking NOS show reduced LV function and increased 
adverse remodeling after MI [48, 49]. It has been reported that specific NOS1 overexpression in 
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cardiomyocytes reduces infarct size and oxidative stress and improves cardiac function after 
infarction [50]. NOS3 can help recruit EPCs, induce neovascularization, and limit LV 
remodeling and dysfunction after infarction [44, 51]. Improving the bioavailability of 
endothelial NO after MI using statin treatment leads to increased angiogenesis and EPC 
mobilization and reduces fibrosis and cardiac dysfunction [52].  
Relaxin is another molecule with potent vasodilation properties and can affect cardiac 
remodeling [53]. It has also been shown to have anti-inflammatory, anti-fibrotic, and angiogenic 
effects, all considered beneficial to treat MI patients. Relaxin exerts its effects on the 
cardiovascular system by binding to relaxin family peptide receptor 1 (RXFP1) and triggering 
intracellular signaling pathways that induce cyclic adenosine monophosphate (cAMP) 
production, NO signaling, tyrosine kinases, and others. Clinical trials of relaxin suggest it has 
important cardioprotective roles and can relieve symptoms of acute heart failure [53].  
1.1.2 Inflammatory response 
1.1.2.1 Effects of inflammation after MI 
Inflammatory cells such as neutrophils and monocytes rush into the ischemic heart in the early 
stages after MI triggering a strong inflammatory response. The therapeutic targeting of the 
inflammatory response after MI has been met with controversy mainly because the presence of 
inflammatory cells acts as a double-edged sword. Inflammatory cells can promote beneficial 
effects such as inducing angiogenesis by monocytes secreting proangiogenic factors and 
phagocytosis of dead cells and their cellular debris. However, they can also have detrimental 
effects on cell survival and cause tissue damage, infarct expansion, and LV dilation [54, 55]. 
Neutrophils produce large amount of reactive oxygen species (ROS) and elastase which cause 
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cell apoptosis and elastin degradation [55, 56]. In addition, they can reduce the proangiogenic 
effects of progenitor cells and bolster ischemic conditions [57, 58]. A limited presence of 
neutrophils is necessary to initiate the inflammatory response. Macrophages are also strong 
regulators of post-infarction events such as angiogenesis and scar formation. Macrophage 
activation can lead to two major distinct phenotypes: M1 and M2. M1 macrophages promote 
further inflammation and ECM degradation, while M2 macrophages contribute to anti-
inflammation, angiogenesis, and ECM reconstruction [59]. Therefore, specific reduction in the 
levels of specific inflammatory mediators might show a therapeutic benefit after MI. 
1.1.2.2 Implicated proteins and anti-inflammatory therapy 
Pro-inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, 
and IL-1 levels are elevated in the infarct zone and activate matrix metalloproteinases (MMPs), 
which degrade the ECM (Table 1) [55]. For example, leukocyte-derived MMP-9 deletion 
protects the ischemic heart from LV dilation and cardiac rupture, but also disrupts angiogenesis 
[60]. LV dilation and inflammatory response are significantly attenuated in IL-1 and MCP-1 
knockout mouse models, but not infarct size [61]. TNF-α upregulates in heart failure, promotes 
invasion of inflammatory cells to the ischemic myocardium, induces MMP production, triggers 
cell apoptosis, and exacerbates adverse LV remodeling [62, 63]. Transforming GF (TGF)-β can 
deactivate macrophages, downregulate pro-inflammatory cytokines, and promote ECM 
preservation [61]. Tissue inhibitor of MMPS (TIMP)-3 inhibits TNF-α-converting enzyme 
(TACE), the enzyme activator of TNF-α [64]. Other studies suggest a cytoprotective role of 
TNF-α in preventing myocyte apoptosis after MI [65]. Ultimately, clinical trials using TNF 
inhibitors were unsuccessful [33]. This might suggest pleiotropic actions of some cytokines 
such as TNF-α or that the failed outcome might be as a result of toxic effects due to high doses 
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used. IL-10 is an anti-inflammatory cytokine that inhibits the production of pro-inflammatory 
cytokines. IL-10 can induce TIMP-1 production by mononuclear cells which may help in 
reducing ECM degradation by MMPs [54]. Treating the infarcted heart with IL-10 can improve 
ejection fraction and angiogenesis, and reduce infarct size, fibrosis, and cardiomyocyte death 
[66, 67]. In contrast, a knockout study reported that IL-10 does not have a critical role in LV 
remodeling [68]. Decreasing the neutrophil invasion after ischemia through the inhibition of 
CCAAT/enhancer binding protein (C/EBP) pathway results in less fibrosis and improves 
cardiac function [69]. 
It seems logical that quenching the inflammatory response completely will not yield the 
desired functional benefits for the injured heart, because clearing dead cells from the infarct area 
helps reduce tissue necrosis and damage. It appears imperative that a tightly regulated 
inflammatory response, both temporally and spatially, should be available for a limited time 
after MI. Therefore, the goal of anti-inflammation therapy should not be a complete suppression 
of the post-infarction inflammatory response, but rather to properly modulate it in order to 
reduce the potentially dangerous consequences of uncontrolled activity. Because the MI 
inflammatory response activates both detrimental and protective signaling pathways, it is crucial 
for therapeutic strategies to respond to the pathophysiologic complexity of the infarct 
environment and optimize dose and spatiotemporal profiles of applied agents in order to achieve 
a successful outcome. 
1.1.3 Myocardial cell death and strategies to improve myocardium viability 
A human LV contains up to 4 billion cardiomyocytes. In a few hours, an MI can kill 25% of 
them [70]. The intense inflammatory reaction, ischemic conditions, adverse remodeling, LV 
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dilation, and infarct expansion put millions of surviving cardiomyocytes at risk of death through 
apoptosis or necrosis (Figure 3). The immediate generation of ROS after ischemia, mainly by 
inflammatory cells, induces apoptosis among myocytes [71]. This massive death of myocytes 
sets into motion a cascade of events that lead to the replacement of damaged tissue with a scar. 
Scar tissue reduces the ability of the LV to contract and pump blood efficiently, thus markedly 
reducing overall cardiac function.  
1.1.3.1 Cell apoptosis mechanisms and anti-apoptotic therapy 
Apoptosis is characterized by cell shrinkage, fragmentation of intracellular structures, and 
phagocytosis into neighbor cells [72]. The balance between pro-apoptotic proteins such as Bax, 
Bak and Bid, and anti-apoptotic proteins such as Bcl-2 and Bcl-xL is essential to determine a 
cell’s survival or death after an apoptotic signal (Figure 3). In the post-MI environment, 
elevated expression levels of Fas receptor, an apoptosis mediator, were reported [73]. In 
addition, increased activation of caspases, the key executioner proteins of cell apoptosis, and 
increased ratio of Bax to Bcl-2 have been linked to cardiomyocyte apoptosis [74, 75]. The 
activation of the PI3K/Akt and Ras-Raf-MEK-ERK pathways inhibits apoptosis and imparts 
cardioprotective effects (Figure 3) [76-78]. 
Insulin-like GF (IGF)-I and HGF can activate the PI3K/Akt pathway, enhance cell 
survival, and reduce cardiomyocyte apoptosis resulting in improved heart function [79]. G-CSF 
is another chemokine that prevents apoptosis of myocytes and inhibits the decrease in levels of 
Bcl-2 and Bcl-xL forced under oxidative stress conditions [80]. EPO has demonstrated anti-
apoptotic activities in many studies [81-83]. In a rat MI model, EPO upregulated Bcl-2 and 
downregulated Bax, which led to improvements in the heart hemodynamic function [84]. FGF-
2, Shh, SDF-1α, Thymosin-β4, PDGF-BB, IL-33, and TIMP-1 can also reduce cardiomyocyte 
 13 
apoptosis and improve overall cardiac function after MI (Table 1) [27, 85-88]. Targeting of 
specific miRNAs has also been recently investigated to prevent cardiomyocyte death [89, 90]. 
Additionally, β-blockers demonstrate anti-apoptotic actions that ameliorate ischemic effects 
[91]. 
Cardiomyocyte apoptosis is detected during all phases after MI and not only in the 
infarct zone, but also extends to the viable myocardium in remote noninfarcted region [75, 92]. 
This suggests that apoptosis could be responsible for a significant amount of myocyte death 
from the onset of MI injury and throughout the progression to heart failure. It is therefore 
crucial to design anti-apoptotic therapeutic interventions that counter cell death following MI. 
 
Figure 3. Ischemia, reactive oxygen species (ROS), and inflammation can trigger pro-apoptotic protein 
signaling (Bax, Bak) and inhibit anti-apoptotic protein signaling (Bcl-2, Bcl-xL) within cardiomyocytes 
leading to release of cytochrome c and activation of caspases causing apoptosis. Pro-survival proteins that 
bind to their respective receptors on the myocyte surface can trigger PI3K/Akt and Ras-Raf-MEK-ERK 
pathways anti-apoptotic molecular pathways to prevent cell death. 
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1.1.3.2 Cardiomyocyte proliferation 
The view that adult mammalian cardiomyocytes lose their regenerative capacity shortly after 
birth has been long-held. The rarity of primary myocardial tumors, the limited recovery after 
myocardial injury, and the difficulty to stimulate proliferation in mature adult cardiomyocytes, 
all support the view of the heart as an organ with effectively no regenerative capacity [93]. 
However, recent findings contested the notion that cardiomyogenesis in adult hearts doesn’t 
occur and proved that new cardiomyocytes can arise to replace old or dead ones even though the 
turnover rate is very low [9, 10, 94, 95]. The controversy about the origin of new 
cardiomyocytes persists. Do these new myocytes result from the division of pre-exiting ones or 
are they a result of differentiation of resident or recruited progenitor cells? It seems there is 
evidence for both origins and mechanisms, but possibly with different extents of contribution. 
In this subsection, we focus on factors that promote proliferation of existing cardiomyocytes; 
and in the next subsection we focus on cardiomyogenic differentiation of progenitor cells. 
There have been several attempts to induce cell cycle reentry for cardiomyocytes by 
removing inhibitors such as p27 or triggering activators such as cyclinD1 and E2F2 [96, 97]. 
Activating the Hippo signaling pathway increases cardiomyocyte proliferation postnatally in 
mice [98, 99]. Moreover, regulation of the expression of certain miRNAs can affect 
cardiomyocyte proliferation and heart function [100, 101]. Periostin, an ECM protein, was 
shown to stimulate a cardiomyocyte subpopulation to reenter the cell cycle and proliferate. 
Periostin treatment improved cardiac function and angiogenesis, and reduced fibrosis and 
infarct size after MI in rodents [102]. However, another study reported no increase in 
cardiomyocyte proliferation after periostin treatment [103]. Another protein, neuregulin (NRG)-
1, has recently shown ability to stimulate survival, differentiation, and proliferation of 
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cardiomyocytes through ErbB2 and ErbB4 [104]. In a cardiomyopathy model, NRG-1 
administration improved cardiac function and survival; and when combined with ACE inhibitor 
therapy, the effects were additive [105]. Another study demonstrated that NRG-1 therapy 
reduces infarct size and improves cardiac function due to proliferation of a small subpopulation 
of existing adult mouse cardiomyocytes rather than an increased differentiation of resident or 
recruited progenitor cells or decreased cardiomyocyte apoptosis [106].  Ongoing human clinical 
trials suggest promising results of NRG-1 therapy on increasing ejection fraction of heart 
patients [107]. FGF-1 administration, in conjunction with p38 inhibition, can induce 
cardiomyocyte proliferation, improve angiogenesis and cardiac function, and reduce scarring 
and wall thinning [108].  
The formation of new cardiomyocytes happens at a low rate even with the highest 
estimates, and therefore remains inadequate for the full replacement of lost myocardial tissue 
after infarction. It is thus important for therapies that aim to repair infarcted myocardiums to be 
designed with a broader focus than just aiming to boost the cardiomyocyte turnover with either 
mechanism. In addition, protein therapies that focus on cardiomyocyte proliferation need to 
consider the duration of the signal required to trigger significant cardiomyocyte mitosis. They 
also need to be localized and selective for myocytes, so as to prevent any potential tumor 
formation in remote tissues.  
1.1.3.3 Stem/progenitor cell homing and differentiation 
The envisioned goal of having stem/progenitor cells in the injury site after MI, whether 
transplanted or recruited by chemokines, is to differentiate into functional cardiomyocytes to 
replace the lost ones and improve cardiac performance. Genetic fate mapping provides evidence 
that some endogenous progenitor cells undergo myogenic differentiation after MI and give rise 
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to new cardiomyocytes [94, 109-111]. Cardiosphere-derived cells (CDCs) have been suggested 
to express a cardiomyocyte phenotype and electrically couple to surrounding cardiomyocytes 
[112]. Other studies provided evidence suggesting that most progenitor cells being investigated 
in cell therapies do not differentiate into cardiomyocytes, but rather might improve heart 
function via paracrine signaling that activates repair and regeneration pathways [94, 113-115]. 
Regardless of the mechanisms that progenitor cells undertake in the infarcted region, it seems 
there is a consensus that they result in benefits at the tissue and functional levels, which 
explains why many cell therapies have reached the clinical trials stage [7, 8, 116]. 
Many molecules play important roles in the repair of the myocardium by recruiting 
stem/progenitor cells to the injury site. Mobilizing endogenous progenitors might compensate 
for the low retention and survival of exogenous transplanted cells. SDF-1α is a powerful 
chemokine that can mobilize EPCs, hematopoietic stem cells (HSC), mesenchymal stem cells 
(MSCs), and cardiac stem cells (CSCs) to the infarct zone [85]. Recruitment of one or more 
kinds of progenitor cells to the heart by SDF-1α promotes beneficial effects after MI, possibly 
through enhancing angiogenesis and myocyte survival and differentiation [85, 117-119]. G-CSF 
induces proliferation and mobilization of stem cells to the infarcted myocardium [27, 28]. It 
exerts beneficial effects on heart function after MI [120, 121]. Clinical trials using G-CSF have 
not been as promising possibly due to patient ages or timing of administration, but research on 
G-CSF therapy continues [28]. In addition, HGF has been reported to be chemotactic on CSCs 
and to improve cardiac function after MI when applied alongside IGF-I [122]. Establishing an 
IGF-I gradient at the infarct border zone enhances the recruitment of endogenous CSCs and 
improvement in myocardial regeneration [122]. Moreover, Thymosin-β4 can induce the 
mobilization of adult epicardial progenitor cells and coronary vasculogenesis and angiogenesis 
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[123]. EPO has also been suggested to mobilize endothelial progenitors [124], with positive 
effects on cardiac function in heart disease patients [125, 126]. More recently, prostaglandin E2, 
an endogenous fatty acid derivative, was reported to recruit CSCs and potentially regulate their 
differentiation to cardiomyocytes after infarction [127]. Other mobilizers of stem cells to the 
ischemic myocardium include MCP-1, MCP-3, stem cell factor (SCF), VEGF, and nerve GF 
(NGF) (Table 1) [128]. As for differentiation, IGF-I is suggested to induce the differentiation of 
CSCs into myocytes and contribute to the recovery of heart function and structure after 
infarction [129]. FGF-2 has also been suggested to differentiate resident CSCs into functional 
cardiomyocytes in vitro [130]. 
The ideal route for recruited endogenous or transplanted adult progenitor cells in the 
infarcted myocardium is to differentiate into cells of cardiac lineages, including 
cardiomyocytes, vascular endothelial, and mural cells, and become properly integrated into the 
tissue to replace the lost dead cells. However, although these progenitors’ ability to differentiate 
is still controversial, their variable but widely-accepted therapeutic benefit after MI, likely 
through paracrine activities, is a testimony to their importance in advancing cardiac repair after 
infarction. The identity of the most efficient progenitor cells needed after MI and a suitable 
strategy to improve their presence in the infarct zone are still matters of debate and extensive 
investigation. 
1.1.4 ECM degradation and ventricular remodeling 
1.1.4.1 ECM structure and imbalance after MI 
MI results in an adverse remodeling process in the cardiac muscle manifesting clinically by LV 
dilation and heart pump dysfunction ultimately progressing to heart failure [5, 6]. The 
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remodeling process brings about major alterations in the structure of the ECM. Serving as the 
base that provides structural stability, contractile force transmission, and correct cardiomyocyte 
geometry, the ECM composition and orientation are strictly regulated in a healthy myocardium 
mainly by MMPs and their endogenous inhibitors, the TIMPs (Figure 4) [131]. The imbalance 
in the MMP/TIMP ratio contributes to the abnormal remodeling of the ECM post MI. 
The appropriate presence of important structural proteins in the ECM, collagen and 
elastin, allows the optimal transmission of contractile force (Figure 4). Approximately 85% of 
the myocardial collagen is type I and 11% is type III. Type I collagen fibrils have very high 
tensile strength and provide resistance to deformation, while type III collagen fibrils are more 
distensible and provide resilience. The extent of collagen fibril maturation through crosslinking 
helps determine ventricular compliance. On the other hand, elastic fibers allow passive recoil in 
the myocardium after stretching [131, 132].  
After an ischemic insult, the profile of collagen changes at different phases of cardiac 
remodeling and the region within the myocardium. For instance, during the initial phase, 
collagen is degraded in the infarct region; however in later stages, abnormal collagen synthesis, 
orientation, and crosslinking in the infarct region and then in remote noninfarct areas lead to 
fibrosis and further pathological remodeling [132]. Collagen has a long half-life and a slow 
turnover compared to other proteins [133]; thereby ECM replacement after degradation will also 
be slow, which places the myocardium at increased vulnerability for adverse remodeling after 
MI. 
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Figure 4. The myocardial extracellular matrix (ECM) serves as the base that connects cardiomyocytes, 
provides structural stability, and enables the transmission of chemical signals and contractile forces. The 
ECM contains structural proteins such as collagen and elastin, proteoglycans such as heparan sulfate, and 
adhesive glycoproteins such as fibronection and laminin. The ECM composition and orientation are strictly 
regulated in a healthy myocardium mainly by matrix metalloproteinases (MMPs) and their endogenous 
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). TIMPs can help reduce early ECM 
degradation after MI alongside GFs involved in promoting cell survival, cardiomyogenesis, and 
angiogenesis. 
1.1.4.2 Implicated proteins in adverse remodeling 
Many MMPs have been implicated in cardiovascular diseases. During cardiac remodeling, 
MMPs are released by different cells including cardiac fibroblasts, cardiomyocytes, vascular 
cells, and inflammatory cells [134, 135]. MMPs are usually activated by serine proteases and 
other MMPs through the cleavage of a propeptide in the amino terminus [136]. The functions of 
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MMPs after infarction are complex and could involve both positive and negative effects, 
because multiple molecular pathways are involved and can regulate distinct and overlapping 
processes including angiogenesis, wound healing, ECM homeostasis, proliferation, and 
apoptosis [137, 138]. MMP activity can be regulated by transcriptional and post-translational 
factors such as TNF-α, IL-1β, TGF-β, other MMPs, oxidative stress, and mechanical stretch 
[139]. Additionally, MMP activity can be regulated by TIMPs which prevent MMP access to its 
substrates by binding to the MMP’s catalytic domain; however affinities differ (Figure 4) [136, 
140]. 
After MI, a significant increase in MMP activity leads to an imbalance in the 
MMP/TIMP ratio favoring the degradation of the myocardial ECM over deposition. MMP-2 
and MMP-9 have been implicated in early ECM degradation [141] and in advancing contractile 
dysfunction by degrading cardiac proteins such as myosin heavy chain, myosin light chain-1, 
troponin I, and α-actinin [131]. MMP-7 null mice show improved survival after MI [142]. 
Fibrosis and LV dilation are reduced when MMP-9 was deleted [143]. Knocking out MMP-2 or 
MMP-9 in mice protects them from cardiac rupture post infarction [60, 144]. However, healing 
and angiogenesis are impaired in the long term indicating different effects temporally and 
spatially [60].  
1.1.4.3 Therapeutic interventions to alter ECM remodeling 
The inhibition of NF-κB by IκB leads to a reduction in MMP-2 and MMP-9 expression, thereby 
reducing LV dilation after MI [145]. TIMP-4 null mice show increased LV dysfunction, 
fibrosis, hypertrophy, and MMP activity [146]. Deficiencies of TIMP-1 or TIMP-3 in mice can 
lead to increased LV remodeling, dilation, and dysfunction after MI [147-150]. Cell-based 
TIMP-3 gene delivery improves cardiac function [151]. TIMP-1 or TIMP-3-based therapies are 
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able to improve ejection fraction and reduce MMP-2 activity and apoptosis in the ischemic 
myocardium of rats [88]. Greater functional improvement and preservation of elastic fibers are 
observed in TIMP-3-treated group, possibly because TIMP-3 is ECM-bound, giving it a greater 
advantage in protecting the myocardial ECM [152]. ACE inhibitors, β-blockers, and statins 
have also been suggested as anti-remodeling agents that reduce MMP activity and ECM 
degradation after MI [153-155]. 
MMP/TIMP-based therapies need to be applied soon after MI because excessive ECM 
degradation can accelerate adverse remodeling and result in wall thinning and cardiac rupture. 
On the other hand, some therapies might also need to focus on preventing excessive ECM 
deposition which could promote fibrosis that spreads in the later stages after MI and extends 
from infarct to noninfarct zones leading to LV stiffness and contractile dysfunction [156]. ECM 
homeostasis is urgently needed to be restored in the post-MI environment, with therapies 
preventing ECM degradation favored early on in infarct region, while therapies preventing 
excessive ECM deposition may be beneficial at the later stages in noninfarct regions. While a 
few-fold increase in collagen above normal levels in the myocardium can cause ventricular 
stiffness and moderate malfunction [157], only a slight collagen level decrease below normal 
can lead to detrimental effects including dilation, rupture, and adverse remodeling [60, 140, 
158]. So, determining which MMPs and/or MMP functions to inhibit, the optimal timing of 
intervention, the optimal dose of therapeutic agents, and the myocardium regions to be treated 
are all essential parameters to achieve a successful cardiac repair and ECM homeostasis. 
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1.1.5 Fibrosis 
1.1.5.1 Role of cardiac fibroblasts and myofibroblasts 
Cardiac fibroblasts make up 50-70% of the cells within the myocardium while only occupying a 
quarter of the tissue volume [159]. They synthesize ECM components, regulate their turnover 
and maintain homeostasis through MMPs and TIMPs, and help transport mechanical and 
chemical signals [159]. After MI injury, many fibroblasts differentiate into their activated form, 
myofibroblasts, under the actions of mechanical stress and different chemical stimuli such as 
TGF-β [131, 160]. Myofibroblasts express α-smooth muscle actin (α-SMA) and are not 
normally found in healthy adult hearts. They are attracted to the infarct region and participate in 
the remodeling process by producing collagen and other proteins that form a matrix and replace 
dead cardiomyocytes [131, 159]. This increased collagen deposition ultimately leads to 
interstitial fibrosis and the formation of the myocardial scar in the infarct area [160]. Using 
connexins, myofibroblasts form gap junctions with each other and cardiomyocytes [161]. Being 
nonexcitable cells, the myofibroblasts, lying between cardiomyocytes and expanding the ECM, 
will create gaps between the myocytes which may result in impulse conductivity problems such 
as arrhythmias [162, 163].   
1.1.5.2 Implicated proteins and anti-fibrotic therapy 
Myofibroblasts are activated by different proteins and cytokines such as TGF-β, Angiotensin-II, 
and TNF-α (Table 1). In the cardiac tissue, TGF-β stimulates proliferation, migration, and 
differentiation of fibroblasts into myofibroblasts, thereby considered the top regulator of the 
fibrotic response after MI [164]. Antagonizing TGF-β in the early stage after MI might 
exacerbate ECM degradation and promote LV dilation [165], while antagonizing it in the late 
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stage might be more beneficial to prevent fibrosis and adverse remodeling in noninfarct regions. 
The administration of c-Ski, an endogenous inhibitor of TGF-β, helps inhibit fibroblast 
differentiation into myofibroblasts, which might limit fibrosis and adverse remodeling after MI 
[166]. IL-6 promotes fibroblast proliferation, but reduces collagen synthesis and induces MMP 
secretion. IL-1β and TNF-α inhibit fibroblast proliferation and collagen synthesis and increase 
MMP levels [164]. Recent studies have suggested an important role for the WNT/Frizzled 
(FZD) pathway in regulating myofibroblast migration and differentiation [167-169]. The 
administration of an FZD receptor antagonist improves cardiac function after MI [169]. 
Angiotensin-II induces fibroblast proliferation and differentiation, with ACE and angiotensin-II 
receptors being expressed actively by myofibroblasts after MI [170]. ACE inhibitors have been 
part of the standard of care for heart patients for a long time, as they are associated with 
reducing TGF-β levels and fibrosis [171, 172]. The β-adrenergic sympathetic system is an 
important regulator of cardiac function and because of the massive loss of cardiomyocytes after 
MI, the system’s activity increases with β2-adrenoceptor receptors dominating cardiac 
fibroblasts [164]. Β-blockers have been shown to inhibit fibroblast proliferation [173]. Also, 
relaxin reduces fibroblast differentiation and proliferation, thereby preventing cardiac fibrosis 
[53]. Statins such as simvastatin can suppress human myofibroblast proliferation [174]. 
Simvastatin was also shown to reduce fibroblast α-SMA expression and that effect is abolished 
with TGF-β administration [175].  
The fibrotic tissue that develops in the infarct area also expands to the noninfarct regions 
of the left and right ventricles driven by the excess collagen deposition accompanied by 
distorted crosslinking of collagen fibers [176]. This results in reduced compliance and increased 
stiffness of the heart muscle, thus leading to CHF [160]. Some studies argue in favor of some 
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myofibroblast presence stressing on their roles as providers of contractile force across the ECM 
and wound-healing mediators [88, 177]. Therefore, it is important for anti-fibrotic therapies to 
be employed in late stages and prioritize the prevention of ECM deposition and fibrosis in 
noninfarct regions. This brings to attention the importance of optimizing doses and 
spatiotemporality of injected agents, because early excessive degradation of the ECM and 
suppression of collagen synthesis in the infarct region can contribute to LV dilation and possible 
rupture. The right balance is needed for proper repair and functional recovery. 
1.1.5.3 Reprogramming cardiac fibroblasts into myocytes 
Because replacing millions of lost cardiomyocytes is a difficult task and in order to counter the 
negative effects of interstitial fibrosis, the idea of turning a portion of endogenous cardiac 
fibroblasts into functional cardiomyocytes is quite intriguing. Recently, a new therapeutic 
approach that aims to reprogram and convert fibroblasts into cardiomyocyte-like cells emerged 
[9, 178]. The introduction of combinations of cardiac transcription factors to fibroblasts such as 
GATA4, Mef2c, Tbx5, HAND2 and/or microRNAs such as miR-1, miR-133, miR-208, miR-
499 has shown potential to activate cardiac gene expression and directly convert fibroblasts 
from different sources into cardiomyocyte-like cells [179-182]. Additionally, blocking JAK/ 
STAT and WNT signaling pathways has been suggested to generate cardiomyocytes from 
fibroblasts [183]. However the reprogramming efficiency remains low.  
In infarcted mouse hearts, gene delivery of combinations of the above-mentioned 
transcription factors led to the generation of myocytes from endogenous cardiac fibroblasts, 
which seemed to integrate and form gap junctions with pre-existing myocytes after several 
weeks. This therapeutic intervention in turn reduced infarct scar size and improved heart 
function [182, 184]. It is possible that other cell types within the heart such as progenitor cells 
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and ECs might undergo reprogramming to adopt myocyte-like phenotypes. Introducing VEGF 
alongside cardiac transcription factors was found to enhance heart function and reduce fibrosis 
more than the transcription factors alone, showing that revascularization mediated by VEGF can 
improve the survival of cardiomyocytes, new and preexisting, and add to the overall therapeutic 
benefit [184]. Using lentiviruses, the introduction of relevant miRNAs to infarcted mouse hearts 
led to the reprogramming of cardiac fibroblasts into cardiomyocytes [181]. 
It is important to develop the necessary tools that can increase the yield and efficacy of 
cell reprogramming. For instance, reprogrammed cells would be more beneficial if they were 
able to proliferate and couple electromechanically with the preexisting myocytes as well, in 
order to preserve proper contractile and conductive function. However, cell reprogramming 
should be performed under tight controls, so that abnormalities like cardiac arrhythmias do not 
develop. Also, specific targeting of cardiac fibroblasts with reprogramming factors is important 
so that off-target fibroblasts will not be affected. Deeper understanding of the molecular 
mechanisms underlying cell reprogramming would help advance the therapeutic approaches 
based on this new technology. 
1.1.6 Electrical conduction abnormalities after MI 
Proper electrical conduction is necessary for optimal cardiac output. Calcium plays an important 
role in the contractile function of the heart. Following an action potential, the rush of calcium 
into the cytosol of a cardiomyocyte via its respective channels induces adenosine triphosphate 
(ATP) hydrolysis, which in turn drives the interaction between actin and myosin and causes the 
cardiomyocytes to contract [185]. It has been reported that patients with dilated cardiomyopathy 
show an impaired uptake of calcium, thus compromising the heart’s contractile function [186, 
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187]. The ischemic environment causes oxidative stress and elevation of intracellular calcium 
levels that affect the survival and function of cardiomyocytes [188, 189]. Therapeutic 
interventions could benefit from the use of calcium channel blockers which block the 
cardiomyocyte L-type calcium channels to reduce excessiveness in the heart’s contraction and 
conduction velocity [190]. 
1.2 PROTEINS AND PROTEIN-BASED THERAPIES: IMPORTANCE AND 
ADVANTAGES 
1.2.1 Physiological roles of proteins and the microenvironment 
Proteins including GFs, morphogens, hormones, cytokines, chemokines, antibodies, 
transcription factors, and enzymes are very important in cell signaling, function, and behavior 
(Table 1). Proteins transmit signals that trigger various cellular processes between cells of same 
and different types, their ECM, and between different tissues and organs. Identifying the target 
cells is important because distinct types of cells can have different responses to the same 
protein. Equally important is the determination of the proteins of interest in the process of tissue 
regeneration (Table 1). Proteins can initiate different processes such as proliferation, migration, 
differentiation, apoptosis, growth, and adhesion by binding to their specific receptors expressed 
by the target cells. This receptor binding can almost exclusively occur when proteins are in their 
soluble form having been secreted by cells or released from the ECM by enzymes and 
proteases.  
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1.2.1.1 Role of protein concentration and gradient formation 
The effects exerted by proteins depend on their concentration in the cellular microenvironment, 
thereby influencing the expression of their receptors and the levels of other proteins, whose 
secretion and effects can be either antagonized or promoted [191]. For example, depending on 
the concentration of VEGF in the microenvironment, angiogenesis can be inadequate, normal, 
or aberrant and excessive [192]. Different cellular effects of HGF have been observed 
depending on its concentration, level of activation, and receptor expression [79]. A threshold 
concentration of TGF-β can change the molecular signal from growth to apoptosis [193]. Also, 
the concentrations of signaling proteins and the expression of their receptors are time-dependent 
and change at different stages of repair and regeneration. There are temporal differences in the 
presence of certain proteins and the expression of their receptors during events such as 
angiogenesis, inflammation, cardiac remodeling, and bone repair suggesting their physiological 
roles might be limited to certain stages. 
The formation of a protein gradient enables the cells to detect directional and spatial 
cues, so as to respond to the protein signal. The diffusion rate, receptor binding, size, half-life, 
ECM affinity, and secretion or inhibition of a protein are all factors that determine the formation 
of a gradient and its steepness [194-196]. It was demonstrated that cells can modify their 
receptors through endocytosis and reorient itself towards the direction of a chemoattractant 
[197, 198]. This directed migration of cells requires a concentration gradient to effectively guide 
the cells towards the target site, and the threshold of the concentration gradient might differ 
from one chemoattractant to another depending on the signaling cascades it activates. For 
instance, NGF can stimulate extracellular-signal-regulated kinases (ERK) activity at 30% lower 
concentration threshold than epidermal GF (EGF) [199]. The direction of axonal growth can be 
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affected by different chemical gradients of NGF and laminin [196]. A density gradient of Arg-
Gly-Asp (RGD)-containing peptides can direct the alignment of fibroblasts [200].  
1.2.1.2 Effect of biomechanics and architecture on protein behavior 
The ECM is comprised of architectural, mechanical, and molecular components responsible for 
the structural integrity of tissues and transfer of information and signals between cells, tissues, 
and organs (Fig. 5). The signaling cascades can be triggered to activate cellular processes and 
regulate cell behavior by the binding of ECM proteins and polysaccharides to integrins on the 
cell surface [131]. ECM glycosaminoglycans (GAG) such as heparan sulfate contribute to the 
formation of protein gradients by facilitating the interaction between GFs such as VEGF and 
FGF and their receptors (Fig. 5). This prolongs the duration of GF signaling by protecting them 
from proteolytic degradation, thus rendering their actions on processes like proliferation, 
migration, and differentiation more effective [201].  
The mechanics of the ECM influenced by traction forces, shear stresses, fluid flows, and 
others can affect the behavior of cells and tissues and how they respond to protein signals [202]. 
Abnormal matrix synthesis or degradation can have dire consequences on the cells of a 
mechanically stressed tissue. Mechanical forces can induce the release of proteins and work in 
conjunction with them to remodel the ECM or affect cell behavior. For instance, fibroblast 
differentiation into myofibroblasts needs both TGF-β and mechanical stress [203]. Vascular 
SMCs are triggered to express various differentiation markers in response to the cyclic 
stretching of arterial walls [204]. Cells in a constrained collagen matrix generate different 
contractile forces depending on the stimulation of different GFs, while their responses are 
similar in a floating collagen matrix [205, 206]. In cases of laminar, pulsatile, and steady blood 
flow, resultant shear stresses modulate endothelial cell function, phenotype, gene and protein 
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expression in a different way than when the flow is disturbed [204]. The mechanics of the 
microenvironment help determine the fate of cells when stimulated by proteins, including 
apoptosis, growth, differentiation, migration, and contraction. Cell behavior is also dependent 
on the structural organization of the ECM. It has been shown that interactions between cells, 
ECM, and signaling proteins can differ between two-dimensional (2D) and three-dimensional 
(3D) architectures [207]. Cells in a 3D microenvironment enjoy the ability to spread, attach, 
cluster ligands, change integrin and receptor expression, and perform chemokinesis or 
chemotaxis more effectively.  
Therefore, the process of tissue repair and regeneration depends in a collective fashion 
on a complex network of signaling proteins that are present in specified concentrations and 
spatiotemporal gradients in the wider context of the ECM microenvironment with its mechanics 
and architecture. All of these parameters and aspects are crucial when designing therapeutic 
strategies to treat cardiovascular diseases. 
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Figure 5. Repair and regeneration of the infarcted myocardium can be driven by delivery of proteins that 
address MI pathologies. To treat MI, a therapy needs to promote ECM homeostasis, stem cell homing, 
cardiomyogenesis, and angiogenesis, and prevent excessive inflammation, calcium imbalance, cardiomyocyte 
death, and fibrosis. Processes needed to be promoted or prevented after MI can have temporal differences. 
Some such as ECM homeostasis and calcium balance need to happen early on, while others such as fibrosis 
prevention should happen later. Injecting a protein delivery system carrying specific proteins of interest and 
delivering them per their physiologic cues offers the potential to trigger repair and regeneration signaling 
cascades leading to the restoration of a functional myocardium. 
1.2.2 Advantages and challenges of protein-based therapy 
Exogenous proteins can be produced at high yields in a cost-effective manner with the aid of 
recombinant DNA and phage display technologies. Proteins can also be stabilized for relatively 
long periods, thus offering off-the-shelf availability. Additionally, protein administration can be 
potentially regulated spatially and temporally with specific doses used. Moreover, protein 
therapies offer the advantage for enhanced targeted interventions with the ability to elucidate 
mechanisms of action and regulatory molecular pathways involved [20, 33, 208]. The 
exogenous administration of therapeutic proteins can be utilized to supplement inadequate 
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endogenous levels or replace defective proteins. They can also be used to upregulate or 
downregulate other molecules or to trigger certain cellular processes and activate specific 
molecular pathways (Figure 5). 
Because proteins play a central role in the process of tissue repair and regeneration, 
strategies to exogenously administer proteins of interest that have the potential to repair and 
restore normal function are continuously developed and improved (Table 1). No protein therapy 
has made it to the cardiovascular market and achieved clinical use yet [33]. Therapies that were 
dependent on bolus administration of proteins showed some efficacy in improving the function 
of ischemic hearts in animal models [20, 27]. However, in clinical trials, such method of 
administration proved ineffective and results were generally disappointing. For instance, VEGF, 
FGF-2, HGF, EPO, GM-CSF, and NRG-1 therapies did not demonstrate consistently significant 
improvements in revascularization and myocardial function compared to placebo in Phase I and 
II clinical trials, despite being tolerable and reasonably safe at different doses used [8, 20, 28, 
34]. This is likely due to the drawbacks of bolus injections and the use of single proteins to 
repair tissues that likely require the complex signals and cooperation of many proteins. Proteins, 
administered by bolus injections, have poor retention at the target tissue because they are 
diluted and diffuse away quickly. In addition, soluble proteins are highly unstable and typically 
have short half-lives because they are prone to proteolytic degradation and enzymatic 
deactivation. High doses are often needed to induce small therapeutic benefit, and such high 
systemic levels of proteins can be potentially toxic [208]. 
Thus, in order to make a breakthrough in the field of protein-based therapy for cardiac 
regeneration, it is logical to use multiple proteins that have different functions to address 
different challenges (Table 1). Equally important is the use of controlled delivery systems that 
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can present these proteins in a bioactive form spatiotemporally per their physiological cues. 
Such presentation allows, as close as possible, the recapitulation of the natural 
microenvironment of a healthy functional heart. Developing such sophisticated strategies might 
yield a comprehensive cardiac repair and regeneration process for MI patients (Figure 5).  
1.3 CONTROLLED RELEASE SYSTEMS: IMPORTANCE AND POTENTIAL IN 
CARDIAC REPAIR 
1.3.1 Development and characterization of properties 
Controlled release systems provide an exciting potential to overcome the challenges posed by 
bolus administration of proteins for cardiac repair after MI. These systems can be designed to 
protect, control, sustain, and localize the delivery of proteins to the ischemic heart muscle 
(Figure 6, 7). In addition to the potential protein-mediated therapeutic benefits, some delivery 
systems are based on biomaterials that can also provide mechanical support and reduce adverse 
LV remodeling [209]. The main challenges that face the development of effective delivery 
systems include the optimal combination of proteins and the ability to control their 
concentration and spatiotemporal gradients upon delivery. Ideally, a controlled delivery vehicle 
would serve as a depot that provides physiological cues of crucial proteins needed for proper 
tissue regeneration, thus assuming the essential role of the ECM in protection, stabilization, 
regulation of activity, control of concentration, and spatial translocation of proteins within the 
myocardium (Figure 6, 7). 
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Biomaterials used in the development of controlled release systems can be natural or 
synthetic polymers. Natural polymers include fibrin, collagen, gelatin, alginate, chitosan, 
hyaluronic acid, heparin, and others [20, 210]. These natural materials are appealing because 
they can be easily recognized by the natural microenvironment, thereby reducing potential 
immunogenicity or toxicity. In addition, they can be degraded by endogenous enzymes. 
However, their mass production can be costly and the modification of their mechanical and 
chemical properties can be challenging. On the other hand, synthetic polymers include 
poly(lactic-co-glycolic acid)  (PLGA), polyethylene glycol (PEG), polycaprolactone (PCL), 
poly-L-lactide (PLLA), and others [20, 210]. These synthetic materials offer the advantage of 
easier tailoring of material properties to fit the specialized needs of biomedical applications. 
Moreover, synthetic materials can be typically produced in a cost-effective fashion and in large 
quantities. Major challenges to the successful and effective use of synthetic materials include 
biocompatibility and biodegradability. They need to be non-toxic and tolerated by the immune 
system. The material should completely degrade and resorb into the body or excrete from the 
body. They may also need to mimic the behavior of natural materials in strength, compliance, 
stiffness, porosity, among other properties (Figure 6). 
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Figure 6. Desirable properties of an effective protein delivery system. Practically, it may be difficult to 
satisfy all of the desirable properties and a balance has to be made based on cost and resources. 
There are various methods for protein encapsulation in a delivery vehicle, which 
ultimately determine the release rate of these proteins (Figure 8). Physical entrapment requires 
the mixing of proteins with polymers before they gel or solidify. The crosslinking density and 
structural stability of the polymeric network determine the encapsulation efficiency and release 
of the protein via diffusion and/or degradation mechanisms depending on the size of the protein 
relative to pore sizes of the matrix [211]. Proteins can be immobilized to the matrix using 
electrostatic interactions, ionic and hydrogen bonds, and covalent attachment (Figure 7). These 
methods can employ macromolecules and polymers such as heparin, heparan sulfate, hyaluronic 
acid, PEG, MMP linkers, and functional groups such as carboxyl, amino, and hydroxyl groups 
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[195, 208]. Some encapsulation methods include steps of leaching, use of organic solvents, 
processing at high temperatures, freeze-drying, and chemical modification which can be 
harmful to the stability and bioactivity of the proteins [208]. Therefore, it is essential to employ 
techniques that prevent potential denaturation and deactivation of proteins, so that they can 
perform their intended activity upon release from the delivery system (Figure 6, 7). By 
modifying polymerization conditions, composition, stoichiometry, functional groups, and other 
tunable parameters, natural and synthetic polymers can form different kinds of injectable 
matrices for the controlled delivery of proteins that can be implemented in cardiac repair 
strategies (Figure 6, 7). Different kinds of release profiles can be achieved depending on the 
type and property of a delivery vehicle (Figure 8). Injectable delivery platforms such as 
hydrogels, micro- and nanoparticles, coacervates, peptide nanofibers, and liposomes are 
discussed in the next sections (Figure 7). 
1.3.2 Hydrogels 
Hydrogels are made through physical or chemical crosslinking of polymers to create 
hydrophilic networks swollen by water (Figure 7) [3]. They are often biocompatible, can be 
made to have soft tissue-like elasticity and permeability. Certain hydrogels can be injected into 
the body through minimally invasive techniques. The water content of hydrogels can help 
reduce interfacial tension with other tissue fluids allowing gas permeation and small compound 
diffusion. They typically have burst releases of embedded proteins and can sustain their release 
for short periods (Figure 8). Gaining a better control over the release kinetics and the tailoring 
of hydrogel mechanical and chemical properties are areas of continued investigation. For 
instance, the mechanical properties of hydrogels based on natural materials can be enhanced by 
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conjugating inhibitors or crosslinkers that reduce hydrolysis. Immobilizing affinity groups on 
hydrogels can strengthen their binding of proteins and prolonging their release. Moreover, 
biodegradability of synthetic hydrogels can be improved by introducing proteolytic sequences 
in their synthesis, while injectability can arise through crosslinks triggered by in vivo stimuli. 
Gelatin and chitosan hydrogels have been used to deliver proteins such as FGF-2 and EPO to 
induce revascularization and cardiac repair [212, 213]. Fibrin gels have been utilized to release 
angiogenic factors and increase the formation of microvessels [214]. Collagen gels containing 
TIMP-1 and TIMP-3 can improve cardiac function and reduce adverse remodeling after 
infarction [88]. Alginate hydrogels have been used for sequential delivery of proteins such as 
IGF-1 followed by HGF or VEGF followed by PDGF to improve ischemic heart function [41, 
215]. Recently, hyaluronic acid-based hydrogel loaded with SDF-1α and angiogenic peptide 
Ac-SDKP was delivered to the infarcted myocardium improving ejection fraction, stem cell 
recruitment, and angiogenesis [216]. The delivery of TIMP-3 using a hyaluronic acid hydrogel 
improves ejection fraction and reduces ventricular dilation, LV wall stress, MMP activity, 
inflammation, and infarct size in a porcine model [177]. An ECM-derived hydrogel releasing an 
engineered HGF fragment demonstrated cardiomyocyte protection and downregulation of pro-
fibrotic markers in vitro, and improved cardiac function and angiogenesis in vivo [217]. PEG-
based hydrogels have been used to treat infarcted hearts and deliver single or multiple proteins 
such as VEGF, HGF, and IGF-1 which reduced scar burden and enhanced heart function [218-
220].  
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Figure 7. Commonly used and developed drug delivery systems include hydrogels, nano/micro particles, 
coacervates, self-assembled nanofibers, porous scaffolds, and liposomes. The structural, mechanical, and 
chemical properties of these systems can be modified to control the release kinetics of cargo. 
1.3.3 Micro- and nanoparticles 
Micro- and nanoparticles are injectable small particles often produced from polymers, 
functionalized to target specific injury sites, and control the release of embedded bioactive 
molecules like proteins which can be dissolved within, entrapped, encapsulated, or adsorbed 
(Figure 7). Because of their small size, micro- and nanoparticles are injectable and can diffuse 
and accumulate in different tissues. The particle size also plays an important role in the release 
rate of encapsulated proteins because of changing surface-to-volume ratios and the ability of 
cells to endocytose them (Figure 8) [221]. The loading of proteins into micro- and 
nanoparticles usually requires the use of relatively harsh conditions and organic solvents that 
put the proteins at risk of denaturation and loss of bioactivity [208]. Such conditions prompted 
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the utilization of surfactants, carrier proteins, and sugars as stabilizers during the process of 
protein encapsulation in a bid to minimize potential loss of protein bioactivity [222]. PLGA is 
one polymer that has shown a lot of potential in controlled delivery because of its high 
biocompatibility and safety. It is also FDA-approved for various medical applications. PLGA 
microparticles have been used to release SDF-1α, thus increasing the extent of stem cell 
recruitment in vitro [223]. Delivering VEGF to the ischemic heart using PLGA microparticles 
induces angiogenesis and reduces LV wall thinning and adverse remodeling [224]. In another 
study by the same group, these microparticles are used to co-deliver FGF-1 and NRG-1 to the 
heart after MI which improved cardiac function, revascularization, cardiomyocyte proliferation, 
progenitor cell homing, and reduced infarct size and fibrosis [225]. IGF-1 delivered by PLGA 
nanoparticles can significantly improve Akt activation and ejection fraction and reduce 
apoptosis and infarct size in mice hearts [226]. Heat shock protein 27 (HSP27)-loaded PLGA 
microparticles inside an alginate hydrogel improved cardiac cell protection under hypoxia 
[227]. PLGA microparticles loaded with milrinone have also been used to improve ejection 
fraction and reduce inflammation in a rodent MI model [228]. Micro- and nanoparticles based 
on other biomaterials such as porous silicon, silica, lecithin, pluronic, and dextran have been 
recently investigated for delivery of proteins to repair the infarcted myocardium [229-232]. 
1.3.4 Coacervates 
Complex coacervates are a new class of drug delivery vehicles [233]. They can be formed by 
the mixing of oppositely charged polyelectrolytes resulting in aggregates of colloidal droplets 
held together by electrostatic attractive forces and apart from the surrounding liquid (Figure 7) 
[234-236]. The coacervation process leads to phase-separation of a polymer-rich liquid phase 
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from a polymer-poor one. Only recently, the investigation of coacervates as drug delivery 
vehicles started with the advancement of this field. Particularly interesting features of 
coacervates include their ability to load molecules with high capacity and self-assemble in 
aqueous solutions without the need for organic solvents, thereby evading the risk of denaturing 
loaded proteins [235-237]. Once proteins, drugs, or small molecules are embedded within the 
coacervate, they become protected from the proteolytic and enzymatic degradation, thus 
maintaining their bioactivity and sustaining their release (Figure 8) [235].  The coacervate 
droplets exist in dynamic equilibrium, thus reducing their likelihood of aggregation in response 
to ionic concentration or temperature changes in their environment. The small size of 
coacervates, on the order of nanometers, allows them to be injectable through fine gauge 
needles. The stability of ionic coacervates is an area that needs improvement, especially for a 
systemic delivery route when blood carries the coacervate [234, 235]. Even though coacervates 
have only been utilized in drug delivery applications for a relatively short time, they have 
shown many advantages over conventional methods of protein delivery which calls for the 
continued experimentation of coacervates in tissue engineering applications. 
 Elastin-like polypeptides (ELPs) are one of the coacervate systems recently explored for 
drug delivery [238]. ELPs are recombinant proteins made to mimic the hydrophobic domains of 
tropoelastin which undergo a coacervation process above their tunable transition temperature. 
ELP fusion proteins have been designed to increase retention at the target tissue. For example, 
interleukin-1 receptor antagonist (IL-1RA) has been fused with ELP, and was found to mitigate 
different arthritis-type conditions and reduce cartilage degeneration in the knee joint after injury 
[239]. ELPs have also been employed to develop nanocarriers for cancer treatment. The 
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anticancer drug placitaxel (PTX) was conjugated to ELPs and found to accumulate more in 
tumors than free PTX showing better tumor regression in mice prostates [240]. 
 Another coacervate system utilizes the complexation between polycations and heparin to 
control the release of heparin-binding GFs [235, 236]. The use of heparin in delivery systems 
advantageously imitates the native signaling environment involving ECM proteoglycans, 
ligands, and cell receptors. Heparin is allowed to bind to the GFs first, and then a synthetic 
polycation is added at specific stoichiometric ratios to induce the charged-based phase 
separation resulting in the formation of GF-loaded coacervates. This type of coacervate has 
been used to induce wound healing, therapeutic angiogenesis, and cardiac repair [86, 241-243]. 
FGF-2 coacervate was effective in inducing angiogenesis, reducing fibrosis and myocardial 
scarring, and improving contractile function in a mouse MI model [241]. Shh coacervate has 
been shown to improve cardioprotection, vascularization, and heart function in rodents after MI 
[86, 244]. 
1.3.5 Other delivery systems 
A few other delivery systems have been utilized in protein delivery to the ischemic heart 
(Figure 7). Lipid-based vehicles have been developed for use in cardiac repair, however 
challenges posed by liposomes such as instability and interaction with circulating lipoproteins 
are still being addressed [232, 245]. Anti-P-selectin-conjugated liposomes loaded with VEGF 
were delivered to the infarcted myocardium leading to an improved systolic function and 
fractional shortening [246]. Self-assembled peptides, formed by alternating hydrophilic and 
hydrophobic domains of oligopeptides, are another platform used for delivery of proteins 
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(Figure 7) [247]. They have been used to deliver IGF-1, PDGF-BB, FGF-2, VEGF, and others 
to improve cardiac function post infarction [248-251].  
 
Figure 8. Different release profiles can be attained by different controlled release systems. The rate and style 
of release over a certain period can be controlled by changing the design and chemical and mechanical 
properties of the delivery vehicle. 
1.3.6 A clinical and market perspective on protein delivery systems 
Following the limited success of protein-based therapies in the clinic, there has been a rising 
interest in the development of more effective methods of administering proteins to the target 
tissues. Commercially marketed protein-containing products such as Regranex and InFUSE 
have not been fully adopted in regenerative medicine because of safety and efficacy concerns. 
Much testing and validation need to be performed before successful adoption of protein delivery 
systems in the market. In particular, in vivo studies are necessary to develop appropriate 
administration methods and demonstrate safety and efficacy of the encapsulated proteins in 
inducing the desired response. Proving safety, scalability, reproducibility, ease of 
manufacturing, cost-effectiveness, biocompatibility, and biodegradability are all factors that can 
help push controlled release systems past clinical trials and pave the road towards full adoption 
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in the clinics. There is a long way to go and many hurdles to overcome, but the potential market 
for therapeutic proteins for the heart is just beginning to open up and has a huge growth 
potential. This motivates many researchers to improve the controlled protein delivery field and 
race to clinical success. 
1.4 THE POTENTIAL OF POLYCATION:HEPARIN COACERVATE IN TISSUE 
REPAIR AND REGENERATION 
Drug delivery systems can gain a new level of effectiveness when they are designed to mimic 
the physiologic microenvironment as much as possible. Heparin-based coacervates are one 
example of such biomimetic systems (Figure 7, 9) [236, 237, 242, 252]. A complex coacervate 
can be formed by the electrostatic interactions between polycations and polyanions leading to 
phase separation (Figure 9). Heparin-based coacervates take into account the essential role of 
the ECM in protection and translocation of GFs within tissues. Heparin, the most negative 
natural polymer in the body, binds over 400 proteins and peptides, many of which have 
important biological functions [253]. By employing heparin, these coacervates imitate the 
signaling methods of the native environment that involve ECM proteoglycans, ligands, and cell 
receptors. The inspiration in the design of our coacervate came from the stable, ternary complex 
formed by heparin, fibroblast growth factor (FGF), and its cell receptor FGFR, whereby heparin 
facilitates their association [236]. We decided to create a simplistic mimic of the heparin-
binding domain of FGFR. The heparin-binding domain of many proteins contains residues such 
as lysine and arginine, which are important for inter-molecular interaction and downstream 
signaling [253]. So, we conjugated the most basic amino acid, Arginine, to a hydrolyzable 
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backbone of ethylene glycol and aspartic acid resulting in the formation of a synthetic 
polycation, a polycation poly(ethylene arginyl aspartate diglyceride) (PEAD) (Figure 9A) 
[235]. PEAD bears 2 cationic groups (amine and guanidine) per repeating unit and thus interacts 
strongly with polyanions such as heparin (Figure 9). To form the coacervate, we allow the 
protein and heparin to bind and then add PEAD which induces phase separation that can be 
macroscopically seen as a turbid solution indicating the neutralization of the charge. In our 
coacervate system, heparin is non-covalently immobilized within the complex by electrostatic 
interactions, which can guarantee the preservation of its natural bioactivity. The polycation 
PEAD was designed specifically for protein delivery [235]. It is biodegradable with minimal 
cytotoxicity [237]. 
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Figure 9. (A) Chemical structure of the polycation PEAD. PEAD has a hydrolyzable backbone of ethylene 
glycol and aspartic acid and bears 2 cationic groups per repeating unit, located on its arginine. (B) The 
natural polyanion heparin and heparin-binding proteins can form a complex, which upon mixing with 
PEAD leads to the formation of a protein-loaded coacervate complex based on electrostatic interactions. 
Heparin-based coacervates are able to encapsulate proteins with high efficiency, 
protect them from proteolytic degradation, prolong their bioactivity, and sustain their release 
over time (Figure 9) [235, 236, 242]. There are a number of ways to control the formation of 
coacervates and their release kinetics such as altering the molecular weights of the 
polyelectrolytes, their charge density, the stoichiometric ratio of positively- and negatively-
charged polymers, pH, salt concentration, and others [234-236, 252]. Our group has 
utilized the coacervation process 
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between a PEAD and heparin to control the delivery of proteins for various biomedical 
applications such as therapeutic angiogenesis, wound healing, cardiac repair, and bone 
regeneration [233].  
The administration of heparin-binding epidermal growth factor (HB-EGF)-loaded 
coacervates to full-thickness excisional normal and diabetic mouse wounds led to fast wound 
closure compared to free HB-EGF by improving re-epithelialization, angiogenesis, keratinocyte, 
and angiogenesis [243]. FGF-2 coacervate triggered comprehensive angiogenesis in a 
subcutaneous model, increasing the formation of mature and stable vasculature that participates 
in blood circulation [242]. BMP-2 coacervate enhanced the osteogenic effect of muscle-derived 
stem cells by increasing their differentiation and ectopic bone formation [254]. In regards to 
cardiac repair, FGF-2 coacervate improved cardiac function and angiogenesis, and reduced 
inflammation, fibrosis, and cardiomyocyte death after MI injury [241]. In addition, Shh 
coacervate was shown to protect cardiomyocytes from apoptosis and induce important GF 
signaling in vitro, and improve vascularization and heart function in rats after MI [86, 244].  
1.5 CONCLUSIONS AND FUTURE DIRECTIONS 
Current treatments only defer further cardiac damage and dysfunction rather than restore the 
normal function of the heart. Given the limited potential of the adult mammalian heart to repair 
and regenerate on its own after MI, and the identification of favorable proteins that are able to 
induce cardiac protection, repair, and regeneration, protein therapeutics remain a hopeful, 
feasible, and effective path for future treatments of ischemic heart disease, even though the road 
towards clinical translation is still filled with obstacles (Figure 5, 10).  
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Further understanding and elucidation of molecular mechanisms of myocardial tissue 
repair and regeneration will contribute to the development of more effective treatment strategies 
(Figure 10). Working on multiple aspects such as revascularization, remodeling prevention, and 
cardiomyogenesis is posed to be a more promising approach towards full recovery and 
comprehensive regeneration of the infarcted myocardium than single-focus approaches (Figure 
5, 10). Therefore, the decision on which proteins to combine to address many of the aspects 
discussed in this chapter is important. Additionally, the ability to design therapeutic strategies 
that can mimic the natural regenerative microenvironment is a key determinant of successful 
repair process after MI (Figure 6, 7).  
The notion of recapitulating the physiology of the heart environment can be facilitated 
and potentially achieved through the utilization of efficient, targeted, biocompatible, and tightly 
controlled protein delivery systems that can support the bioactivity, stability, and retention of 
released proteins at the target site (Figure 6, 7). Proteins are not meant to be available at any 
time or any place during the repair process. Delivery and release kinetics of proteins need to be 
tightly regulated spatially and temporally, so that their physiological concentrations, gradient 
formations, and biological cues are optimal for preservation and regeneration of the 
myocardium. Because hundreds of millions of cardiomyocytes are lost after an ischemic insult, 
it is extremely hard to replace such a vast amount of lost tissue. Many researchers support the 
idea of combination therapy that combine the use of cell and protein therapies. Such an 
approach needs to clearly identify the source and quantity of cells to use. If the cells become 
fully differentiated into functional adult cardiomyocytes that are electromechanically coupled 
with the rest of the heart muscle, it will be a powerful way to regenerate the damaged heart.  
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The complexity of biological systems makes it difficult to integrate all the aspects of 
tissue repair and regeneration. Systems biology approaches can potentially help combine 
massive experimental data with computational modeling to design highly effective strategies. 
The physiology and pathology of the heart are intrinsically complex, thus it is indispensable to 
design strategies that can yield substantial therapeutic benefit and pave the way to full clinical 
adoption in the cardiovascular market (Figure 5, 10).  
 
Figure 10. Schematic of a protein therapy design. An effective therapy requires the elucidation of the 
pathological changes after MI, leading to the identification of involved proteins. It is also essential to develop 
a proper delivery technology that can encapsulate proteins of interest and deliver them in a physiologic 
manner. The optimized strategy can potentially counter or reverse the pathological progression and trigger 
the repair and regeneration mechanisms in the heart. 
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1.6 SPECIFIC AIMS 
The central hypothesis of this research is that controlled protein delivery using a vehicle, 
capable of sequential release of proteins necessary at different stages of the repair process, can 
trigger significant tissue repair and regeneration in the clinically-relevant context of treating 
myocardial infarction (MI). Our preliminary results, previous publications, and the current 
literature demonstrate the therapeutic potential of many proteins in cardiac repair (Table 1). The 
desired controlled release patterns were achieved using our heparin-based coacervates in 
combination with fibrin gel. Towards our central hypothesis, I tested the efficacy of controlled 
delivery of combinations of therapeutic proteins with roles in cardiac function, VEGF, HGF, 
PDGF, FGF-2, IL-10, TIMP-3, and SDF-1α, using in vitro assays and an in vivo rat MI model. 
This dissertation is outlined in the following three Specific Aims: 
Specific Aim 1: Characterize the ability of the heparin-based coacervate to co-
release proteins and evaluate its efficacy using angiogenic in vitro assays. The heparin-
based coacervate was tested for its ability to co-release VEGF and HGF. The protein-loaded 
coacervates were characterized for their charge, size, and morphology. The stimulatory effects 
of combining these two proteins and controlling their delivery were evaluated on endothelial 
cell proliferation and tube formation using in vitro assays. 
Specific Aim 2: Design a delivery vehicle to achieve sequential release of proteins 
and evaluate its efficacy in stimulating therapeutic angiogenesis in vitro and in an in vivo 
rat myocardial infarction model. To achieve sequential release of VEGF, an early-stage 
angiogenic factor, followed by PDGF, a late-stage angiogenic factor, I tested embedding VEGF 
in fibrin gel, while embedding PDGF inside heparin-based coacervates and distributing them 
inside the same gel. The efficacy of sequential release was tested on cell proliferation and 
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microvasculature formation in vitro. In vivo testing followed using a rat MI model to evaluate 
the effect of sequentially-released VEGF and PDGF on cardiac function, angiogenesis, 
cardiomyocyte survival, inflammation, and fibrosis at 4 weeks after MI. 
Specific Aim 3: Optimize a combination of complementary proteins for cardiac 
repair using factorial design of experiment (DOE) and evaluate the efficacy of the 
optimized combination using the sequential release system in a rat myocardial infarction 
model. I chose a combination of four proteins with relatively distinct cardiac functions, FGF-2, 
IL-10, SDF-1α, and TIMP-3, to be tested for their potential in cardiac repair. I embedded TIMP-
3 and IL-10 in fibrin gel, while embedding FGF-2 and SDF-1α inside heparin-based coacervates 
and distributing them inside the same gel. The combination and doses of proteins were first 
optimized based on their improvement of cardiac function utilizing a statistical fractional 
factorial design. Using a rat MI model, the efficacy of the optimized combination was then 
tested on cardiac function, myocardial strain levels, left ventricle dilation and wall thinning, 
angiogenesis, cardiomyocyte survival, inflammation, stem cell homing, fibrosis, matrix 
metalloproteinases activity, survival molecular pathways, and protein level signaling at 2 and/or 
8 weeks after MI. 
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2.0  DUAL DELIVERY OF VEGF AND HGF TO TRIGGER STRONG 
ANGIOGENIC RESPONSES 
Note: The research work of chapter 2 was published in Macromolceular Bioscience Journal. 
H.K. Awada, N.R. Johnson, Y. Wang. 2014. “Dual delivery of vascular endothelial growth 
factor and hepatocyte growth factor coacervate displays strong angiogenic effects”. 
Macromolecular Bioscience 14: 679-686. 
 
Controlled delivery of multiple growth factors (GFs) holds great potential for the clinical 
treatment of ischemic diseases and might be more therapeutically effective to reestablish 
vasculature than the provision of a single GF. Vascular endothelial GF (VEGF) and hepatocyte 
GF (HGF) are two potent angiogenic factors. However, due to rapid degradation and dilution in 
the body, their clinical potential will rely on an effective mode of delivery. We have developed 
a coacervate, comprised of heparin and a biodegradable polycation, which protects GFs from 
proteolysis and potentiates their bioactivities. Here we show that the coacervate incorporates 
VEGF and HGF and sustains their release for at least 3 weeks. We confirm their strong 
angiogenic effects on endothelial cell proliferation and tube formation in vitro. Furthermore, we 
demonstrate that coacervate-based dual delivery of these factors has stronger effects than free 
application of both factors and individual GF delivery. 
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2.1 INTRODUCTION 
Harnessing the body’s ability to regenerate damaged tissues and enhance functional recovery 
presents an exciting and challenging opportunity for growth factor (GF) therapy. The 
regenerative microenvironment is influenced by the interactions between cells, the extracellular 
matrix (ECM), and signaling molecules. GFs, chemokines, and cytokines can trigger 
endogenous repair mechanisms by providing the appropriate signals for cells to proliferate, 
migrate, differentiate, or apoptose [208, 255, 256]. Although the delivery of a single GF has 
shown promise in the treatment of some diseases, many conditions require a more complex 
approach [195, 257]. Co-delivery of multiple GFs may be paramount to successful therapeutic 
angiogenesis for ischemic tissues such as infarcted myocardiums and chronic wounds. 
According to the Angiogenesis Foundation, at least 314 million patients in Western nations 
could benefit from some form of pro-angiogenic therapy [258]. Vascular endothelial GF 
(VEGF) and hepatocyte GF (HGF) are potent stimulators of angiogenesis and play important 
roles in promoting endothelial cell growth, proliferation, migration, differentiation, and survival 
[259-264]. Several studies have demonstrated that the combination of VEGF and HGF in free-
form triggers an angiogenic response that is stronger than either GF alone [265-268]. This 
underscores the complexity of the neovascularization process and the need to develop therapies 
which adequately address this complexity. 
The efficacy of GF therapy hinges on a delivery system that can appropriately maintain 
their bioactivity and bioavailability [208, 255]. Effective delivery vehicles may achieve this by 
protecting the GFs from proteolytic degradation and controlling their spatiotemporal release, 
while also avoiding side effects from high GF concentrations systemically or at unwanted distal 
locations [191, 195, 208, 255]. Concentrating efforts on the development of delivery systems 
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with the capability of delivering GFs in a time-dependent and dose-dependent fashion might be 
the key to obtaining sufficient tissue development [195]. We have previously described a new 
class of controlled release vehicles: an injectable polyvalent coacervate formed by a polycation, 
poly(ethylene arginyl aspartate diglyceride) (PEAD), and heparin that can control the release of 
heparin-binding GFs [235, 237]. More than 400 human proteins bind heparin, many of which 
are important for healthy vasculature and tissue regeneration [253]. The coacervate is 
biodegradable, has excellent biocompatibility, and can enhance the bioactivity of the GFs [86, 
235, 241-243]. The objective of this study was to characterize the ability of the heparin-based 
coacervate to co-release VEGF and HGF and examine the effect of their dual release on human 
endothelial cell (EC) proliferation and tube formation. This is the first study to investigate the 
ability of heparin-based coacervates at multiple GF release. We hypothesized that co-delivery of 
VEGF and HGF would yield stronger and more robust angiogenic effects than those of the 
individual GF coacervates and the co-administration of free GFs. 
2.2 MATERIALS AND METHODS 
2.2.1 Characterization of VEGF and HGF coacervates  
2.2.1.1 Zeta potential and dynamic light scattering (DLS) measurements 
PEAD was synthesized as previously described [235, 237]. Heparin (Scientific Protein Labs, 
Waunakee, WI) and PEAD were each dissolved at 10mg/ml in deionized (DI) water and filter-
sterilized at 0.22μm. Heparin was initially combined with either VEGF165 or HGF (Peprotech, 
Rocky Hill, NJ) or both at 100:1 mass ratio of heparin:GF to ensure that the solution was 
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saturated with heparin to bind all the available GFs. Solutions were then titrated  with PEAD to 
obtain different PEAD:heparin:GF mass ratios.  The solution was diluted with DI water to a 
total of 750µl before zeta potential was measured with a Zetasizer Nano ZS90 (Malvern, 
Worcestershire, UK). Results were reported as a mean with standard deviation for 25 
measurements.  The same instrument was used to determine the hydrodynamic diameters of 
PEAD:heparin (mass ratio 5:1), heparin:VEGF (100:1), PEAD:heparin:VEGF (500:100:1), 
heparin:HGF (100:1), and PEAD:heparin:HGF (500:100:1) by dynamic light scattering (DLS). 
Results were reported as a mean with polydispersity index (PDI) for 25 measurements. PDI in 
the area of light scattering is used to describe the width of the particle size distribution. 
2.2.1.2 Fluorescent imaging of the coacervate 
PEAD solution was mixed with rhodamine-labeled heparin at the previously optimized 5:1 
PEAD:heparin mass ratio [235]. The coacervate was centrifuged at 12,100g for 10 minutes to 
form a pellet. The supernatant was aspirated to remove unbound heparin and the pellet was 
resuspended in DI water and added to a 96-well plate for fluorescent imaging (Eclipse Ti; 
Nikon, Tokyo, Japan). 
2.2.1.3 Scanning electron microscopy (SEM) 
Samples were prepared with PEAD:heparin mass ratio 5:1 for blank coacervate and 
PEAD:heparin:GF mass ratio 500:100:1 for VEGF or HGF coacervates. The complex was 
dropped on an aluminum stub, lyophilized, gold sputter-coated, and examined by SEM (JSM-
6335F field emission SEM; JEOL, Peabody, MA). 
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2.2.2 Growth factor loading efficiency and release assay 
The release profiles of VEGF and HGF were determined by sandwich ELISA. VEGF+HGF 
coacervates (n=3) were formed using 200ng of each GF combined with heparin followed by 
PEAD at 500:100:1 mass ratio of PEAD:heparin:GF in 200µl of DI water. Solution was 
centrifuged at 12,100g for 10 minutes to pellet the coacervate. The supernatant was collected 
and stored, and pellet was resuspended in DI water. The samples were incubated at 37°C. The 
first collection (Day 0) was used to determine the loading efficiency. The same centrifugation 
and supernatant collection procedure was repeated on days 1, 3, 7, 14, and 21. Sandwich ELISA 
was performed to detect the amount of released GF in the supernatants according to the 
instructions of VEGF ELISA kit (Peprotech, Rocky Hill, NJ) or HGF ELISA kit (R&D 
Systems, Minneapolis, MN). After the addition of sulfuric acid stop solution, the absorbance at 
450/540nm was recorded by a SynergyMX plate reader (Biotek, Winooski, VT). Standard 
solutions (n=3) that contained 200ng of each of free VEGF and HGF in 200µl of DI water were 
prepared to create standard curves and determine total release.  
2.2.3 Endothelial proliferation and live cell count assays 
Similar culture conditions were used for cell proliferation and live cell count assays. Passage 6 
human umbilical vein endothelial cells (HUVEC) (ATCC, Manassas, VA) were labeled with 
Calcein AM (Molecular Probes, Eugene, OR) for 2 hours before seeding 104 cells in 100µl 
EGM-2 media (Lonza, Walkersville, MD) per well in a 96-well plate. Six hours after seeding, 
group-specific media was added and 8 groups were tested (n=3 wells/group): basal media, blank 
coacervate, free HGF, free VEGF, free VEGF+HGF, HGF coacervate, VEGF coacervate, and 
VEGF+HGF coacervates. Each GF was added at a final 30ng/ml concentration.  
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For the BrdU cell proliferation assay (Millipore, Billerica, MA), the plate was incubated 
at 37°C for 16 hours, then 20µl of BrdU label was added to each well and incubated for 4 hours. 
The proliferation assay protocol was then followed according to the kit’s instruction manual. 
After the addition of the stop solution, the absorbance at 450/540nm was recorded by a 
SynergyMX plate reader and normalized to the basal media control.  
For the live cell count assay, the plate was incubated at 37°C for 3 days, then cells were 
observed using a fluorescence microscope. Cell number was determined by manually counting 
the cells in a 0.67mm2 field in the center of the well (n=3 wells/group). Fluorescent images of 
cells were taken of 4mm2 fields. 
2.2.4 Endothelial tube formation assay 
Fibrin gels were prepared for a three-dimensional (3D) cell culture environment as previously 
described [269]. Briefly, 6mg/ml bovine fibrinogen (Sigma-Aldrich, St. Louis, MO) was 
dissolved in EGM-2 media, added in 150μl volumes per well of a 24-well plate, activated with 
150μl of 0.1mg/ml thrombin solution (Sigma-Aldrich, St. Louis, MO) in EGM-2, swirled gently 
to mix and solidified at 37°C. Passage 5 HUVEC were labeled with Calcein AM for 2 hours, 
then 1.5x105 cells were seeded on top of each gel in 1ml EGM-2 media and incubated at 37°C 
overnight. After confluent cell monolayers formed next day on top of each gel, media was 
removed and 300μl group-specific fibrin gels were overlaid and solidified as before, followed 
by 1ml EGM-2 media on top. Group-specific additions to top gels included 8 groups: basal 
media, blank coacervate, free VEGF, free HGF, free VEGF+HGF, VEGF coacervate, HGF 
coacervate, and VEGF+HGF coacervates. In all groups, the dose of VEGF or HGF was 250ng. 
After culturing for 3 days, media was removed and wells were imaged with a fluorescence 
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microscope. An endothelial tube was defined as a straight cellular extension joining two cell 
masses or branch points [269]. Tube number, lengths, and thicknesses were measured as 
angiogenic indices [269-271]. Using NIS-Elements AR imaging software (Nikon, Tokyo, 
Japan), endothelial tubes were manually counted and quantified in length and thickness in a 
0.67mm2 field in the center of each well (n=3 wells/group). 
2.2.5 Statistical analysis 
GraphPad Prism 5.0 statistical software (La Jolla, CA) was used for statistical analysis. One-
way ANOVA followed by the post-hoc Tukey’s comparison test was used to analyze the data 
for bioactivity assays. Data is presented as mean ± standard deviations (SD). Statistical 
significance was set at p<0.05. 
2.3 RESULTS AND DISCUSSION 
2.3.1 VEGF and HGF coacervates characterization 
The zeta potential of the strongly negative solution of heparin:GF (100:1 mass ratio) turned 
more positive as it was titrated with the polycation PEAD (Figure 11A). At 100:100:1 mass 
ratio of PEAD:heparin:GF, VEGF coacervate and HGF coacervate had negative zeta potentials 
of approximately -52mV and -42mV, respectively. Zeta potentials approached neutrality at a 
mass ratio of approximately 500:100:1 with high turbidity in the solution, regardless of the GF 
used (-0.9mV for VEGF, and -1.8mV for HGF). As more PEAD was added, the zeta potential 
reached a positive plateau of 22mV for VEGF coacervate and 17mV for HGF coacervate at 
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1000:100:1 mass ratio (Figure 11A). Previously we reported that a 5:1 mass ratio of 
PEAD:heparin produced a neutral coacervate [235]. Our results indicate that a small amount of 
GFs does not have a significant effect on zeta potential. Therefore, for the rest of this study, we 
used a PEAD:heparin:GF mass ratio of 500:100:1 to achieve maximal coacervation. 
 
Figure 11. (A) Zeta potentials of VEGF and HGF coacervates were measured at different mass ratios of 
PEAD:heparin:GF by titrating negative heparin:GF solutions with positive PEAD. Coacervates approached 
neutrality at 500:100:1. (B) DLS measurements show the hydrodynamic diameters of heparin:GF, 
PEAD:heparin, and PEAD:heparin:GF particles. (C) Spherical droplets of rhodamine-labeled blank 
coacervates were imaged by fluorescence microscope showing variable sizes. Scale bar=25µm. 
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DLS measurements showed significant increases in hydrodynamic diameters upon 
addition of PEAD to heparin:GF complexes. The blank coacervate had a hydrodynamic 
diameter of 425nm. VEGF coacervate and HGF coacervate had diameters of 476nm and 
461nm, respectively; demonstrating a small increase in size possibly due to GF addition (Figure 
11B). Fluorescent imaging of a blank coacervate using rhodamine-labeled heparin revealed 
thousands of spherical liquid droplets that are sub-micron in size and can aggregate over time to 
create larger coacervate droplets (Figure 11C). SEM images revealed the morphology of VEGF 
coacervate and HGF coacervate to be mainly composed of ribbon-like structures with globular 
beads of various sizes (Figure 12). There were no apparent morphological differences between 
blank coacervates and GF-loaded coacervates (Figure 12). This suggests that the ribbon-like 
structures are likely generated from PEAD while the globular bead structures originate from 
heparin, as was deduced from our previous characterization of the coacervate [235].  
59 
Figure 12. SEM images at low magnification (500X) show the ribbon-like structures and globular domains 
of blank coacervate, VEGF coacervate, and HGF coacervate. 
2.3.2 Coacervate loading and release of VEGF and HGF 
We studied the GF release kinetics from the coacervate by detecting the amount of released 
VEGF and HGF in the supernatant after pelleting the coacervate solution. The loading 
efficiency of VEGF was approximately 99%. The VEGF release profile showed a relatively 
small initial burst of 6% by 1 day. After 3 days, the release became nearly linear and resulted in 
a total release of approximately 35% by 21 days (Figure 13). The loading efficiency of HGF 
was approximately 98%. The HGF release profile also showed a relatively small initial burst of 
5% by 1 day. After 3 days, the release became nearly linear and resulted in a total release of 
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approximately 27% by 21 days (Figure 13). Our results suggest a significant impact of the 
heparin-binding affinity of each GF on release rate. HGF, with a strong heparin-binding affinity 
(Dissociation constant Kd= 12nM), released slower from the coacervate than VEGF which has a 
relatively weaker heparin-binding affinity (Kd= 165nM) [272]. However, the release rate of any 
GF can also be influenced by the hydrolytic degradation of PEAD, degradation of the 
coacervate components by enzymes such as esterases and heparinases, and dissociation of the 
complex in an ionic environment. Therefore, the release rate is expected to be faster in vivo 
where such conditions might be prevalent. 
Figure 13. Sustained in vitro release of VEGF and HGF from the heparin-based coacervate. Approximately 
35% of VEGF and 27% of HGF amounts were released by 3 weeks. Data are presented as means ± SD 
(n=3). 
Without effective controlled release systems, GFs tend to diffuse away from the target 
sites, degrade quickly, lose their bioactivities, and are potentially harmful when injected at high 
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concentrations [208]. Current protein delivery systems including hydrogels, polymeric 
microspheres, and peptide nanofibers face a number of challenges [255]. For example, the 
formation of poly(lactic-co-glycolic acid) (PLGA) microspheres requires organic solvents 
which may compromise the bioactivity of the loaded GF [273]. Some hydrogels, on the other 
hand, face challenges to control the GF release kinetics and result in large initial burst releases 
[274]. Peptide nanofibers are expensive to synthesize which may be a roadblock to clinical 
translation [249]. In addition, all of these types of delivery vehicles often have relatively low 
GF loading efficiencies.  
The coacervate delivery system was developed to overcome challenges faced by other 
delivery approaches. The coacervate was used in this study to simultaneously release VEGF and 
HGF. The coacervate release kinetics can be controlled by changing some parameters such as 
the molecular weight of PEAD and/or heparin, the charge density of PEAD, and the 
[PEAD:heparin] mass ratio. The coacervate preserves the native properties and function of 
heparin through the ionic interactions with PEAD without covalent cross-linking to the delivery 
matrix. Intact heparin supports a high GF loading efficiency and preservation of GF bioactivity, 
and the phase-separation induced by coacervation helps localize the GFs to the target tissues 
[235, 236, 242]. Finally, the coacervate is injectable and therefore can be easily utilized in a 
clinical setting. 
2.3.3 VEGF+HGF coacervates display strong angiogenic effects 
VEGF is an established promoter of blood vessel formation and remains the main driver of 
angiogenesis [275]. However, the administration of VEGF alone might lead to the formation of 
immature, leaky, and unstable neovessels [264]. The utility of VEGF is also restricted by a dose 
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limit, which could lead to undesirable side effects if surpassed [276, 277]. Additional factors are 
therefore necessary to trigger a more robust angiogenesis process. HGF is another potent 
angiogenic factor that stimulates endothelial cell proliferation and migration, and can induce 
endogenous expression of VEGF [259, 263, 278]. In addition, HGF has demonstrated 
chemotactic and anti-apoptotic activities on different cell types [279].  
It has been shown that the combination of VEGF and HGF results in a more robust 
angiogenic response in vitro and in vivo than either factor alone [265-268, 280]. A combined 
gene therapy of VEGF and HGF amplified the activation of ERK1/2 signaling pathway in vitro, 
involved in cell survival and proliferation, and increased perfusion in a hindlimb ischemia 
mouse model compared to single plasmid injection [280]. Another study concluded that 
combining VEGF and HGF promoted endothelial cell survival and tubulogenesis in collagen 
gels with enhanced expression of anti-apoptotic genes Bcl-2 and A1 [268]. Although these 
studies demonstrate the benefit of VEGF and HGF combination therapy, their clinical potential 
might be limited because bolus and systemic injections of free-form GFs tend to have low 
efficacy. A study that displayed the capability to release VEGF and HGF simultaneously and 
sequentially, using poly(trimethylene carbonate) based photo-cross-linked elastomers, did not 
evaluate any angiogenic effects of the two factors together or compare their bioactivity results 
to free GF administration [281]. Therefore, we were prompted in this study to investigate the 
potential benefit of coacervate-based dual delivery of VEGF and HGF on angiogenic 
applications. 
To investigate the effects of controlled release of VEGF and HGF on endothelial 
proliferation, we applied each GF separately or together, and in free-form or delivered by the 
coacervate to cell cultures and detected levels of administered BrdU, which is a thymidine 
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analog that incorporates into newly synthesized DNA strands of actively proliferating cells. One 
day after application, both GFs together in free-form significantly induced higher proliferation 
(p<0.05) compared to each GF alone, which showed little effect compared to control (p>0.05) 
(Figure 14A). Each GF alone delivered by the coacervate also significantly stimulated 
proliferation (p<0.01) compared to each GF alone in free-form. Finally, coacervate delivery of 
both GFs together significantly induced higher proliferation (p<0.01) compared to all other 
groups (Figure 14A).  
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Figure 14. Endothelial cell proliferation and live cell count assays. Treatment groups with 30ng/ml 
concentration for each of VEGF or HGF were applied to cell culture wells with seeded HUVEC. (A) One day 
after incubation, BrdU cell proliferation assay was performed and absorbance was recorded (n=3 
wells/group). Data is presented as a fold-change from the basal media (n=3 wells/group). (B) Live endothelial 
cell number was quantified after 3 days incubation in 0.67mm2 fields in the center of wells (n=3 wells/group). 
(C) Microscope fluorescent images of calcein-stained HUVEC in 4mm2 fields. Bars indicate means ± SD. * p
value <0.05. 
To verify that cell proliferation continued beyond 1 day and that the cells were still 
viable, we used Calcein staining after 3 days culture and counted the number of live ECs. The 
results were similar to that of the proliferation assay with combined VEGF and HGF showing 
significantly more live cells (p<0.05) compared to each GF alone, and coacervate delivery of 
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both factors inducing significantly higher viability (p<0.001) than all groups (Figure 14B,C). 
These results show the benefit of dual delivery of VEGF and HGF using the coacervate on 
endothelial cell proliferation, a key process in angiogenesis. 
To investigate the tubulogenesis potential of coacervate delivery of HGF and VEGF, we 
performed an established HUVEC tube formation assay within fibrin gels [269, 282]. This 3D 
angiogenesis assay better preserves the vessel architecture and represents a closer mimicking of 
in vivo events than 2D models [282, 283]. After 3 days of culture, no significant tube formation 
was observed in the basal media or blank coacervate control groups (Figure 15A). VEGF and 
HGF each induced tube formation which was improved with coacervate delivery compared to 
free-form application, and their coacervate dual delivery induced the most well-interconnected, 
thick endothelial tubes (Figure 15A).  
Both GFs applied together in free-form significantly increased EC tube number (p<0.05) 
and thickness (p<0.05) compared to each GF alone. Each GF alone delivered by the coacervate 
significantly increased the EC tube number (p<0.05) and thickness (p<0.01) compared to each 
GF alone in free-form. More importantly, coacervate delivery of both GFs administered 
together significantly increased EC tube number (p<0.05) and thickness (p<0.01) compared to 
all groups (Figure 15B,C). Although combining VEGF and HGF induced more and thicker 
tubes in both free-form and using the coacervate, this combination interestingly did not have a 
significant effect on tube length (p>0.05) compared to delivery of each GF alone. However, the 
coacervate groups did induce significantly longer tubes (p<0.01) than their corresponding free-
form groups (Figure 15D).  
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Figure 15. Endothelial tube formation assay between fibrin gels. HUVEC were seeded on bottom gel and 
specific treatment groups (n=3 wells/group) were added to top gel and incubated for 3 days. (A) Microscope 
fluorescent images of calcein-stained endothelial tubes formed in different groups. (B) Number of 
endothelial tubes, (C) tube thickness, and (D) tube length were quantified by microscope imaging analysis 
software in 0.67 mm2 fields at center of wells. Bars indicate means ± SD. * p value < 0.05. 
As it has been previously reported, our results confirm the stronger angiogenic effects of 
VEGF and HGF when applied together to promote angiogenesis [265-268, 280]. A gene 
expression profiling study demonstrated that there exists distinct signal transduction pathways 
for VEGF and HGF in vascular endothelial cells with little overlap between the genes regulated 
by each [284]. This could serve as an explanation to the synergism between VEGF and HGF 
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leading to beneficial effects that exceed the application of each alone. Additionally, we 
demonstrated in this study that controlled dual delivery of the two factors using a 
polycation:heparin coacervate does not impede the cooperation between the two GFs, but rather 
enhances it compared to free-form GF application. In the design of the coacervate platform, we 
were inspired by the stable ternary complex formed by heparin, fibroblast growth factor, and its 
cell receptor, whereby heparin facilitates their association [236, 285]. We mimicked the 
heparin-binding domain of fibroblast growth factor receptor (FGFR) which contains many basic 
amino acids to create the synthetic polycation PEAD. Utilizing heparin in its native 
conformation facilitates the GF-receptor interaction and likely results in the improved 
angiogenic effects demonstrated in this study. As we have demonstrated with other heparin-
binding GFs, the coacervate serves as an effective delivery vehicle for VEGF and HGF. The 
coacervate sustained their release for at least 3 weeks, localized their actions, and potentiated 
their bioactivities compared to free-form GFs. This study also validated the use of this delivery 
platform for sustained delivery of multiple factors, motivating future investigations of other GF 
combinations and simultaneous and sequential delivery of multiple proteins.  
2.4 CONCLUSIONS 
Many ischemic tissues cannot recover their normal functions and structure without proper 
vascular support. Angiogenesis is a complicated process which involves the signaling of many 
proteins. Therefore, regulating the local availability of different GFs can prove a powerful tool 
in controlling tissue regeneration. The coacervate may serve as an effective system to deliver 
GFs either individually or in combinations. In this study, the coacervate displayed its ability to 
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load VEGF and HGF with high efficiency and sustain their release for at least 3 weeks. 
Combining VEGF and HGF yielded strong angiogenic effects, shown by endothelial cell 
proliferation and tube formation assays. More importantly, we demonstrated that coacervate-
based dual delivery of these factors had more profound angiogenic effects than free GFs and 
controlled delivery of each GF alone, suggesting the potential benefit of this approach for 
therapeutic angiogenesis in vivo. 
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3.0  SEQUENTIAL DELIVERY OF VEGF AND PDGF TO PROMOTE 
THERAPEUTIC ANGIOGENESIS AND HEART FUNCTION AFTER MI 
Note: The research work of chapter 3 was published in the Journal of Controlled Release. H.K. 
Awada, N.R. Johnson, Y. Wang. 2015. “Sequential delivery of angiogenic growth factors 
improves revascularization and heart function after myocardial infarction”. Journal of 
Controlled Release 207:7-17. 
 
Treatment of ischemia through therapeutic angiogenesis still faces significant challenges. 
Growth factor (GF)-based therapies can be more effective when concerns such as GF 
spatiotemporal presentation, bioactivity, bioavailability, and localization are addressed. During 
angiogenesis, vascular endothelial GF (VEGF) is important at an early stage to initiate 
neovessel formation, while platelet-derived GF (PDGF) is needed later to stabilize the 
neovessels. The spatiotemporal delivery of multiple bioactive GFs involved in angiogenesis, in 
a close mimic to physiological cues, holds great potential to treat ischemic diseases. To achieve 
sequential release of VEGF and PDGF, we embedded VEGF in fibrin gel and PDGF in a 
heparin-based coacervate that is distributed in the same fibrin gel. In vitro, we show the benefits 
of this controlled delivery approach on cell proliferation, chemotaxis, and microvessel 
formation. A myocardial infarction (MI) rat model demonstrated the effectiveness of this 
delivery system in improving cardiac function, angiogenesis, cardiomyocyte survival, and 
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reducing ventricular wall thinning, fibrosis, and inflammation in the infarct zone 4 weeks after 
MI. Collectively, our results suggest that this delivery approach mitigated the injury caused by 
MI and may serve as a new therapy to treat ischemic hearts. 
3.1 INTRODUCTION 
Ischemic heart disease is a leading cause of morbidity and mortality in the United States. In 
2010, the estimated direct and indirect cost of heart disease was approximately $200 billion. In 
that year, myocardial infarction (MI) was prevalent in 7.6 million Americans. Approximately, 
15% of the people who experience a heart attack (MI) in a given year will die of it [2]. During 
MI, insufficient blood supply to a region of the heart muscle (infarct zone) leads to cell death 
and pathological remodeling which often progresses to heart failure over time [5]. Therapeutic 
angiogenesis aims to restore blood flow to the affected ischemic heart muscle by new blood 
vessel formation from existing vasculature [16, 27, 286]. Revascularization by pro-angiogenic 
therapies has so far failed to provide satisfactory outcomes in clinical trials [20, 287, 288]. 
Bolus injections of single growth factors (GFs) usually lead to limited efficacy because of loss 
of bioactivity, missing critical signals in the cascade of events that lead to stable angiogenesis, 
among others. An effective angiogenesis-based therapy can be developed when a 
comprehensive understanding of angiogenic mechanisms becomes available [256, 288]. Repair 
and regeneration strategies should focus on utilizing the GFs that play vital roles in the process 
of angiogenesis, as well as the need to administer them spatiotemporally and in bioactive 
conformations [20, 195, 208, 255, 287].  
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Many studies have shown that GFs such as fibroblast GF-2 (FGF-2), vascular 
endothelial GF (VEGF), angiopoietin-2 (Ang-2) are key factors in triggering angiogenesis, but 
these factors alone may result in leaky and immature blood vessels that are susceptible to early 
regression [35, 36]. Other GFs such as platelet-derived GF (PDGF) and angiopoietin-1 (Ang-1) 
help stabilize neovessels [289, 290]. Among potential angiogenic candidates, VEGF and PDGF 
are promising due to their potency, specificity, and cardioprotective roles [17, 20, 27, 249]. 
VEGF, an endothelial-specific factor, triggers the process through endothelial cell (EC) 
sprouting, proliferation, migration, and lumen formation, and is thus primarily needed in the 
first few days of angiogenesis [17, 291, 292]. After lumenal formation, mural cells are recruited 
by PDGF to cover the neovessels and provide stabilization; therefore PDGF is required at a later 
stage of angiogenesis to prevent vessel regression or the formation of aberrant and leaky vessels 
[17, 289]. It has been shown that early-stage angiogenic factors can have antagonistic effects on 
late-stage factors and vice versa, when present simultaneously [39, 40, 43]. Therefore, it appears 
imperative to sequentially administer these two GFs to imitate their physiological presence 
during angiogenesis. 
To control the spatiotemporal cues and protect the bioactivity of VEGF and PDGF, we 
developed a controlled delivery system composed of fibrin gel and a recently developed 
biocompatible heparin-based coacervate that we characterized in previous reports [235, 293]. 
Fibrin gel, formed through the polymerization of fibrinogen by thrombin, is commercially 
available and has been used for protein and cell delivery [210]. Complex coacervates are formed 
by mixing oppositely charged polyelectrolytes resulting in spherical droplets of organic 
molecules held together noncovalently and apart from the surrounding liquid and have shown 
potential in sustained protein delivery [233, 294]. VEGF was embedded into the fibrin gel, 
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while PDGF was loaded into the coacervate then embedded into the gel (Figure 16A). The 
coacervate was used to sustain the release of PDGF. This system provided rapid release of 
VEGF followed by slower and sustained release of PDGF from a single injection. Here we 
report the effects of sequentially delivered VEGF and PDGF on revascularization and heart 
function after MI in rats. 
3.2 MATERIALS AND METHODS 
3.2.1 Release assays of VEGF and PDGF  
Poly(ethylene argininylaspartate diglyceride) (PEAD) was synthesized as previously described 
[237]. The release assays (n=3) were performed using 100ng of VEGF165 and 100ng of PDGF-
BB (PeproTech, Rocky Hill, NJ). All solutions were prepared in 0.9% saline. For the release 
assay of both factors from the coacervate, PDGF or VEGF coacervates were made by mixing 
1µl of 100ng/µl of the GF with 1µl of 10mg/ml heparin first (Scientific Protein Labs, 
Waunakee, WI), then with 5µl of 10mg/ml of PEAD, at PEAD:heparin:GF mass ratio of 
500:100:1, creating 7µl coacervate solution for each GF. Solution was diluted up to 100µl. 
For the release assay of the two GFs from the fibrin gel-coacervate composite, the 
composite was made by mixing 83µl of 20mg/ml fibrinogen solution (Sigma-Aldrich, St. Louis, 
MO) containing 100ng of unbound VEGF with 7µl of PDGF coacervate solution (as described 
above), 5µl of 1mg/ml aprotonin solution (Sigma-Aldrich, St. Louis, MO), and lastly adding 5µl 
of 1mg/ml thrombin solution (Sigma-Aldrich, St. Louis, MO). A 100µl of 0.9% saline was 
deposited on top of the composite gel. 
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For both release assays at 1h, solutions were centrifuged at 12,100g for 10 min and 
supernatant was aspirated and stored at -80°C to detect amount of released GFs by ELISA kits 
(PeproTech, Rocky Hill, NJ). A fresh 100µl of 0.9% saline solution was deposited on top and 
the procedure was repeated at 16h, 1, 4, 7, 14, and 21 days. The samples were incubated at 
37°C. After ELISA procedure was performed, the absorbance at 450/540 nm was measured by a 
SynergyMX plate reader (Biotek, Winooski, VT). Standard solutions (n=3) that contained 
100ng of each of free VEGF and PDGF in 100µl of 0.9% saline were prepared to create 
standard curves and determine total release. 
3.2.2 Smooth muscle cell chemotaxis assay 
Chemotactic media was prepared as 500μl MCDB-131+10% fetal bovine serum (FBS) per well 
in a 24-well plate with group-specific addition of saline (basal media), empty vehicle, or 100ng 
free PDGF or in the coacervate. Culture inserts of 8μm pore size (BD Falcon, Franklin Lakes, 
NJ) were placed in each well and 104 isolated baboon smooth muscle cells (SMCs) were 
pipetted into the insert in 200μl basal media and plate was incubated at 37°C. After 12h, cells 
remaining inside the insert were removed from the upper surface of the membrane with a cotton 
swab. Cells that had migrated to the lower surface of the membrane were then fixed in methanol 
for 15 min. Cells were incubated for 15 min in the dark with PicoGreen fluorescent dye from 
Quant-iT PicoGreen dsDNA Kit (Molecular Probes, Eugene, OR), diluted 200-fold to working 
concentration in DPBS. Cells were imaged with a fluorescent microscope (Eclipse Ti; Nikon, 
Tokyo, Japan) and images were taken in the center of each well and counted manually (n=3 
wells/group). 
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3.2.3 Endothelial and smooth muscle cells proliferation assays 
Human umbilical vein endothelial cells (HUVEC) (ATCC, Manassas, VA) or isolated baboon 
SMCs were seeded at 104 cells per well in a 96-well plate and cultured in EGM-2 media (Lonza, 
Walkersville, MD) or MCDB131+0.2% FBS media, respectively. Group-specific additions (n=3 
wells/group) were made to media with GF concentrations at 20ng/ml per well for SMCs and 
25ng/ml of each GF per well for HUVEC. The plates were incubated for 48 h at 37°C. 20µl of 
pre-prepared BrdU label was then added for 4 h and the proliferation assays were performed 
according to kit’s instructions (Millipore, Temecula, CA). The absorbance at 450/540nm was 
measured by a SynergyMX plate reader. Absorbance proliferation values were normalized to 
the average basal media value (n=3 wells/group). The endothelial proliferation assay compared 
the 4 groups: basal media, empty vehicle, Free VEGF+PDGF, and sequentially delivered 
VEGF+PDGF. The SMC proliferation assay compared the 4 groups: basal media, empty 
vehicle, free PDGF, and PDGF coacervate. 
3.2.4 Ex vivo rat aortic ring assay 
Thoracic rat aortae (n=3 per group) were dissected according to established protocols [295, 
296], cleaned from fibro-adipose tissue, and cut into approximately 1.5mm ring segments. 
Rings were serum-starved overnight in serum-free endothelial basal medium (EBM). Next day, 
fibrin gels were made by dissolving 6mg/ml bovine fibrinogen (Sigma-Aldrich, St. Louis, MO) 
in EGM-2 media, added in 150μl volumes per well of a 24-well plate, activated with 150μl of 
0.1mg/ml thrombin solution (Sigma-Aldrich, St. Louis, MO) in EGM-2, swirled gently to mix 
and solidified at 37°C. The aortic rings were embedded in the center of the 3D fibrin matrix 
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(one per well) that contained different treatment groups (GF dose of 250ng) with luminal axis 
perpendicular to the bottom of the well in a 24-well plate. 500µL of EBM was placed on top of 
gel and plate was incubated at 37°C for 6 days. Rings were then imaged using brightfield (BF) 
microscopy and quantified in terms of microvasculature sprouting area (n=3 wells/group). The 
aortic ring assay compared the 4 groups: basal media, empty vehicle, free VEGF+PDGF, and 
sequentially delivered VEGF+PDGF. 
 
3.2.5 Rat acute myocardial infarction model 
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approval was 
obtained prior to beginning all animal studies. MI and injections were performed as previously 
described [297]. Briefly, 6-7 week old (175-225g) male Sprague-Dawley rats (Charles River 
Labs, Wilmington, MA) were anesthetized first then maintained with 2% isoflurane at 0.3L/min 
(Butler Schein, Dublin, OH), intubated, and connected to a mechanical ventilator to support 
breathing during surgery. The body temperature was maintained at 37°C by a hot pad. The 
ventral side was shaved and a small incision was made through the skin. Forceps, scissors, and 
q-tips were used to dissect through the skin, muscles, and ribs. Once the heart was visible, the 
pericardium was torn. MI was induced by permanent ligation of the left anterior descending 
(LAD) coronary artery using a 6-0 polypropylene suture (Ethicon, Bridgewater, NJ). Infarct was 
confirmed by macroscopic observation of a change in color from bright red to light pink in the 
area below the ligation suture.  Five minutes after the induction of MI, different treatment and 
control solutions were injected intramyocardially at 3 equidistant points around the infarct zone 
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using a 31 gauge needle (BD, Franklin Lakes, NJ). Groups included: saline, empty vehicle, free 
VEGF+PDGF, or sequentially delivered VEGF+PDGF. 
The saline group (n=7) underwent the surgery in which MI was induced and 100µl of 
0.9% sterile saline was injected around the infarct region. The empty group (n=7) underwent the 
surgery in which MI was induced and 100µl of empty fibrin gel-coacervate composite was 
injected around the infarct region. The free VEGF+PDGF group (n=7) underwent the surgery in 
which MI was induced and 100µl of 0.9% sterile saline containing 1.5µg each of free VEGF 
and PDGF was injected around the infarct region. The sequentially delivered VEGF+PDGF 
(n=7) underwent the surgery in which MI was induced and 100µl of fibrin gel-coacervate 
composite loaded with the GFs was injected around the infarct region.  
The GF-loaded fibrin gel-coacervate composite was prepared as follows: PDGF 
coacervate was made by mixing 1.5µl of 1µg/µl of PDGF (1.5µg dose) with 3µl of 5mg/ml 
heparin first, then with 3µl of 25mg/ml of PEAD, at PEAD:heparin:PDGF mass ratio of 
50:10:1, creating 7.5µl PDGF coacervate solution, which was added to 82.5µl of 20mg/ml 
fibrinogen solution containing 1.5µg VEGF, and then 5µl of 1mg/ml aprotonin was added 
(Sigma-Aldrich, St. Louis, MO). Lastly, 5µl of 1.5mg/ml thrombin (Sigma-Aldrich, St. Louis, 
MO) was added and the total solution was injected shortly before gelation occurred, 
approximately 40 seconds after mixing (Figure 16A). All solutions were prepared in 0.9% 
sterile saline. The chest was closed and the rat was allowed to recover. At multiple time points, 
rats were imaged using echocardiography. At 4 weeks after MI, animals were sacrificed and 
hearts were harvested for histological and immunohistochemical evaluations. 
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3.2.6 Echocardiography 
Echocardiography was performed 2 days before surgery (baseline) and at 2, 14, and 28 days 
post-MI surgery to evaluate cardiac function. Rats (n=7 per group) were anesthetized then 
maintained with 1-1.5% isoflurane gas throughout the echocardiographic study. Rats were 
placed in the supine position, immobilized on a heated stage equipped with echocardiography, 
and the hair in the abdomen was removed. The body temperature was maintained at 37°C. 
Short-axis videos of the left ventricle (LV) by B-mode were obtained using a high-resolution in 
vivo small animal imaging system (Vevo 2100, Visual Sonics, Ontario, Canada) equipped with 
a high-frequency linear probe (MS400, 30 MHz) (FUJIFILM VisualSonics, Canada). End-
systolic (ESA) and end-diastolic (EDA) areas were measured using NIH ImageJ and fractional 
area change (FAC) was calculated as: [(EDA-ESA)/EDA]×100%. Percent improvements of one 
group over another were calculated as the difference between the % drops in FAC values of the 
first and second groups divided by the higher % drop of the two groups.  
3.2.7 Histological analysis 
At 4 weeks post-infarction, rats were sacrificed by injecting 2ml of saturated potassium chloride 
(KCl) solution (Sigma Aldrich, St. Louis, MO) in the LV to arrest the heart in diastole. Hearts 
were harvested and frozen in O.C.T compound (Fisher Healthcare, Houston, TX). Specimens 
were sectioned at 6µm thickness from apex to the ligation level with 500µm intervals. Sections 
were fixed in 2-4% paraformaldehyde (fisher Scientific, Fair Lawn, NJ) prior to all staining 
procedures.  
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Hematoxylin and eosin (H&E) staining was performed for general evaluation. H&E 
stained slides were randomly selected (n=5-6 per group) and the ventricular wall thickness in 
the infarct zone was measured near the mid-section level of the infarct tissue using NIS 
Elements AR imaging software (Nikon Instruments, Melville, NY). 
For assessment of fibrosis, picrosirius red staining was used to stain collagen fibers and 
imaged under polarized light. The fraction area of collagen deposition in the infarct region was 
measured by NIS Elements AR software near the mid-section level of the infarct tissue (n=5-6 
per group). An object count tool was used to include RGB pixels specific to the stained collagen 
fibers in the infarct area by defining a proper threshold value. 
3.2.8 Immunohistochemical analysis 
For evaluation of inflammation, a mouse anti-rat CD68 (1:100, Millipore, Temecula CA), a 
pan-macrophage marker, was used followed by an Alexa fluor 594 goat anti-mouse antibody 
(1:200, Invitrogen, Carlsbad, CA). Slides were counterstained with 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Carlsbad, CA). For quantification near the mid-section level 
of the infarct tissue, CD68-positive cells were counted in two opposite regions of the infarct 
border zone, averaged, and reported per mm2 areas (n=4-5 per group).  
For evaluation of angiogenesis, ECs were detected by a rabbit polyclonal von 
Willebrand factor (vWF) antibody (1:200, US Abcam, Cambridge, MA) followed by an Alexa 
fluor 594 goat anti-rabbit antibody (1:200). Mural cells were detected by a FITC-conjugated 
anti-α-smooth muscle actin (α-SMA) monoclonal antibody (1:500, Sigma Aldrich, St. Louis, 
MO). Slides were last counterstained with DAPI. For quantification near the mid-section level 
of the infarct tissue, vWF-positive vessels (defined as those with lumen) and α-SMA-positive 
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vessels were counted in two opposite regions of the infarct border zone, averaged, and reported 
per mm2 areas (n=4-5 rats per group). 
For evaluation of cardiac muscle viability, a mouse anti-rat cardiac troponin I (cTnI) 
antibody (1:200, US Abcam, Cambridge, MA) followed by an Alexa fluor 488 goat anti-mouse 
antibody (1:200, Invitrogen, Carlsbad, CA). Slides were counterstained with DAPI. The fraction 
area of viable cardiac muscle in the infarct region was measured by NIS Elements AR software 
near the mid-section level of the infarct tissue (n=4-5 per group). An object count tool was used 
to include RGB pixels specific to the stained viable cardiac muscle in the infarct area by 
defining a proper threshold value. 
3.2.9 Statistical analysis 
Results are presented as means ± standard deviations (SD). GraphPad Prism 5.0 software (La 
Jolla, CA) was used for statistical analysis. Statistical differences between groups were analyzed 
by one-way ANOVA (multiple groups) or two-way repeated ANOVA (repeated 
echocardiographic measurements) with 95% confidence interval. Bonferroni multiple 
comparison test was performed for ANOVA post-hoc analysis. Statistical significance was set 
at p<0.05. 
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3.3 RESULTS 
3.3.1 Fibrin gel-coacervate system achieves sequential delivery 
Previously, we studied VEGF release from the coacervate which was relatively slow likely 
because of its mid-range affinity for heparin (Dissociation constant kd=165nM) [272, 293]. With 
a weaker heparin-binding affinity (kd=752nM), PDGF release from the coacervate occurs faster 
than for VEGF (Appendix A) [298]. A proper therapeutic angiogenesis process needs a 
sequential release of VEGF first followed by PDGF. Therefore, the coacervate alone was not 
enough to achieve sequential release (Appendix A). In order to obtain faster VEGF release, we 
embedded it in a fibrin gel without loading it into the coacervate. We then loaded PDGF in the 
coacervate and embedded it in the same fibrin gel to sustain its release (Figure 16A). The 
loading efficiencies were 87% for VEGF and 97% for PDGF as observed 1 hour after loading. 
Approximately 44% of the VEGF released by day 1, while only 14% of PDGF released during 
the same period (Figure 16B). Having a significant release of VEGF by day 1 might prove 
beneficial for angiogenesis and heart function after MI [299]. This delivery system achieved 
sequential release kinetics, where 95% of VEGF was released by 1 week and only 40% of 
PDGF, which continued to release up to 75% after 3 weeks (Figure 16B). The in vivo release 
rate can be further influenced by fibrinolysis, hydrolytic degradation of the PEAD polycation, 
enzymatic degradation by esterases and heparinases, and dissociation of the coacervate in an 
ionic environment. Thus, in vivo release is expected to be faster. Overall, the release kinetics 
attained with the fibrin gel-coacervate delivery vehicle may enhance the formation of 
neovasculature based on the physiological roles of VEGF and PDGF during angiogenesis [17, 
289]. 
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Figure 16. (A) The delivery system was comprised of a fibrin gel embedding VEGF and PDGF-loaded 
coacervates. The coacervate was formed through electrostatic interactions by combining PDGF with heparin 
then with PEAD polycation. (B) The delivery system described achieved sequential quick release of VEGF 
followed by a sustained release of PDGF. Data are presented as means ± SD (n=3 per group). 
3.3.2 PDGF coacervate induces SMC chemotaxis and proliferation 
We reported previously on VEGF bioactivity in free form and using the coacervate [293]. Here, 
we evaluated the effect of PDGF released from the coacervate on SMC migration using a 
porous cell culture inserts. Free PDGF induced significantly more SMC migration compared to 
controls (p<0.001), however the same dose of PDGF delivered by the coacervate had the 
greatest chemotactic effect compared to all groups (p<0.001) (Figure 17A,B). The empty 
vehicle was also demonstrated to be inert with no effect on cell migration compared to basal 
media alone.   
We also tested the effect of coacervate-released PDGF on SMC proliferation using a 
BrdU assay. BrdU is a thymidine analog that incorporates into newly synthesized DNA strands 
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of actively proliferating cells. Again, we observed no significant effect of the empty vehicle 
compared to basal media control. Both free PDGF and PDGF coacervate induced significant 
SMC proliferation compared to control groups (p<0.01). However, PDGF coacervate also 
increased cell proliferation compared to free PDGF (p<0.01) (Figure 17C). Collectively, these 
results demonstrate that PDGF released from the coacervate is highly bioactive and can 
stimulate proliferation and migration of SMCs in vitro. 
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Figure 17. (A) After 12h, images show more migrated SMC through the cell culture insert membrane 
towards PDGF coacervate compared to other groups. Scale bar=250µm. (B) Although free PDGF 
significantly induced migration compared to control, it was less than PDGF coacervate which significantly 
enhanced migration compared to all other groups. (C) After 48h, free PDGF induced significantly more 
SMC proliferation than controls, while PDGF coacervate induced significantly more proliferation than all 
groups. Data are presented as means ± SD (n=3 per group). * p<0.05 vs basal media. ≠ p<0.05 vs free PDGF. 
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3.3.3 Sequential delivery improves endothelial proliferation and vessel sprouting 
In order to evaluate the potential benefit of sequential release of VEGF and PDGF, we 
performed EC proliferation and aortic ring vessel sprouting assays. We hypothesized that high 
initial PDGF concentrations would reduce the effect of VEGF on ECs. Free VEGF+PDGF 
induced significantly more proliferation than basal media (p<0.01), but not more than empty 
vehicle (p>0.05), which showed no difference compared to basal media. However, sequentially 
delivered VEGF+PDGF induced significantly more proliferation than both controls and free 
GFs (p<0.001) (Figure 18A). 
In the aortic ring assay, free VEGF+PDGF induced significantly more microvessel 
outgrowth and greater sprouting area from ring segments compared to basal media (p<0.01), but 
not to empty vehicle (p>0.05). In contrast, sequential delivery showed significantly larger 
sprouting area than all groups (p<0.001) (Figure 18B,C). Taken together, these experiments 
suggest that PDGF has some antagonistic effect on VEGF-mediated angiogenic responses in 
vitro which can be avoided by a sequential delivery approach. 
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Figure 18. After 48h, free VEGF+PDGF induced significantly more endothelial proliferation than basal 
media, while sequential delivery of VEGF and PDGF induced significantly more proliferation than all 
groups. (B) After 6 days, rat aortic ring assay shows that free VEGF+PDGF induced significantly larger 
microvasculature sprouting area than basal media. Sequential delivery induced significantly larger 
sprouting areas compared to all groups. (C) Representative images show microvasculature formation 
around rat aortic rings, with more sprouting observed in the sequential delivery group. Data are presented 
as means ± SD (n=3 per group). * p<0.05 vs basal media. ≠ p<0.05 vs free GFs. Scale bar=500µm. 
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3.3.4 Sequential delivery of VEGF and PDGF improves overall cardiac function 
We next evaluated the in vivo effect of sequential delivery in a rat MI model comparing saline, 
empty vehicle, free VEGF+PDGF, and sequentially delivered VEGF+PDGF. We evaluated 
changes in LV contractility using 2-D echocardiography and reported heart function as 
fractional area change (FAC). ESA and EDA values were statistically similar for all groups 
(p>0.05) suggesting little to no effect on ventricular dilation over the time period evaluated 
(Figure 19A,B).  
MI induction was confirmed by a significant drop in FAC 2 days after infarction (Figure 
19C). No significant differences were found between groups at baseline or at day 2 (p>0.05). At 
2 weeks, sequential delivery group showed a significant improvement in cardiac function 
compared to all other groups (p<0.001) (Figure 19C). No significant differences were found 
between saline, empty vehicle, and free GFs values at 2 weeks (p>0.05). At 4 weeks, FAC 
declined slightly for all groups, but sequential delivery group maintained its improvement in 
cardiac function with a significantly higher FAC compared to all groups (p<0.001). FAC values 
were approximately 30% for saline, 32% for empty vehicle, 34% for free GFs groups, and 44% 
for sequential delivery (Figure 19C). The sequential delivery value represented a 66% 
improvement over saline at 4 weeks, a slight decline from 68% at 2 weeks. The ability of 
sequential delivery to improve and maintain the cardiac function 4 weeks after MI stresses the 
importance of spatiotemporal presentation towards the effectiveness of VEGF and PDGF. 
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Figure 19. (A) End-systolic area (ESA) and (B) End-diastolic area (EDA) showed no statistical difference 
between groups during the evaluated period(C) Fractional area change (FAC) reflected a significantly 
improved cardiac contractility at 2 wks and maintained at 4 wks in the sequential delivery group compared 
to all groups. Data are presented as means ± SD (n=7 per group). * p<0.05 vs saline. ≠ p<0.05 vs free GFs. 
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3.3.5 Sequential delivery reduces ventricular wall thinning and fibrosis in the infarcted 
myocardium 
After evaluation of overall cardiac function, we performed investigations at the tissue level 
using histology and immunohistochemistry. At 4 weeks, H&E stained tissue showed increased 
granulated scar tissue areas with significantly thinner LV walls in the infarct region in saline, 
empty vehicle, and free GFs groups with no statistical differences in wall thicknesses between 
them (p>0.05). In contrast, sequential delivery showed significantly thicker LV walls compared 
to all groups (p<0.01) with less scar tissue and granulation replacing normal cardiac muscle 
(Figure 20A,B). This demonstrates the benefit of our therapy in preserving the ventricular wall 
structure. 
The extent of fibrosis was assessed using picrosirius red staining. Collagen deposition 
was quantified and found to be significantly less in the sequential delivery group (p<0.05) 
compared to all other groups which contained dense deposition of fibrillar collagen along the 
LV wall and extended to the infarct border zone (Figure 20C,D). The area fractions of collagen 
deposition were approximately 36% for saline, 32% for empty vehicle, 31% for free GFs, and 
19% for sequential delivery (Figure 20C). The reduced fibrosis and LV wall thinning due to 
sequential delivery of VEGF and PDGF is likely a contributing factor to the enhanced cardiac 
contractility since less fibrotic tissue reduces the stiffening of the ventricular walls and the 
extent of cardiac remodeling that occurs after MI [300]. 
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Figure 20. (A) At 4 weeks, H&E staining showed ventricular wall thinning with damaged cardiac muscle 
surrounded by scar tissue in saline, empty vehicle, and free GFs groups. However, these damages were 
apparently alleviated in the sequential delivery group. Scale bar=1000µm. Quantitative analysis showed (B) 
significantly reduced ventricular wall thinning and (C) significantly reduced fibrosis in the sequential 
delivery group compared to all groups. (D) At 4 weeks, picrosirius red staining images show the dense 
collagen deposition areas along the LV wall and infarct zone in saline, empty vehicle, and free GFs groups. 
Collagen deposition was significantly reduced in the sequential delivery group. Data are presented as means 
± SD (n=5-6 per group). * p<0.05 vs saline. ≠ p<0.05 vs free GFs. Scale bar=1000µm. 
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3.3.6 Sequential delivery provides persistent angiogenesis in the infarcted myocardium 
Restoring blood flow to the infarcted myocardium through robust angiogenesis is key to tissue 
regeneration and functional recovery. To investigate the development of mature and stable 
vasculature in the borderzone of the infarct region, we stained for the EC marker vWF and 
pericyte marker α-SMA (Figure 21A). In addition to being an EC marker, vWF is a marker of 
cell homeostasis and can be used to evaluate the functionality of new blood vessels [301]. After 
4 weeks, free VEGF+PDGF group showed a significantly higher number of vWF-positive 
vessels (p<0.05) in comparison to saline and empty vehicle groups which showed only few 
vessels in the borderzone zone (Figure 21A,B). In contrast, sequential delivery showed an 
increase in vWF-positive vessels that was significantly higher than all groups (p<0.001). This 
suggests that sequential release of VEGF and PDGF helped improve the formation of 
neovessels with increased functionality. 
The stability and maturity of new vasculature and prevention of its regression is very 
important for successful ischemic tissue repair. The goal of therapeutic angiogenesis is therefore 
to produce neovasculature that is not transient but rather is long-term, stable, mature, and 
robust. To examine the maturity of neovessels, we stained for α-SMA to detect pericytes 
associated with newly formed vWF-positive vessels (Figure 21A). Few α-SMA-vWF-positive 
vessels were found in saline, empty vehicle, and free GFs groups with no statistical difference 
among them (p>0.05). On the other hand, sequential delivery showed significantly more α-
SMA-vWF-positive vessels than all groups (p<0.001) likely due to the recruitment of pericytes 
by PDGF released in a sustained manner by the fibrin gel-coacervate delivery system (Figure 
21A,C). These results indicate the formation of stable and mature neovessels including 
capillaries and arterioles that are likely involved in tissue perfusion. This robust angiogenesis 
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process is seemingly a key factor in the observed improvement of cardiac contractility at the 
functional level. 
 
Figure 21. (A) Representative images show co-staining of vWF (red) and α-SMA (green) that reflect the level 
of neovessel formation, their functionality and maturity, with noticeable improved angiogenesis in the 
sequential delivery group at 4 weeks. Scale bar=200µm. (B) Saline and empty vehicle groups show few vWF-
positive vessels. While free GFs induced significantly more vWF-positive vessels than controls, sequential 
delivery induced significantly more than all groups. (C) Sequential delivery induced significantly more α-
SMA-vWF-positive vessels than all groups. Data are presented as means ± SD (n=4-5 per group). * p<0.05 vs 
saline. ≠ p<0.05 vs free GFs. 
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3.3.7 Sequential delivery maintains cardiac viability in the infarcted myocardium 
Cardiomyocyte survival is essential to maintain proper contractile function of the LV after MI. 
The viability of the cardiac muscle in the infarcted myocardium was examined by staining for 
cardiomyocyte marker cTnI (Figure 22A). At 4 weeks, saline, empty vehicle, and free GFs 
groups showed reduced cardiomyocyte survival in the infarct region with cTnI-positive area 
fractions of approximately 31%, 29%, and 27%, respectively (Figure 22A,B). There was no 
statistical differences noted among the three groups (p>0.05). In contrast, sequential delivery 
showed a significantly higher cTnI-positive area fraction of 56% in the infarct region compared 
to all groups (p<0.05) suggesting better viability and preservation of the cardiac myofibers 
which help in the improvement of overall cardiac function (Figure 22A,B).  
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Figure 22. (A) At 4 weeks, cardiac troponin I (cTnI) staining (green) showed a less viable cardiac muscle in 
saline, empty vehicle, and free GFs groups, while sequential delivery group significantly preserved a larger 
area of viable cardiac muscle in the infarct zone. Scale bar=500µm. (B) Quantitative analysis revealed that 
the sequential delivery group showed a significantly larger cTnI-positive area fraction in the infarct region 
compared to all groups. Data are presented as means ± SD (n=4-5 per group). * p<0.05 vs saline. ≠ p<0.05 vs 
free GFs. 
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3.3.8 Sequential delivery reduces inflammation in the infarcted myocardium 
Reducing inflammation triggered by MI is an important goal towards recovery and repair of the 
myocardium [66]. Local inflammation in the infarct zone was evaluated by staining for a pan-
macrophage marker, CD68 (Figure 23A). At 4 weeks, we observed that both free GFs (p<0.05) 
and sequential delivery (p<0.001) groups significantly reduced the presence of macrophages 
compared to saline (Figure 23B). Sequential delivery group showed many less macrophages 
than free GFs group, however no statistical difference was found between the two (p>0.05). 
Saline and empty vehicle groups showed a high presence of CD68-positive cells (Figure 
23A,B). This result suggests a role for VEGF and/or PDGF in reducing macrophage infiltration 
into the infarct zone after MI possibly due to reduced tissue damage or down-regulation of pro-
inflammatory cytokines. 
 95 
 
Figure 23. (A) Representative images of CD68 (red) staining show less positive cells in free GFs and 
sequential delivery groups at 4 weeks. Scale bar=250µm. (B) Quantitative analysis showed large numbers of 
CD68-positive cells in saline and empty vehicle groups, while significantly less cells were found in free GFs 
group and even less in sequential delivery group. Data are presented as means ± SD (n=4-5 per group). * 
p<0.05 vs saline. 
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3.4 DISCUSSION 
With the aim of promoting tissue repair and functional recovery, restoring the blood supply to 
ischemic tissues through therapeutic angiogenesis remains an exciting route. VEGF and PDGF 
are potent angiogenic factors with relatively distinct roles [17]. One key to successful 
therapeutic angiogenesis is careful consideration of the spatiotemporal profiles of administered 
GFs. It has been shown that VEGF can inhibit PDGF signaling where VEGFR-2, activated by 
VEGF, complexes with PDGFR-β to block its signal transduction, thus compromising its role in 
pericyte recruitment and neovessel stabilization [39]. One study using synthetic modified RNA 
encoding human VEGF concluded that VEGF administration can effectively improve heart 
function when present for just 2 days after MI [299]. This strongly suggests that certain GFs are 
only needed in the early stage of angiogenesis, while others should be present in the later stages. 
Administration of various angiogenic GFs has been studied for a long time [16, 20, 27]. 
However, most strategies showed limited therapeutic effect because they focus on delivering 
single GFs involved in the early stages of angiogenesis, while overlooking the importance of 
stabilizing the sprouting neovessels through the actions of late-stage GFs [17, 195, 208]. With a 
more comprehensive understanding of the mechanisms of angiogenesis, researchers realized the 
need to administer more than one GF in their therapeutic strategies [195]. However, these 
therapies still demonstrated low efficacy when important factors such as the spatiotemporal 
presentation and protection of GFs were not considered. For example, one study found that 
combinatorial plasmid gene transfer of VEGF and PDGF did not improve angiogenesis more 
than single plasmid treatments did in infarcted rat myocardium [302]. When the shortcomings 
of bolus injections were realized, investigators shifted their focus towards controlled delivery 
vehicles capable of sequential and spatiotemporal presentation of GFs. Factors such as GF 
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loading efficiency, spatiotemporal profiles, burst releases, control over release kinetics, GF 
bioactivity and bioavailability, and cost of manufacturing are challenges that should be 
addressed to create an effective delivery system [191, 195, 208, 210, 274]. Several systems 
demonstrated the ability to sequentially deliver two GFs, however they are not injectable, and 
thus difficult to apply towards treating heart diseases [40, 42, 303, 304].  Others were able to 
develop injectable platforms that displayed the benefit of sequential delivery using various GFs 
and in vivo models [41, 215, 305, 306]. 
In studies where an early-stage factor was presented first followed by a late-stage factor, 
improved angiogenic responses over single factors or non-sequential delivery were observed. 
For example, when presented simultaneously, PDGF-BB and Ang1 inhibited the VEGF and 
Ang2-mediated EC sprouting and pericyte detachment in vitro and microvessel formation in a 
subcutaneous implant in vivo model; yet presentation of PDGF-BB and Ang1 at a later stage 
enhanced the angiogenic process [40]. Similarly, when applied together, FGF-2 and PDGF-BB 
were shown to inhibit each other; however, sequential delivery of FGF-2 followed by PDGF-
BB improved EC migration, EC and vascular pericyte colocalization, and functional 
angiogenesis in a subcutaneous implant model [43]. These results are in support of our in vitro 
findings regarding antagonism between VEGF and PDGF signaling. Therefore, in order to 
achieve a robust angiogenic response, therapies must take into consideration the multiple GFs 
involved, their spatiotemporal cues in the natural tissue microenvironment, and the translational 
potential of the delivery platform. 
The delivery system described in this study is based on a combination of fibrin gel and a 
complex coacervate for sequential delivery of VEGF followed by PDGF. The coacervate 
contains heparin and a biocompatible polycation, PEAD, which closely and advantageously 
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imitates the native signaling environment involving extracellular matrix proteoglycans, ligands, 
and cell receptors [233, 285, 307, 308]. This vehicle can protect the GFs from rapid enzymatic 
degradation and potentiate their bioactivities [235].  
We demonstrated that the fibrin gel-coacervate composite achieved early release of 
VEGF to trigger EC proliferation and sprouting and delayed release of PDGF to recruit 
pericytes that stabilize the newly formed vessels. Even though PDGF is still present in the early 
stage, our delivery system largely limited its overlap with VEGF presence and thus limited the 
antagonism between the two factors. Our in vitro assays demonstrated that PDGF coacervate 
significantly improved SMC proliferation and migration. We also showed the importance of 
sequential delivery of VEGF followed by PDGF towards EC proliferation by limiting PDGF-
mediated inhibition of VEGF angiogenic effects, concurring with previous reports [39, 40, 43]. 
The benefit of sequential release was further demonstrated by improved microvasculature 
sprouting from rat aortic rings.  
In vivo, we demonstrated using a rat MI model that the fibrin gel-coacervate system led 
to a robust angiogenic response with extensive formation of mature and functional blood vessels 
in the infarct zone. The significant increase in the number of vWF- and α-SMA positive vessels 
reflects the formation of new, stable, and mature vasculature. Our results further demonstrate a 
reduction in myocardial fibrosis, thus mitigating the loss in contractile function [66, 300]. 
Moreover, cardiomyocyte survival, essential for preserving contractile function, was improved 
as a result of sequential delivery of VEGF and PDGF. Several variables not investigated in this 
study may have played a role in the improvement of cardiomyocyte survival and angiogenesis. 
For example, VEGF has been shown to elevate the levels of nitric oxide (NO) [309, 310], which 
is a potent vasodilator and an endothelial survival factor that prevents apoptosis and improves 
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EC proliferation and migration [311]. Vasodilation soon after infarction may improve 
cardiomyocyte survival. VEGF also improves FGF-2-mediated angiogenesis [292]. Moreover, 
VEGF induces the release of SDF-1α which promotes cardiac stem cell and other progenitor 
cell mobilization to the infarct region [31]. In addition to its role in stabilizing neovessels, 
PDGF can also activate cardioprotective signaling pathways in cardiomyocytes [249].  
Maintaining a viable cardiac muscle is essential to improving cardiac function after MI as 
demonstrated in studies attempting to stimulate proliferation of cardiomyocytes, prevent their 
apoptosis, and recruit cardiac progenitor cells to the heart [10, 102, 106, 312-315]. Moreover, 
we demonstrated that sequential delivery of VEGF and PDGF reduced the presence of 
macrophages in the infarct zone 4 weeks after MI. This reduction might be due to indirect 
VEGF and/or PDGF down-regulation of pro-inflammatory cytokines. It is also possible that the 
improved angiogenesis and better preservation of cardiac muscle observed in our study reduced 
tissue damage, which may have in turn reduced inflammation. The culmination of these many 
benefits was reflected on a functional level by improved cardiac contractility with 
approximately 66% improvement over untreated infarcted hearts at 4 weeks.  
Many studies have investigated different types of delivery vehicles for spatiotemporal 
control over the release or expression of two or more GFs [40, 42, 43, 303-306, 316-319]. 
However, very few have been tested in an animal model of MI [41, 215, 320]. In a study testing 
sequential delivery of VEGF and PDGF to the infarcted myocardium, an increased systolic 
velocity-time integral, a measure of displacement of the myocardium during contraction, was 
reported, but surprisingly no significant improvement in ejection fraction or LV end-systolic 
dimension was observed compared to saline control or single GF delivery [41]. Our study 
demonstrates significantly improved cardiac function through the measurement of LV 
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contractility based on the FAC parameter. This functional improvement is corroborated by 
comprehensive histological and immunohistochemical analyses showing the beneficial effects 
of sequential delivery of VEGF and PDGF at the tissue level of the infarct region. 
3.5 CONCLUSIONS 
This study demonstrated that sequential controlled release of VEGF and PDGF can trigger the 
formation and stabilization of neovasculature, and improve cardiac function after MI in a rat 
model. The improvement was reported at 2 weeks and maintained at a similar level at 4 weeks. 
Improvements at the tissue level include increased mature blood vessel formation, 
cardiomyocyte survival, and decreased collagen deposition and inflammation in the infarct 
zone. These results suggest that VEGF and PDGF released spatiotemporally by the fibrin gel-
coacervate delivery system can induce robust angiogenesis, reduce scar burden, and potentially 
halt the pathological progression post MI.  
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4.0  DEVELOPMENT OF A COMPREHENSIVE CARDIAC REPAIR APPROACH 
BY SPATIOTEMPORAL DELIVERY OF COMPLEMENTARY PROTEINS 
After a heart attack, the infarcted myocardium is in urgent need for repair and regeneration to 
reestablish functionality and prevent death. Protein signaling plays a pivotal role in the natural 
tissue regeneration and repair process. With multiple pathologies developing after myocardial 
infarction (MI), treatment therapies should develop a comprehensive controlled release strategy 
that delivers therapeutic proteins spatiotemporally to prevent or reverse these pathologies. Here, 
we studied the combination of four complementary factors: tissue inhibitor of 
metalloproteinases 3 (TIMP-3) and interleukin-10 (IL-10) were embedded in a fibrin gel for 
early release, while basic fibroblast growth factor (FGF-2) and stromal cell-derived factor 1 
alpha (SDF-1α) were embedded in heparin-based coacervates and distributed inside the same 
gel for a more sustained release. After optimizing this combination, we tested the efficacy of the 
spatiotemporal delivery of TIMP-3, FGF-2, and SDF-1α to the infarcted heart in a rat MI 
model. We report its significant ability to augment revascularization, myocardial elasticity, 
cardiomyocyte survival, and stem cell homing; reduce remodeling, dilation, inflammation, 
fibrosis, and extracellular matrix (ECM) degradation; and improve overall contractile function 
of the heart. Overall, our strategy indicates that addressing the multi-faceted pathological nature 
of MI is paramount to a successful repair and regeneration therapy. 
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4.1 INTRODUCTION 
Myocardial infarction (MI) affects 7.6 million Americans. Approximately 720,000 Americans 
experience a heart attack each year, or one American every 44 seconds [2]. MI leads to the 
prolonged starvation of a portion of the heart muscle of blood flow, oxygen, and nutrients due to 
an occlusion in one of the two coronary arteries. This leads to defects in the contractile function 
of cardiomyocytes and alterations in the extracellular matrix (ECM) and the left ventricle (LV) 
geometry. The ischemic cardiac tissue starts experiencing necrosis and cell apoptosis, 
perivascular fibrosis, and fibrillar collagen deposition around myocytes. As a result of all these 
pathological changes, a scar tissue forms and a pathological remodeling of the ventricle starts, 
eventually leading to congestive heart failure. Current treatments for MI patients, such as 
reperfusion, β-blockers, and ACE inhibitors, do not suffice. They are able to delay further 
damage to the heart, but have not been successful at inducing significant cardiac repair and 
regeneration. Therefore, alternative and more comprehensive therapies that can reduce the 
damage of infarction, prevent or reverse the multiple pathologies developed by MI, regenerate 
the myocardium, and restore cardiac function are urgently needed.  
In this work, we explored the efficacy of the controlled and timed release of a 
combination of complementary proteins, which are relatively distinct in their roles in cardiac 
function. Tissue inhibitor of metalloproteinases 3 (TIMP-3), interleukin-10 (IL-10), basic 
fibroblast growth factor (FGF-2), and stromal cell-derived factor 1 alpha (SDF-1α) are proteins 
with therapeutic potential in cardiac repair and regeneration (Figure 24). TIMP-3 inhibits the 
activity of matrix metalloproteinases (MMPs) which cleave ECM proteins [136]. Therefore, 
TIMP-3 might have an essential role in reducing ECM degradation early after infarction. IL-10 
is an anti-inflammatory cytokine that has been shown to suppress infiltration of inflammatory 
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cells into the myocardium [67, 314]. FGF-2 plays a chief role in formation of neovasculature by 
inducing the proliferation, migration, and differentiation of vascular cells and enhancing the 
signaling of other angiogenic factors [16, 20]. SDF-1α is a potent chemotactic factor that can 
recruit stem cells to the infarct region [118, 119, 321]. TIMP-3 and IL-10 were intended to 
modulate, but not eliminate ECM degradation and inflammation soon after MI. FGF-2 and 
SDF-1α were intended to promote angiogenesis and recruit progenitor cells to the infarct region 
at the later stage of the repair process. Therefore, we designed a composite hydrogel comprised 
of fibrin gel and heparin-based coacervate to achieve the sequential release of TIMP-3 and IL-
10 followed by FGF-2 and SDF-1α. To achieve this controlled release, TIMP-3 and IL-10 were 
encapsulated in fibrin gel to offer early release, while FGF-2 and SDF-1α were encapsulated in 
heparin-based coacervates and distributed in the same fibrin gel to offer a sustained release 
(Figure 25A). We have utilized the fibrin gel-coacervate composite previously to sequentially 
release proteins for therapeutic angiogenesis post-MI [322]. Coacervates can be formed by 
electrostatic interactions between a polycation and a polyanion [234, 235]. We utilize a 
synthetic polycation poly(ethylene argininylaspartate diglyceride) (PEAD), the natural 
polyanion heparin, and heparin-binding proteins to form protein-loaded coacervates that have 
been shown to encapsulate proteins with high efficiency and sustain their release for a long time 
[235, 293].   
The endogenous biological system and tissue repair process are intrinsically very 
complex with many proteins involved, some of which interact with each other. Considering the 
four proteins of interest in our study and the combinations of controls that can result from them, 
it is cost-prohibitive to test all possible combinations and doses. To address this challenge, we 
used factorial design of experiments (DOE), a powerful statistical method, to reduce study 
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groups [323, 324]. Fractional factorial designs are commonly utilized in scientific studies and 
industrial applications. However, they have not been taken advantage of as commonly in 
biomedical research. These designs have been utilized previously to study drug combinations 
for treating Herpes simplex virus type 1 (HSV-1) and as a method to investigate the effects of 
different processing parameters for a tissue-engineering scaffold [325, 326]. Fractional factorial 
designs allow us to build statistical models using a small number of subjects. Such models can 
identify proteins important for therapeutic outcome, potential protein interactions, optimal 
protein doses, and optimal protein combinations.  
Using a fractional factorial design, this initial combination of four proteins was 
optimized based on the contribution and dose of each protein to improve cardiac function after 
MI. The experimental results showed significant contributions of TIMP-3, FGF-2, and SDF-1α 
at improving cardiac function 4 weeks after MI. The optimized protein combination was then 
tested in an in-depth study for efficacy in cardiac repair and regeneration post-infarction. We 
demonstrate that the controlled and timed release of TIMP-3, FGF-2, and SDF-1α at optimized 
doses can significantly improve cardiac function and repair. Functional and histological 
evaluations were performed at 2 and/or 8 weeks after MI in a rat model. Improvements at the 
tissue level are reported through increased myocardial strain levels, angiogenesis, 
cardiomyocyte survival, stem cell homing, and reduced ventricular dilation, ECM degradation, 
inflammation, fibrosis, MMP activity, and cell apoptosis. We demonstrate, for the first time, 
that a more comprehensive therapy of controlled delivery of complementary proteins can 
mitigate the MI injury and set into motion a robust cardiac repair process, giving hope of 
driving the functional and structural recovery of the infarcted heart to a new level. 
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Figure 24. The four proteins FGF-2, SDF-1α, IL-10, and TIMP-3 have relatively distinct, but 
complementary cardiac functions. FGF-2 promotes angiogenesis by endothelial sprouting and pericyte 
recruitment and also cardiomyocyte survival. SDF1-α has the critical role of recruiting cardiac, endothelial, 
hematopoietic, and mesenchymal stem and progenitor cells to the infarcted area, while also promoting 
angiogenesis and cardiomyocyte survival. IL-10 reduces inflammation by inhibiting the infiltration of 
immune cells into the myocardium and also reduces cardiomyocyte death. TIMP-3 helps preserve the 
cardiac ECM structure by inhibiting the activity of MMPs and also promotes anti-inflammatory activities 
and cardiomyocyte survival. 
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4.2 MATERIALS AND METHODS 
4.2.1 Release assay of complementary proteins 
PEAD was synthesized as previously described [237]. The release assay was performed using 
100ng of each of TIMP-3 (R&D Systems, Minneapolis, MN), IL-10, FGF-2, and SDF-1α 
(PeproTech, Rocky Hill, NJ). All solutions were prepared in 0.9% sterile saline. FGF-2 and 
SDF-1α coacervates were made by mixing 1µl of 100ng/µl for each of FGF-2 and SDF-1α with 
2µl of 5mg/ml heparin first (Scientific Protein Labs, Waunakee, WI), then with 2µl of 25mg/ml 
of PEAD at PEAD:heparin:protein mass ratio of 250:50:1. This formed 6µl of FGF-2/SDF-1α 
coacervates. Fibrin gel-coacervate composite was made by mixing 80µl of 20mg/ml fibrinogen 
(Sigma-Aldrich, St. Louis, MO), 2µl of 5mg/ml heparin,  1µl of 100ng/µl for each of TIMP-3 
and IL-10; then the 6µl FGF-2/SDF-1α coacervates were added, followed by 5µl of 1mg/ml 
aprotonin (Sigma-Aldrich, St. Louis, MO). Lastly, 5µl of 1mg/ml thrombin (Sigma-Aldrich, St. 
Louis, MO) was added to induce gelation, resulting in a 100µl fibrin gel-coacervate composite 
(Figure 25A). A 100µl of 0.9% saline was deposited on top of the gel composite to be collected 
at 1h, 16h, 1, 4, 7, 14, 28, and 42 days. The samples (n=3) were incubated at 37°C. After 
centrifugation at 12,100g for 10 min, supernatant was collected and stored at -80°C to detect 
amount of released proteins by sandwich enzyme-linked immunosorbent assay (ELISA) kits 
(PeproTech, Rocky Hill, NJ) (R&D Systems, Minneapolis, MN). The absorbance at 450/540nm 
was measured by a SynergyMX plate reader (Biotek, Winooski, VT). Standard solutions (n=3) 
that contained 100ng of each of the proteins in free-form in 100µl of 0.9% saline were prepared 
to create standard curves and determine total release. 
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4.2.2 Two-level half fractional factorial design 
We formulated a two-level half fractional factorial design to select the combination of proteins 
and their doses that are the most effective at recovering cardiac function post MI. The two levels 
refer to upper and lower doses for each protein and were chosen based on previous experiments 
and literature review. The half fractional factorial design means half of the total runs were 
performed. For this design, we can estimate all main effects and some 2-factor interactions, 
which is quite reasonable in practice to evaluate the significance of each protein in the 
combination and find the corresponding optimal dose to use in the in-depth study [324].  
Using the design formula 2(k-p) with k = 4 factors, and p = 1 (for half fractional factorial), 
we studied 23= 8 dose groups. From our previous studies, preliminary results, and literature, we 
selected the most commonly used dose for each protein as the high doses and one-fifth of that as 
the low doses. The high doses for FGF-2, SDF-1α, IL-10, and TIMP-3 were 3, 3, 2, and 4µg 
respectively; while the lower doses are 0.6, 0.6, 0.4, and 0.8µg respectively (Table 2). Here, we 
refer to the protein dose as the amount of each protein embedded in the delivery vehicle. For 
example, for the average rat used in this study, a high dose 3 µg would correlate to 
approximately 15 µg /kg body weight (i.e. 3 µg/0.2kg rat). TIMP-3 and IL-10 were 
encapsulated in fibrin gel, while FGF-2 and SDF-1α were encapsulated in heparin-based 
coacervates and distributed in the same fibrin gel (Figure 25A). With n=3 per dose group and a 
sham group, we utilized 27 rats for this initial-stage study.  
Using Minitab statistical software (State College, PA), this initial-stage design provided 
a data collection plan with 8 groups of varying protein doses to be tested (Table 2). Each group 
with varying protein doses was tested in a rat acute MI model. The key outcome measurement 
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of cardiac function was the LV ejection fraction (EF%) computed using cardiac magnetic 
resonance imaging (MRI) at 4 weeks post-MI. Ejection fractions were analyzed in Minitab 
software to provide estimates of the relative importance of each protein and its optimal dose in 
the context of improving cardiac function after MI. The results and analysis of this experiment 
allowed us to proceed to the in-depth study with a refined combination and doses of the 
proteins. 
4.2.3 Rat acute myocardial infarction model 
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approval was 
obtained prior to beginning all animal studies. MI and injections were performed as previously 
described [297]. Briefly, 6-7 week old (175-225g) male Sprague-Dawley rats (Charles River 
Labs, Wilmington, MA) were anesthetized first then maintained with 2% isoflurane at 0.3L/min 
(Butler Schein, Dublin, OH), intubated, and connected to a mechanical ventilator to support 
breathing during surgery. The body temperature was maintained at 37°C by a hot pad. The 
ventral side was shaved and a small incision was made through the skin. Forceps, scissors, and 
q-tips were used to dissect through the skin, muscles, and ribs. Once the heart was visible, the 
pericardium was torn. MI was induced by permanent ligation of the left anterior descending 
(LAD) coronary artery using a 6-0 polypropylene suture (Ethicon, Bridgewater, NJ). Infarct was 
confirmed by macroscopic observation of a change in color from bright red to light pink in the 
area below the ligation suture.  Five minutes after the induction of MI, different treatment and 
control solutions were injected intramyocardially at 3 equidistant points around the infarct zone 
using a 31-gauge needle (BD, Franklin Lakes, NJ). 
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For the factorial design optimization study, 100µl of fibrin gel-coacervate composite 
was prepared as follows: 18µl coacervate solution (PEAD:heparin:protein mass ratio at 50:10:1) 
containing respective doses of FGF-2 and SDF-1α as outlined in Table 2, 65µl of 20mg/ml 
fibrinogen, 10µl of solution containing heparin and respective doses of TIMP-3 and IL-10 as 
outlined in Table 2, 5µl of 1mg/ml aprotonin (Sigma-Aldrich, St. Louis, MO). Lastly, 2µl of 
1.5mg/ml thrombin (Sigma-Aldrich, St. Louis, MO) was added and the total solution was 
injected shortly before gelation occurred, approximately 50 seconds after mixing (Figure 28A). 
The chest was closed and the rat was allowed to recover. After 4 weeks, all animals (n=27) were 
imaged using cardiac MRI and sacrificed. 
For the in-depth study with refined protein combination and doses, four groups (n=56 
rats) were studied: sham, saline, free proteins, and delivered proteins. Empty vehicle (empty 
fibrin gel-coacervate composite) was not tested as a control in this study as it has shown no 
difference to saline in our previous work [322]. The sham group (n=13) underwent the surgery 
in which the heart was exposed and pericardium was torn, then chest was closed and rat 
recovered. The saline group (n=14) underwent the surgery in which MI was induced and 100µl 
of 0.9% sterile saline was injected around the infarct region. The free proteins group (n=14) 
underwent the surgery in which MI was induced and 100µl of 0.9% sterile saline containing 
3µg each of free TIMP-3, FGF-2, and SDF-1α was injected around the infarct region. The 
delivered proteins group (n=15) underwent the surgery in which MI was induced and 100µl of 
fibrin gel-coacervate composite was injected around the infarct region. The fibrin gel-
coacervate composite was prepared briefly as follows: 18µl coacervate solution containing 3µg 
each of FGF-2 and SDF-1α, 67µl of 20mg/ml fibrinogen, 6µl of solution containing heparin and 
3µg of TIMP-3, 5µl of 1mg/ml aprotonin (Sigma-Aldrich, St. Louis, MO). Lastly, 4µl of 
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1.5mg/ml thrombin (Sigma-Aldrich, St. Louis, MO) was added and the total solution was 
injected shortly before gelation occurred, approximately 40 seconds after mixing (Figure 28). 
All solutions were prepared in 0.9% sterile saline. The chest was closed and the rat was allowed 
to recover. At multiple time points, rats were imaged using echocardiography. At 8 weeks, a 
subset was imaged using cardiac MRI. After 2 (n=17) or 8 weeks (n=39), animals were 
sacrificed and hearts were harvested for histological, immunohistochemical, and western blot 
evaluations. 
4.2.4 Echocardiography 
At pre-MI, 1, 2, 5, and 8 weeks post-MI, rats (n=9-10 per group) were anesthetized then 
maintained with 1-1.5% isoflurane gas throughout the echocardiographic study. Rats were 
placed in the supine position, immobilized on a heated stage equipped with echocardiography, 
and the hair in the abdomen was removed. The body temperature was maintained at 37°C. 
Short-axis videos of the LV by B-mode were obtained using a high-resolution in small animal 
imaging system (Vevo 2100, Visual Sonics, Ontario, Canada) equipped with a high-frequency 
linear probe (MS400, 30 MHz) (FUJIFILM VisualSonics, Canada). End-systolic (ESA) and 
end-diastolic (EDA) areas were measured using NIH ImageJ and fractional area change (FAC) 
was calculated as: [(EDA-ESA)/EDA]×100% (Figure 29A). Percent improvements of one 
group over another were calculated as the difference between the % drops in FAC values of the 
first and second groups divided by the higher % drop of the two groups.  
 Myocardial strain level measurements: The ultrasound B-mode frames of LV short-axis 
view acquired at 8 weeks post-MI were analyzed (n=5 rats per group) using a strain analysis 
algorithm (VevoStrainTM, Vevo2100). Five regions of interest (ROI) were selected along the LV 
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mid-wall including one ROI in the anterior lateral (infarcted area) and four ROIs in the anterior 
medial, septal, posterior, posterior lateral (unaffected areas) walls of the LV (Figure 31A). The 
peak strain in the infarcted area was normalized to the average peak strains of the four ROIs in 
unaffected LV walls during full cardiac cycles (from end-diastole to end-diastole). Both radial 
and circumferential strains were computed. The radial strain is defined as the percent change in 
myocardial wall thickness, and the circumferential strain is defined as the percent change in 
myocardial circumference. 
4.2.5 Cardiac MRI 
Cardiac MRI was used to measure LV volumes and ejection fraction from infarcted rat hearts at 
4 weeks for the factorial design study (n=3 per group) or at 8 weeks for the in-depth follow-up 
study (n=5-8 per group). MRI was preformed using a Bruker Biospec 4.7-Tesla 40-cm scanner 
equipped with a 12-cm shielded gradient set, a 72mm transmit RF coil (Bruker Biospin, 
Billerica MA), and a 4-channel rat cardiac receive array (Rapid MR International, Columbus, 
OH).  Rats were induced with isoflurane, intubated, and ventilated at 1mL/100g of body weight 
and maintained at 2% isoflurane in 2:1 O2:N2O gas mixture at 60 BPM.  During the MRI 
procedure rats were continually monitored and rectal temperature was maintained at 37°C with 
warm air (SA Instruments, Stony Brook, NY).   Following pilot scans, rats were imaged using a 
self-gated cine FLASH sequence (IntraGate) with the following parameters: TR/TE= 9.0/3.0 
ms, 40x40mm FOV, 256x256 matrix, FA=10°, and 200 repetitions. 10-12 slices were collected 
to cover the area between the heart apex to the mitral valves with 1.5mm slice thickness with 
common navigator slice (Appendix B). End-systolic and end-diastolic phases were identified 
for each subject and the LV cavity manually traced using NIH ImageJ to determine LV end-
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systolic (ESV) and end-diastolic (EDV) volumes (Figure 30A). These volumes were used to 
compute ejection fraction as EF% = [(EDV-ESV)/EDV]×100%. Percent improvements of one 
group over another were calculated as the difference between the % drops in EF values of the 
first and second groups divided by the higher % drop of the two groups. 
4.2.6 Histological analysis 
At 2 weeks (n=4-5 per group) and 8 weeks (n=5-7 per group) post-infarction, rats were 
sacrificed by injecting 2ml of saturated potassium chloride (KCl) solution (Sigma Aldrich, St. 
Louis, MO) in the LV to arrest the heart in diastole. Hearts were harvested, fixed in 2% 
paraformaldehyde (fisher Scientific, Fair Lawn, NJ) for 1-2 hours, deposited in 30% sucrose 
solution (w/v) overnight, frozen in O.C.T compound (Fisher Healthcare, Houston, TX), and 
stored at -20°C until cryosectioning. Specimens were cryosectioned at 8µm thickness from apex 
to the ligation level with 500µm intervals.  
Hematoxylin and eosin (H&E) staining was performed for general evaluation. H&E 
stained slides were selected and the ventricular wall thickness in the infarct zone (n=3-4 per 
group at 2 wks, n=4-6 at 8 wks) was measured near the mid-section level of the infarct tissue 
using NIS Elements AR imaging software (Nikon Instruments, Melville, NY). 
For assessment of interstitial fibrosis, Picrosirius red staining was used to stain collagen 
fibers and image under polarized light. The fraction area of collagen deposition in the cross-
sectional area of the whole heart was measured by NIS Elements AR software near the mid-
section level of the infarct tissue (n=3-5 per group at 2 wks, n=4-7 at 8 wks). An object count 
tool was used to include RGB pixels specific to the stained collagen fibers in the heart area by 
defining a proper threshold value. 
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4.2.7 Immunohistochemical analysis 
For evaluation of inflammation, a rabbit polyclonal antibody F4/80 (1:100, Santa Cruz 
Biotechnology, Dallas, TX), a pan-macrophage surface marker, was used followed by an Alexa 
fluor 594 goat anti-rabbit antibody (1:200, Invitrogen, Carlsbad, CA). Slides were also co-
stained by a mouse anti-rat CD163 (1:150, Bio-Rad Laboratories, Hercules, CA), an M2 
macrophage phenotype marker, followed by an Alexa fluor 488 goat anti-mouse antibody 
(1:200, Invitrogen, Carlsbad, CA).  Slides were last counterstained with 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Carlsbad, CA). For quantification near the mid-section level 
of the infarct tissue, F4/80-positive and CD163-positive cells were counted in two opposite 
regions of the infarct border zone, averaged, and reported per mm2 areas (n=3-4 rats per group 
at 2 wks).  
For evaluation of cardiac muscle viability, a rabbit polyclonal cardiac troponin I (cTnI) 
antibody (1:200, US Abcam, Cambridge, MA) was used followed by an Alexa fluor 488 goat 
anti-rabbit antibody (1:200, Invitrogen, Carlsbad, CA). Slides were counterstained with DAPI. 
The fraction area of viable cardiac muscle in the cross-sectional area of the whole heart was 
measured by NIS Elements AR software near the mid-section level of the infarct tissue (n=3-5 
per group at 2 wks, n=5-6 at 8 wks). An object count tool was used to include RGB pixels 
specific to the stained viable cardiac muscle in the heart area by defining a proper threshold 
value. 
For evaluation of angiogenesis, endothelial cells (ECs) were detected by a rabbit 
polyclonal von Willebrand factor (vWF) antibody (1:200, US Abcam, Cambridge, MA) 
followed by an Alexa fluor 594 goat anti-rabbit antibody (1:200). Mural cells were detected by 
a FITC-conjugated anti-α-smooth muscle actin (α-SMA) monoclonal antibody (1:500, Sigma 
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Aldrich, St. Louis, MO). Slides were last counterstained with DAPI. For quantification near the 
mid-section level of the infarct tissue, vWF-positive vessels (defined as those with lumen) and 
α-SMA-positive vessels were counted in two opposite regions of the infarct border zone, 
averaged, and reported per mm2 areas (n=3-4 rats per group at 2 wks, n=5-6 per group at 8 
wks).  
For evaluation of stem cell homing, stem/progenitor cells were detected by a rabbit 
polyclonal c-Kit antibody (1:100, Santa Cruz Biotechnology, Dallas, TX) followed by an Alexa 
fluor 488 goat anti-rabbit antibody (1:200). Slides were counterstained with DAPI. For 
quantification near the mid-section level of the infarct tissue, c-Kit-positive cells were counted 
in two opposite regions of the infarct border zone, averaged, and reported per mm2 areas (n=5 
rats per group at 8 wks).  
4.2.8 Molecular markers expression by western blot 
Rat hearts (n=15) were harvested and rapidly stored at −80°C for western blotting. For protein 
extraction, myocardial specimens weighing approximately 100mg were excised from the LV 
generating a composite material comprising a spectrum between normal, infarct, and borderzone 
tissue. The tissues were then homogenized at 0.2µg/ml in a modified lysis RIPA buffer (50mM 
Tris–HCl, 1% NP-40, 20mM DTT, 150mM NaCl, pH=7.4) with protease and phosphatase 
inhibitors. The complex was then centrifuged at 12,100g for 10 min, and the supernatant was 
collected and stored at −80°C until use.  
For total protein content, the extracts above were quantified with Pierce 660nm Protein 
Assay (Thermo Fisher Scientific, Waltham, MA). The equivalent of 100μg protein was 
separated using 11.5% gel and then transferred onto a PVDF membrane (Bio-Rad Laboratories, 
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Hercules, CA). The membrane was blocked with 5% BSA in TBS with 0.05% Tween 20 for 1h, 
then incubated with following antibody solutions: AKT, p-AKT, ERK1/2, p-ERK1/2 (all at 
1:300, Santa Cruz Biotechnology, Dallas, TX), cleaved caspase-3 (1:1,000, Cell Signaling 
Technology, Boston, MA), and GAPDH (1:5000, US Abcam, Cambridge, MA). The 
membranes were washed with TBS 3 times and incubated with secondary antibodies for 2h at 
room temperature. Signals were visualized using the ChemiDicTM XRS + Imaging System (Bio-
Rad Laboratories, Hercules, CA), and band densities were quantified using NIH ImageJ 
software (n=3 per group). 
4.2.9 Myocardial protein secretion levels analysis by ELISA 
The tissue lysates acquired in the western blot section (n=3-4 rats per group) were used for 
detecting the levels of insulin-like growth factor-I (IGF-I), vascular endothelial growth factor 
(VEGF), sonic hedgehog (Shh), and transforming growth factor-β1 (TGF-β1) in the LV 
myocardium. Sandwich ELISA kits for VEGF and IGF-I (PeproTech, Rocky Hill, NJ) were 
used per the manufacturer’s instructions. Lysates were diluted 1:20 for VEGF and 1:50 for IGF-
I. For Shh and TGF-β1, indirect ELISAs were run using rabbit polyclonal antibodies against 
Shh and TGF-β1 (both at 1:30, Santa Cruz Biotechnology, Dallas, TX) followed by a secondary 
biotinylated goat anti-rabbit IgG (1:100, Santa Cruz Biotechnology, Dallas, TX). Lysates were 
diluted 1:15 for Shh and 1:25 for TGF-β1. The absorbance at 450/540nm was measured by a 
SynergyMX plate reader. Results were corrected to account for differences in total protein 
content of samples.  
 116 
4.2.10 MMP-2/9 activity assay 
The tissue lysates acquired in the western blot section (n=3-4 rats per group) were used for 
detecting the activity of MMP-2/9 in the LV myocardium. The Calbiochem InnoZymeTM 
Gelatinase activity assay fluorogenic kit (EMD Millipore, Bellerica, MA) was followed per the 
manufacturer’s instructions. Briefly, lysate samples (diluted 1:2 in activation buffer) were 
incubated with a fluorogenic substrate solution that is highly selective for MMP-2 and MMP-9. 
Gelatinases in the sample lysates of the myocardium cleave the substrate, resulting in an 
increase in fluorescent signal measured at an excitation wavelength of 320nm and an emission 
wavelength of 405nm by a SynergyMX plate reader. The gelatinase control, activated similarly, 
was used at serial dilutions to create a standard curve for converting the fluorescence values of 
MMP activity to concentrations (ng/ml). 
4.2.11 Statistical analysis 
Results are presented as means ± standard deviations (SD). GraphPad Prism 5.0 software (La 
Jolla, CA) and Minitab software (State College, PA) were used for statistical analysis. Statistical 
differences between groups were analyzed by one-way ANOVA (multiple groups) or two-way 
repeated ANOVA (repeated echocardiographic measurements) with 95% confidence interval. 
Bonferroni multiple comparison test was performed for ANOVA post-hoc analysis. Statistical 
significance was set at p<0.05. 
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4.3 RESULTS 
4.3.1 Fibrin gel-coacervate composite achieves sequential protein release 
We have reported the use of the fibrin gel-coacervate composite previously for the early release 
of VEGF followed by the delayed release of PDGF to induce therapeutic angiogenesis in the 
infarcted heart [322]. In this study, we implement a more comprehensive strategy to prevent or 
reverse multiple pathologies developed after MI. We tested the fibrin gel-coacervate 
composite’s ability for early release of TIMP-3 and IL-10 followed by delayed release of FGF-2 
and SDF-1α. In order to obtain faster TIMP-3/IL-10 release, we embedded these two proteins in 
a fibrin gel directly, before gelation. We then embedded FGF-2 and SDF-1α within heparin-
based coacervates distributed in the same fibrin gel to provide sustained release (Figure 25A).  
The loading efficiencies were 85% for TIMP-3, 83% for IL-10, 97% for FGF-2, and 
98% for SDF-1α, as quantified 1h after loading them into the composite. By day 1, 
approximately 40% of TIMP-3 and 50% of IL-10 have been released, reaching 90% and 97% 
total release respectively by one week (Figure 25B). As for FGF-2 and SDF-1α, we observed a 
longer sustained release that lasted for many weeks due to their encapsulation within the 
coacervates inside the gel. By one week, only 21% of FGF-2 and 28% of SDF-1α were released, 
reaching 55% and 48% total release respectively by 6 weeks (Figure 25B). This controlled 
release system achieved sequential release kinetics, where most of TIMP-3 and IL-10 amounts 
were released by 1 week compared to a sustained release of FGF-2 and SDF-1α that lasted at 
least 6 weeks. The in vivo release rates can be further influenced by one or more factors 
including fibrinolysis, enzymatic degradation by esterases and heparinases, hydrolytic 
degradation of PEAD, and dissociation of the coacervate in an ionic environment. Thus, in vivo 
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release is expected to be faster. Overall, the release kinetics attained with the fibrin gel-
coacervate composite reflect the desired goal of providing TIMP-3 and IL-10 early after MI to 
reduce ECM degradation and inflammation, while providing FGF-2 and SDF-1α in a more 
sustained manner for triggering a robust neovasculature formation process and stem cell 
recruitment. 
Figure 25. (A) The release system was comprised of a fibrin gel embedding TIMP-3 and IL-10 aimed for 
early release; and FGF-2/SDF-1α-loaded coacervates distributed within the same gel aimed for late release. 
The coacervate was formed through electrostatic interactions by combining FGF-2 and SDF-1α with 
heparin then with PEAD polycation. (B) The release system described achieved sequential quick release of 
TIMP-3 and IL-10 by 1 week followed by a sustained release of FGF-2 and SDF-1α up to 6 weeks. Data are 
presented as means ± SD (n=3). 
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4.3.2 Optimization of the protein combination and its doses 
The use of TIMP-3, IL-10, FGF-2, or SDF-1α to promote cardiac repair post-MI is well 
supported by the literature [66, 88, 118, 119, 147, 177, 241, 314, 315, 327-332]. However, to 
our knowledge, they have never been tested in combination before. Therefore, the significance 
of each protein in the combination within the context of improving cardiac function and repair 
after MI is unknown. In addition, such a combination has not been evaluated using controlled 
delivery. Finally, there is no existing literature on the optimal dose for each protein in free or 
controlled release form. Therefore, we utilized a two-level half fractional factorial design to 
build a statistical model with a small number of runs, saving time, resources, and money [323, 
324].  
Table 2. Treatment groups according to two-level half fractional factorial design and the corresponding 
ejection fraction obtained by MRI. 
Protein FGF-2 SDF-1α IL-10 TIMP-3 EF% ± SD 
Dose group 1 3 µg 3 µg 2 µg 4 µg 62.3 1.3 
Dose group 2 3 µg 3 µg 0.4 µg 0.8 µg 56.8 1 
Dose group 3 3 µg 0.6 µg 2 µg 0.8 µg 50.7 4.3 
Dose group 4 3 µg 0.6 µg 0.4 µg 4 µg 59.4 3.6 
Dose group 5 0.6 µg 3 µg 2 µg 0.8 µg 44.9 3.6 
Dose group 6 0.6 µg 3 µg 0.4 µg 4 µg 58.9 3.4 
Dose group 7 0.6 µg 0.6 µg 2 µg 4 µg 51.6 1.9 
Dose group 8 0.6 µg 0.6 µg 0.4 µg 0.8 µg 41.1 2.9 
Sham 70.2 2.1 
In this optimization study, we generated, using statistical software, a table organizing 8 
groups with different upper and lower doses for each protein, to be tested for efficacy on 
ejection fraction (EF%) in a rat MI model (Table 2). MRI images were used to compute ESV, 
EDV, and EF values for all 27 rats in the study (Appendix B). The resulting mathematical 
model of the system provided valuable insight on the relative significance of each protein in the 
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combination on improving cardiac function and the optimal dose needed to benefit cardiac 
repair and regeneration. This factorial design has a resolution IV; meaning no main effects are 
aliased with any other main effect or 2-factor interactions, but some 2-factor interactions are 
aliased with other 2-factor interactions and main effects are aliased with 3-factor interactions. 
Aliasing means the loss of the ability to estimate some effects and/or interactions, which is the 
price paid for not running a full factorial design. However, a reasonable and common 
assumption in such designs is that higher-order interactions are assumed to be negligible 
because practically they are less likely to be important than lower-order interactions. The 
regression analysis assumes that the measurement and experimental errors in the data are 
normally distributed, random over time, and of equal variance at all levels of the response. 
These three assumptions were confirmed using analysis of residuals shown (Appendix C). 
Results demonstrated the significant main effects of TIMP-3, FGF-2, and SDF-1α 
(p<0.001), while suggesting minimal effect of IL-10 (p=0.273) on improvement of cardiac 
function (Figure 26). This means that, within the context of improving EF% using controlled 
delivery of this combination, TIMP-3, FGF-2, and SDF-1α were beneficial for improving 
cardiac function while IL-10’s effect was insignificant. Although IL-10 is a strong anti-
inflammatory cytokine, its insignificant effect on improving cardiac function within the context 
of this protein combination might be due to the presence of TIMP-3, which has been shown to 
have anti-inflammation effects [63]. Therefore, we concluded that IL-10 should be removed 
from the protein combination when moving forward to execute the in-depth study with the 
refined parameters. 
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Figure 26. Analysis of variance results show the relative significance of each of the 4 proteins: TIMP-3, 
IL-10, FGF-2, SDF-1α, and some of the 2-way interactions on improvement of ejection fraction (EF%). 
TIMP-3 had the greatest main effect on improvement of EF% accounting for 43% of the 
total sum of squares (598/1395), followed by FGF-2 accounting for 32% (440/1395), then 
SDF-1α accounting for 12.5% (174/1395). Together, the main effects of these proteins dominate 
the system and account for 87.5% of the total sum of squares, suggesting that the combined 
individual effects of these 3 proteins are responsible for 87.5% of the change in EF%, while 
higher-order protein interactions and error account for 12.5% of that change (Figure 26).  
As for the optimal protein doses, the most effective group of the 8 groups is group 1 
restoring EF to 62%, which is closest to the average of 3 sham controls at 70% (Table 2). We 
observed, from the main effects plot, that all of the estimates for FGF-2, SDF-1α, and TIMP-3 
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had significant positive slopes, indicating that improvement of cardiac function, in this study, 
can be best achieved by using the higher doses of FGF-2, SDF-1α, and TIMP-3 (Figure 27A). 
Figure 27. (A) The main effects plot shows the individual effect of each protein on EF% from respective 
lower to upper doses. (B) The interaction between TIMP-3 and FGF-2, nearly significant at p=0.076, 
suggests slight antagonism between the 2 proteins. 
In addition to minimizing the required number of runs, another benefit of factorial 
experimentation is the ability to estimate 2-way interactions. Although, the effects of the 2-way 
protein interactions that this factorial design was able to estimate were all insignificant, the 
interaction between FGF-2 and TIMP-3 was worthy of consideration as it was nearly significant 
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at p=0.076 (Figure 26). The interaction plot suggests slight antagonism between the 2 proteins 
(Figure 27B). The improvement in EF% seen when FGF-2 is increased in dose is smaller when 
TIMP-3 is at the high dose than it is at the low dose (the slopes of the 2 lines are not equal) 
(Figure 27B). Physiologically, the 2 proteins might be fulfilling some similar functions and 
therefore their effects are overlapping when both are at the high dose.  
Reducing the regression model to include only the 3 significant main effects and the 
interaction term (of TIMP-3 and FGF-2) leads to a new model to predict EF% (Figure 28A). 
The contour plot constructed from this model predicts an EF% of approximately 62% if we 
utilize FGF-2, SDF-1α, and TIMP-3 at 3µg each in the designed scheme within the fibrin gel-
coacervate composite (Figure 28B). Taking these statistical results and the cost of each protein 
into consideration, we decided to move forward with FGF-2, SDF-1α, and TIMP-3 in the 
protein combination with a dose of 3µg for each, thereby keeping the upper doses of FGF-2 and 
SDF-1α, while reducing TIMP-3 dose slightly from 4µg to 3µg. 
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Figure 28. (A) Modified regression model, after removing IL-10. (B) A contour plot predicts the value of 
EF% upon choosing doses for TIMP-3 and FGF-2 among a range of values, while fixing SDF-1α dose at 3µg. 
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Figure 29. (A) In rat MI model, a 100µl fibrin gel-coacervate composite is injected intramyocardially shortly 
before gelation at 3 areas around the infarct zone. (B) The refined delivery approach includes injecting the 
infarcted heart with a fibrin gel-coacervate composite containing TIMP-3 within the fibrin gel, and FGF-
2/SDF-1α-loaded coacervates distributed in the same gel, with proteins at 3µg each. 
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4.3.3 Spatiotemporal protein delivery improves cardiac function and reduces dilation 
After refining the protein combination and doses, we evaluated the effect of spatiotemporal 
delivery of TIMP-3, FGF-2, and SDF-1α (3µg each) using the fibrin gel-coacervate composite 
in a rat MI model comparing sham, saline, free proteins, and delivered proteins (Figure 29). 
Empty vehicle (empty fibrin gel-coacervate composite) was not tested as a control in this study 
as it has shown no difference to saline in our previous work [322]. We evaluated changes in LV 
contractility as a measure of heart function. Fractional area change (FAC) was computed from 
ESA and EDA values of 2-D echocardiography videos (Figure 30A). Sham group maintained 
an FAC value of approximately 55% at all time points (Figure 30B). At 1 week post-infarction, 
FAC values of saline, free, and delivery groups dropped significantly, however, both delivery 
and free values were significantly higher than saline (p<0.01). This suggests that the 3-protein 
therapy, whether free or controlled-delivered, helped reduce the significant drop in heart 
function 1 week after MI. At 2 weeks, although free was still significantly higher than saline 
(p<0.001), both FAC values kept dropping, while delivery group started diverging and 
improving function significantly compared to both free and saline (p<0.001). At 5 weeks, free 
group was still significantly higher than saline (p<0.05), but only at a 36% FAC value compared 
to 32.5% for saline; whereas, the delivery group increased its improvement of cardiac function 
compared to both saline and free standing at 47% FAC value (p<0.001). At the terminal 8 
weeks, the delivery group stood at 48% FAC value showing significant improvement compared 
to saline (30%) and free (32%) (p<0.001), while saline and free were statistically similar 
(p>0.05) (Figure 30B). The delivery group improved function approximately 74% over saline 
based on the terminal FAC values at 8 weeks.  
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The results were confirmed at 8 weeks by cardiac MRI measurements (Figure 31). ESA 
and EDA were traced and partial volumes were acquired using slice thickness, then added to 
compute ESV and EDV values (Appendix B) (Figure 31A). Ejection fraction (EF%) was 
computed from ESV and EDV relation. The delivery group (58%) showed a significantly higher 
EF% (p<0.001) compared to both saline (41%) and free (46%), which showed no significance 
between each other (p>0.05) (Figure 31B). Sham EF% stood at 69%, significantly higher than 
all groups (p<0.001). The delivery group improved function approximately 61% over saline 
based on the terminal EF values at 8 weeks. This shows that the spatiotemporal delivery of 
complementary proteins TIMP-3, FGF-2, and SDF-1α can significantly improve cardiac 
function at least 60% compared to no treatment, demonstrating the efficacy of the controlled 
release of these proteins in mitigating the MI injury and preventing the contractile dysfunction 
triggered by it. 
 In our evaluation of the therapy’s effect on ventricular dilation, we assessed the changes 
in EDA and ESA values. When quantified, the saline and free groups showed significantly 
increasing ESA and EDA values at all time points after MI, with no statistical differences 
between them (p>0.05) (Figure 30C,D). The delivery group, on the other hand, showed 
sometimes significant reduction and other times a trend towards decreasing both EDA and ESA 
values at all times after MI compared to saline (Figure 30C). These results were confirmed at 8 
weeks by cardiac MRI measurements (Figure 31C,D). The delivery group demonstrated a 
significantly smaller ESV compared to saline at 8 weeks (p<0.01) and a decreasing trend in 
EDV value (Figure 31C). These results suggest that the spatiotemporal delivery approach 
significantly reduces LV dilation, and thus in turn reduces the risk of cardiac rupture and heart 
failure. The ability of the controlled delivery group to improve cardiac function and reduce 
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ventricular dilation up to 8 weeks after infarction, stresses the importance of choosing 
complementary proteins and their spatiotemporal presentation per physiologic cues towards 
achieving effectiveness in treatment of the infarcted myocardium. 
 
Figure 30. (A) Traces of end-systolic (ESA) and end-diastolic (EDA) areas from short-axis B-mode images of 
the left ventricle (LV) using echocardiography. (B) Fractional area change (FAC) values show differences 
between groups after MI at multiple time points, with significantly higher FAC value of the delivery group 
compared to saline and free from 2 weeks on. (C) Saline and free groups show increasing ESA values, which 
were reduced in delivery group. (D) Saline and free groups show increasing EDA values, which were 
reduced in delivery group. Data are presented as means ± SD (n=9-10 per group). * p<0.05 vs saline, ≠ 
p<0.05 vs free. 
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Figure 31. (A) Traces of end-systolic (ESA) and end-diastolic (EDA) areas from short-axis view images of the 
left ventricle (LV) using cardiac MRI. (B) Ejection fraction (EF%) values show differences between groups 
after MI at 8 weeks, with significantly higher EF% of the delivery group compared to saline and free. (C) 
Saline and free groups show increasing ESV value at 8 weeks, which was significantly reduced in delivery 
group. (D) Saline and free groups show increasing EDV value at 8 weeks, which was reduced in delivery 
group. Data are presented as means ± SD (n=5-8 per group). * p<0.05 vs saline, ≠ p<0.05 vs free. 
4.3.4 Spatiotemporal protein delivery augments myocardial elasticity 
We performed myocardial strain analysis at 8 weeks post-MI to evaluate the changes in the 
radial and circumferential strain levels of the myocardium after infarction and the effect of 
therapy on them. The radial strain, defined as the percent change in myocardial wall thickness, 
and the circumferential strain, defined as the percent change in myocardial circumference, were 
measured from short-axis view images of the LV from echocardiography using VevoStrain 
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analysis algorithm (Figure 32A). The strain of an infarcted sample was estimated by 
normalizing the estimated peak radial or circumferential strain in the infarcted area to that of the 
average of 4 non-infarct areas in LV walls during full cardiac cycles (Figure 32A). The free 
proteins group prevented some reduction in the radial and circumferential strains, but not to a 
significant level over saline (p>0.05) (Figure 32B,C). The delivery group, however, was able to 
significantly maintain the radial (p<0.01)  and circumferential (p<0.01) myocardial strains at a 
higher level in comparison to the saline group, thereby keeping the levels very close to those of 
sham control (Figure 32B,C). This result indicates the efficacy of the spatiotemporal of 
complementary proteins TIMP-3, FGF-2, and SDF-1α in preserving the long-term LV 
myocardial elasticity after MI by preventing the LV wall from becoming stiffer which reduces 
its ability to contract and dilate properly.  
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Figure 32. (A) Strain of an infarcted sample was estimated by normalizing the estimated peak radial or 
circumferential strain in the infarcted area to that of the average of 4 non-infarct areas in LV walls during a 
cardiac cycle. (B) Saline and free groups show decreasing radial strain at 8 weeks, which was significantly 
higher in delivery group. (C) Saline and free groups show decreasing circumferential strain at 8 weeks, 
which was significantly higher in delivery group. Data are presented as means ± SD (n=5 per group). * 
p<0.05 vs saline. 
4.3.5 Spatiotemporal protein delivery reduces LV wall thinning and MMP activity 
After functional evaluations, we performed investigations at the tissue level at 2 and/or 8 weeks.  
H&E stained hearts showed increased granulated scar tissue areas with thinner LV walls in the 
infarct and borderzone regions that exacerbated with time in infarcted groups but to a less extent 
in the delivery group (Figure 33A). The infarct scar tissue soon starts expanding from the 
infarct to non-infarct regions turning healthy tissue into collagenous granulated stiffer tissue, 
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clearly evident in non-treated samples (Figure 33B). LV wall thickness decreased considerably 
in saline and free groups as early as 2 weeks. In contrast, the delivery group significantly 
prevented LV wall thinning at 2 weeks compared to saline (Figure 33C). At 8 weeks, there 
were no statistical differences in LV wall thickness between saline, free, and delivery groups, 
although the delivery group clearly maintained a thicker wall average (Figure 33C).  
At 8 weeks, we evaluated the activity of matrix metalloproteinases (MMPs) in the heart 
samples. MMP-2 and MMP-9 are important players implicated in many cardiovascular diseases 
and ECM degradation [141]. By allowing activated MMP-2/9 in our samples to cleave a 
fluorogenic specific substrate, we were able to detect the activity level of MMP-2/9 in the study 
groups. All infarct groups showed a high level of MMP activity (Figure 34). However, the 
delivery group showed significantly lower MMP activity compared to saline (p<0.01) and also 
lower activity than free group but not to a significant level (p>0.05) (Figure 34). The enhanced 
reduction of MMP activity by the delivery group is likely due to the controlled delivery of 
TIMP-3 within the fibrin gel-coacervate composite, where TIMP-3 can form tight complexes 
with MMP-2 and MMP-9 to prevent their activation, and thereby reducing ECM degradation 
and ventricular dilation and remodeling. 
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Figure 33. (A) Representative H&E images showed ventricular wall thinning with damaged cardiac muscle 
surrounded by scar tissue in saline and free proteins groups at 2 and 8 weeks. However, these damages were 
apparently alleviated in the delivery group. Scale bar=1000µm. (B) Transition between collagenous scar 
tissue and healthy tissue at the borderzone of a non-treated infarct sample. (C) Quantitative analysis shows 
generally reduced ventricular wall thinning by delivery group at 2 and 8 weeks over saline and free groups. 
Data are presented as means ± SD (n=3-4/group at 2 wks, n=4-6 at 8 wks). * p<0.05 vs saline. 
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Figure 34. MMP-2/9 activity assay showed high levels of activity in infarct groups at 8 weeks, but was 
significantly reduced in the delivery group compared to saline. Data are presented as means ± SD (n=3-4 per 
group at 8 wks). * p<0.05 vs saline. 
4.3.6 Spatiotemporal protein delivery reduces inflammation and increases M2 
macrophages 
Modulating the inflammatory response after MI in which certain harmful aspects of 
inflammation are prevented, can be very beneficial for the treatment of the infarcted 
myocardium. In this study, we assessed inflammation by co-staining for F4/80, a pan-
macrophage cell surface marker, and CD163, an M2 macrophage marker (Figure 35A). Non-
M2 macrophages, namely M1, have harmful effects promoting further inflammation, whereas 
M2 macrophages contribute to tissue repair and anti-inflammation [59]. At 2 weeks post-MI, 
both saline and free groups showed high numbers of non-M2 macrophages (red), while the 
delivery group showed a trend towards decreasing the presence of such macrophages (p>0.05) 
(Figure 35A,B). On the other hand, the delivery group significantly increased the presence of 
beneficial M2 macrophages (yellow/green showing co-staining of F4/80 and CD163) in 
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comparison to saline (p<0.01) (Figure 35A,B). Saline and free showed no statistical differences 
in their M2 macrophage numbers (p>0.05) (Figure 35B). The sham control showed minimal 
presence of macrophages. These results are suggestive of the efficacy of the spatiotemporal 
delivery of complementary proteins TIMP-3, FGF-2, and SDF-1α at reducing the detrimental 
effects that may result from an excessive inflammatory response post-MI and promoting healthy 
tissue repair through M2 macrophages.  
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Figure 35. (A) Representative images of the different groups showing co-staining of F4/80 (red), a pan-
macrophage marker, and CD163, an M2 macrophage marker (green) at 2 weeks. Co-localization of the 2 
markers shows the color as yellow. (B) The delivery group shows a reduced number of non-M2 macrophages 
compared to saline and free, but not statistically significant. (C) The delivery group shows a significantly 
increased presence of M2 macrophages compared to saline. Data are presented as means ± SD (n=3-4 per 
group at 2 wks). * p<0.05 vs saline. 
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4.3.7 Spatiotemporal protein delivery supports cardiomyocyte survival and reduces 
apoptosis 
The viability of the cardiac muscle is crucial for the proper function of the heart. 
Cardiomyocytes are responsible for imparting proper and synchronized contractile ability to the 
heart for pumping blood. As MI and the pathologies developing after it trigger a massive death 
of cardiomyocytes, it is extremely beneficial to support the survival of these cells, prevent their 
apoptosis, and trigger the regeneration of a viable myocardium.  To examine the viability of the 
cardiac muscle, we stained for the live cardiomyocyte marker cardiac troponin I (cTnI) (green) 
(Figure 36A). We observed a major loss of viable myocardium in the saline group followed by 
the free group, then by the delivery group which apparently preserved the live cardiomyocytes 
to a larger extent at 2 weeks (Appendix D.1) and at 8 weeks (Figure 36A). Quantitative 
analysis of the area fraction of the viable cardiac muscle demonstrated a reduction in the amount 
of survived cardiomyocytes in all infarct groups at 2 weeks, with no statistical differences 
between them (p>0.05) (Figure 36B). At 8 weeks, the viability of the cardiac muscle was 
reduced more in the saline group (64% viable muscle), followed by the free group (75%) with 
no significant differences between them (p>0.05). In contrast, the delivery group was able to 
maintain the survival of the cardiac muscle (83%) significantly better than saline at 8 weeks 
(p<0.01) (Figure 36B). 
A number of molecular pathways and markers play important roles in promoting 
survival or inducing apoptosis of the cardiomyocytes. The activated (phosphorylated) 
MAPK/ERK and Akt pathways have been shown to provide cardioprotective effects supporting 
the survival of cardiomyocytes after ischemia and preventing their apoptosis [76-78]. We used 
western blot to detect the expression levels of cleaved caspase-3, a pro-apoptosis mediator, and 
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pro-survival markers p-ERK1/2 and p-Akt in our groups at 8 weeks (Figure 37). As shown in 
our results, the intensity of the bands is clearly reduced in the delivery group for cleaved 
caspase-3 and increased in the cases of p-ERK1/2 and p-Akt (Figure 37A). This was confirmed 
by quantifying the intensity of the bands (Figure 37B,C,D). The free group was able to 
significantly increase p-ERK1/2 expression compared to saline (p<0.01) (Figure 37B). 
However, the delivery group significantly reduced the expression of cleaved caspase-3 and 
increased the expression of p-ERK1/2 and p-Akt compared to both saline (p<0.001) and free 
(p<0.01) groups (Figure 37). Taken together, these results demonstrate the effectiveness of the 
spatiotemporal delivery approach at supporting the long-term survival of cardiomyocytes, 
preventing their apoptosis, and providing overall cardioprotection after MI through activation of 
the Akt and ERK1/2 signaling pathways and the suppression of caspase-3 apoptotic mediation. 
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Figure 36. (A) Representative images of the different groups showing staining of viable cardiac muscle by 
cardiac troponin I (cTnI) (green). Reduced viable muscle can be observed in all infarct groups, with better 
preservation of the muscle in the delivery group at 8 weeks. (B) Quantitative analysis shows no differences 
between infarct groups at 2 weeks, but demonstrates the delivery group’s significant preservation of cardiac 
muscle viability at 8 weeks compared to saline. Data are presented as means ± SD (n=3-5/group at 2 wks, 
n=5-6 at 8 wks). * p<0.05 vs saline. 
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Figure 37. (A) Representative western blot images of the expression levels of p-ERK, p-Akt and cleaved 
caspase-3 in different study groups at 8 weeks. (B) The intensity band analysis of cleaved caspase-3 shows 
significant reduction of expression level in delivery group compared to saline and free groups. (C) The 
intensity band analysis of p-ERK1/2 shows significant increase of expression level in delivery group 
compared to saline and free groups, with free showing significance over saline as well. (D) The intensity 
band analysis of p-Akt shows significant of expression level in delivery group compared to saline and free 
groups. Data are presented as means ± SD (n=3/group at 8 wks). * p<0.05 vs saline, ≠ p<0.05 vs free. 
4.3.8 Spatiotemporal protein delivery improves angiogenesis 
The revascularization of the ischemic myocardium is key to tissue regeneration and functional 
recovery. New blood vessel formation can help restore the blood, nutrient, and oxygen flow to 
the damaged myocardial regions, and thereby enhance the survival of cardiomyocytes, reducing 
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the risk of chronic heart failure. To investigate the process of angiogenesis, we co-stained for 
vWF (red), an endothelial cell marker, and α-SMA (green), a pericyte marker (Figure 38A). 
Staining for α-SMA indicates maturity of a neovessel. At 2 weeks (Appendix D.2) and 8 weeks 
(Figure 38A), we observed a higher number of neovessels in the delivery group compared to 
saline and free. The sham control does not show neovessels as infarcted hearts do, but rather 
shows larger and more established blood vessels that are organized and not as frequent in one 
region as found in the borderzone of infarcts (Figure 38A). Quantitative analysis of infarct 
groups showed significantly higher number of vWF-positive vessels in delivery compared to 
saline at 2 weeks (p<0.05) (Figure 38B). At 8 weeks, the delivery group showed a significantly 
higher number of vWF-positive vessels than both saline and free groups (p<0.01) (Figure 38B).  
For the quantitative analysis of the formation of mature neovessels (Co-localized stain of 
vWF and α-SMA), we found no significant differences in the number of vWF-α-SMA-positive 
vessels among the infarct groups at 2 weeks (p>0.05) (Figure 38C). However, at 8 weeks, the 
delivery group showed significantly higher presence of mature vWF-α-SMA-positive vessels 
than both saline and free groups (p<0.001) (Figure 38C). Our results demonstrate the ability of 
the spatiotemporal delivery approach to induce a robust angiogenesis process capable of 
forming stable and mature neovasculature that is likely to participate in perfusion. This 
enhanced revascularization in the delivery group is likely due to the sustained presence of the 
potent angiogenic factor FGF-2 being provided by the heparin-based coacervate within our 
composite gel. 
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Figure 38. (A) Representative images of the different groups showing co-staining of vWF (red), an 
endothelial marker, and α-SMA (green), a pericyte marker at 8 weeks. (B) The delivery group shows a 
significantly greater number of vWF+ vessels compared to saline at 2 weeks and compared to saline and free 
at 8 weeks. (C) The delivery group shows a significantly greater number of vWF+ α-SMA+ vessels than 
saline and free groups at 8 weeks but not at 2 weeks. Data are presented as means ± SD (n=3-4/group at 2 
wks, n=5-6 at 8 wks). * p<0.05 vs saline, ≠ p<0.05 vs free. 
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4.3.9 Spatiotemporal protein delivery increases stem cell homing to the myocardium 
Stem cells, recruited to the infarcted myocardium, have the potential to differentiate into 
functional cells of cardiac lineages such as cardiomyocytes, vascular endothelial, and mural 
cells. Stem cells can also impart beneficial paracrine effects that activate repair and regeneration 
signaling [94]. To examine the homing of stem cells to the infarcted myocardium, we stained 
for c-Kit, a stem cell marker (Figure 39A). At 8 weeks after MI, saline and free groups showed 
no significant differences in the number of c-Kit-positive cells present at the borderzone 
(p>0.05) (Figure 39B). In contrast, the delivery group showed a significantly greater presence 
of c-Kit-positive cells at the borderzone compared to both saline and free groups (p<0.01) 
(Figure 39B). The sham control showed very few stem cells in the area where an infarct would 
have been induced, suggesting their limited presence in absence of an MI injury. These results 
indicate the efficacy of the spatiotemporal delivery approach at recruiting stem cells to the 
infarct region and potentially contribute in the regeneration of the myocardium. The enhanced 
and long-term presence of stem cells in the delivery group is likely due to the sustained 
availability of the powerful chemoattractant SDF-1α within our composite gel, being released 
by the coacervate.  
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Figure 39. (A) Representative images of the different groups showing staining of c-Kit+ stem cells (green) at 
8 weeks. (B) Quantitative analysis shows significantly greater number of c-Kit+ stem cells in delivery group 
compared to saline and free groups. Data are presented as means ± SD (n=5/group at 8 wks). * p<0.05 vs 
saline, ≠ p<0.05 vs free. 
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4.3.10 Spatiotemporal protein delivery reduces interstitial fibrosis after MI 
Interstitial fibrosis develops at the infarct region and extends to non-infarct areas due to the 
excessive and uncontrollable collagen deposition that takes place in later stages after MI. This 
increased collagen deposition leads to increased stiffness in the myocardium, leading to 
contractile dysfunction. The extent of fibrosis was assessed using picrosirius red staining which 
stains collagen fibers with a metallic red color than are viewed under polarized light (Figure 
40A). The saline group, and to a lesser degree the free group, showed extensive amount of 
fibrosis that extended from the infarct to non-infarct regions, while the delivery group showed 
far less fibrosis that seemed limited to the infarct area at 2 weeks (Appendix D.3) and at 8 
weeks (Figure 40A). Collagen deposition was quantified as a positive fraction of the heart area 
and no statistical differences were found between the infarct groups at 2 weeks despite a clear 
reduction in the delivery group (p>0.05) (Figure 40B). At 8 weeks, collagen deposition 
increased in all infarct groups, but it was found to be significantly less in the delivery group 
(11%) compared to both saline (23%) (p<0.01) and free (18%) groups (p<0.01) (Figure 40B).  
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Figure 40. (A) Representative picrosirius red staining images show the dense collagen deposition along the 
LV wall and infarct zone in saline, followed by the free group, whereas it was limited to the infarct region in 
the delivery group at 8 weeks. (B) Quantitative analysis shows that collagen deposition was not different in 
infarct groups at 2 weeks but was significantly less in the delivery group compared to saline and free groups 
at 8 weeks. Data are presented as means ± SD (n=3-5/group at 2 wks, n=4-7 at 8 wks). * p<0.05 vs saline, ≠ 
p<0.05 vs free. 
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4.3.11 Spatiotemporal protein delivery regulates important protein levels  
Certain proteins are involved in triggering cardiac repair mechanisms and others are implicated 
in advancing pathological changes post infarction. Therefore, regulation of the expression levels 
of such proteins represents an important aspect of effective therapies. The bioavailability and 
levels of proteins such as the ones in our complementary combination, TIMP-3, FGF-2, and 
SDF-1α, likely affect the signaling and levels of other proteins involved in the heart 
environment after MI. To investigate the effect of our spatiotemporal delivery approach on the 
levels of relevant proteins, we tested tissue lysates for the levels of insulin growth factor IGF-I, 
VEGF, Shh, and TGF-β1 at 8 weeks (Figure 41). Quantitative analysis by ELISA showed 
significantly higher levels of IGF-I, an anti-apoptotic factor, in free (p<0.01) and delivery 
(p<0.001) groups compared to saline (Figure 41A). Moreover, the delivery group significantly 
increased the levels of VEGF, a potent angiogenic factor, and Shh, a master cardiac morphogen, 
over saline (p<0.05), while the free group was statistically similar to saline (p>0.05) (Figure 
41B,C). Lastly, the free group significantly decreased the levels of TGF-β1, a pro-fibrotic 
factor, compared to saline, but the delivery group reduced TGF-β1 levels even more and was 
significantly less than both saline (p<0.001) and free (p<0.05) groups (Figure 41D). Taken 
together, these results suggest a high level of direct or indirect interaction between different 
proteins during response to tissue injury. The timed and controlled release of our 
complementary proteins augmented the presence of beneficial factors IGF-I, VEGF, and Shh 
that likely contributed to increased cardioprotection, revascularization, and signaling of repair 
mechanisms, while reduced levels of TGF-β1 likely contributed to reducing excessive collagen 
deposition and interstitial fibrosis [16, 27, 79, 165, 333, 334]. All these beneficial outcomes can 
aid in the prevention of heart failure and the restoration of heart function.  
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Figure 41. Levels of relevant proteins in tissue lysates at 8 weeks. (A)  Free and delivery groups significantly 
increased IGF-I levels. (B) Delivery group significantly increased VEGF levels compared to saline. (C) 
Delivery group significantly increased Shh levels compared to saline. (D) Free group significantly decreased 
TGF-β1 levels compared to saline, but delivery group significantly decreased TGF-β1 levels compared to 
both saline and free. Data are presented as means ± SD (n=3-4/group at 8 wks). * p<0.05 vs saline, ≠ p<0.05 
vs free. 
4.4 DISCUSSION 
As MI overwhelms the inflicted with multiple pathologies developing over time and progressing 
the heart towards dysfunction and failure, one can only imagine how complex and challenging 
an effective therapeutic approach, that fully repairs and regenerates the infarcted myocardium, 
would be to develop. Relevant therapeutic proteins, being crucial for cardiac cell signaling, 
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function, and behavior, represent very promising players to employ in MI treatment strategies. 
In order to ensure efficacy of a therapy, it is necessary to mimic the spatiotemporal presence of 
these proteins in the natural microenvironment during a proper tissue repair and regeneration 
process. This brings into spotlight the advantages of using an effective controlled delivery 
system that can release multiple proteins spatiotemporally after MI in order to induce cardiac 
repair and regeneration mechanisms. 
In this work, we first explored the therapeutic potential of timed and controlled release 
of four proteins, which have relatively distinct but complementary roles in cardiac function, 
TIMP-3, IL-10, FGF-2, and SDF-1α, on improving cardiac function after MI in a rat model. To 
reduce inflammation and ECM degradation early after MI, TIMP-3 and IL-10 were 
encapsulated within a fibrin gel. To trigger a robust angiogenesis process and stem cell 
recruitment, FGF-2 and SDF-1α were encapsulated within heparin-based coacervates and 
distributed in the same fibrin gel. We have shown the efficacy of this fibrin gel-coacervate 
system for sequential release of VEGF and PDGF previously [322]. Fibrin gel, formed through 
the polymerization of fibrinogen by thrombin, is commercially available and has been used for 
protein and cell delivery [210]. We have also demonstrated in a number of studies the advantage 
of coacervate-delivered proteins for many biomedical applications, including cardiac repair [86, 
241-244, 293, 322, 335, 336]. Our polyvalent complex coacervate is comprised of a synthetic 
polycation PEAD combined with heparin and a heparin-binding protein, enabling its sustained 
release over time due to PEAD degradation, changes in ionic environment, presence of 
enzymes, and other factors [235, 237]. Our results demonstrated the ability of the fibrin gel-
coacervate composite to provide early release of TIMP-3 and IL-10 by one week, followed by a 
sustained release of FGF-2 and SDF-1α that lasted at least six weeks. The release kinetics 
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provided by this composite gel are deemed suitable for the desired spatiotemporal presence of 
the complementary proteins during the proper repair process. 
Here, we utilized a two-level half fractional factorial design to refine and optimize the 
protein combination and its doses. This powerful statistical tool allowed us to perform a fraction 
of the total runs, providing cost-effectiveness and valuable information about the relative 
significance of each protein in the combination, some of the possible protein-protein 
interactions, and the optimal protein doses for improving cardiac function 4 weeks after MI in a 
rat model [323-325]. Our results demonstrated the significant contributions of TIMP-3, FGF-2, 
and SDF-1α to improving ejection fraction, while indicating minimal contribution of IL-10 
towards that purpose. IL-10 is a potent anti-inflammation cytokine that is reported to improve 
cardiac function and angiogenesis, and reduce scar size and fibrosis after MI [66, 67, 314, 329, 
337-339]. However, a study using IL-10 knock-out models deduced that it doesn’t affect 
ventricular remodeling critically [68]. The insignificant effect of IL-10 reported in our study, 
within the context of the protein combination, might have been influenced by two factors. The 
first factor is that IL-10’s role in improving cardiac function might have been diminished by the 
presence of TIMP-3, which itself has been reported to have anti-inflammation effects through 
its inhibition of TNF-α-converting enzyme (TACE), the enzyme activator of TNF-α [63, 64]. 
TNF-α is a pro-inflammatory factor, involved in inducing inflammatory cell invasion of the 
infarcted myocardium, MMP production, and cell apoptosis [62-64]. The second factor is that 
an appropriate level of inflammatory response is necessary after MI to phagocytose dead cells 
and their debris, and that the presence of IL-10 alongside TIMP-3, within the protein 
combination, might have rendered IL-10 redundant and did not add additional benefit towards 
improving cardiac function. This result prompted us to remove IL-10 from the protein 
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combination and proceed with TIMP-3, FGF-2, and SDF-1α at higher doses (3µg each) that 
proved more beneficial than lower doses at improving cardiac function. 
After refining the protein combination and doses, we performed an in-depth in vivo 
study to test the efficacy of spatiotemporal release of TIMP-3, FGF-2, and SDF-1α from the 
fibrin gel-coacervate composite in a rat MI model and compared it to sham, saline, and free 
proteins groups. We demonstrated the delivery group’s significant potential to improve cardiac 
function and trigger repair mechanisms after infarction bringing it close to the normal case of 
the sham control in many evaluations. In most cases, the delivery group showed significant 
differences compared to saline group, and to free proteins group in many cases. The free 
proteins group, although showing some potential and trends of improvement in different 
evaluations, was not able to induce significant repair as the delivery group did compared to 
saline. This was indicative of the importance of controlled and timed delivery of the 
complementary proteins TIMP-3, FGF-2, and SDF-1α. Many protein therapies failed to prove 
long-term efficacy for MI treatment because of the shortcomings of proteins applied in free 
form, including very short-half lives, low retention at the target site, high doses required, and 
lack of spatiotemporal cues. A study concluded that bolus injections of a cocktail of four 
important proteins: FGF-2, SDF-1α, IGF-I, and hepatocyte growth factor (HGF), did not 
improve cardiac function, reduce infarct size, or promote stable microvasculature [340]. The 
study’s results might be attributed to the absence of controlled release because without properly 
protecting the therapeutic proteins and delivering them spatiotemporally, a therapy might prove 
ineffective at cardiac repair. Our delivery approach offers a solution to these challenges, by 
protecting the proteins within the fibrin gel-coacervate composite, localizing their presence at 
target tissue, and releasing them spatiotemporally.  
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The delivery group significantly improved the heart contractile function as early as 1 
week after MI and lasted up to 8 weeks in comparison to saline and free proteins group, which 
had the cardiac function continuously drop over the period tested, measured by 
echocardiography and further confirmed by cardiac MRI at 8 weeks. We reported a cardiac 
function improvement of 60-75% above non-treated infarcted hearts. This effectively reduced 
the risk of MI progressing to heart failure. We also demonstrated significant reductions in 
ventricular dilation, ventricular wall thinning, myocardial wall stress and stiffness, and MMP 
activity. These assessments are interrelated and linked to adverse remodeling and early ECM 
degradation. The reductions we show in these evaluations might be highly attributed to the vital 
role of early TIMP-3 release from our delivery system. TIMP-3 is an ECM-bound enzyme that 
forms tight non-covalent and stable complexes with the non-activated latent form of MMPs 
(pro-MMP), blocking the MMP’s catalytic domain and preventing its access to substrates [136, 
137, 152]. This effectively inhibits activation of MMPs, responsible for cleaving and 
hydrolyzing many components of the ECM including elastin, fibronectin, collagen, and 
proteoglycans [136-138]. This feature of TIMP-3, being able to reduce ECM degradation, likely 
contributed to mitigating LV adverse remodeling, wall thinning, and dilation; thereby reducing 
the risk of cardiac rupture and contractile dysfunction. Other studies have shown the importance 
of TIMP-3 in cardiac diseases. Deficiency in TIMP-3 has been reported to lead to cardiac 
dilation, dysfunction, rupture, and mortality [147, 332, 341]. Cell-based TIMP-3 gene delivery 
improved heart function and reduced cardiac expression and activity of MMP-2 and -9 [151]. 
TIMP-3 delivered by collagen or hyaluronic gels was able to improve ejection fraction and 
reduce ventricular dilation and infarct size in rat and pig models [88, 177]. 
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The delivery group in our study improved revascularization of the infarcted 
myocardium, triggering a robust angiogenesis process that led to the formation of mature 
neovessels with potential of participating in blood flow and perfusion. The triggers behind the 
formation of mature neovasculature in the borderzones of the infarct region can be linked 
mainly to FGF-2 and, to a lesser degree SDF-1α, present in our protein combination and 
delivered in a sustained manner by the coacervate. As a strong angiogenic factor, FGF-2 
induces endothelial cell proliferation and sprouting leading to the formation of tube-like 
structures that evolve into neovessels with lumens [16, 20]. We have shown in our previous 
studies the ability of FGF-2 coacervate to induce persistent angiogenesis and cardiac repair 
[241, 242, 335]. Our protein signaling results show that the delivery group upregulates VEGF 
expression, which is an endothelial-specific factor that is important for angiogenesis and 
vasodilation [19, 291]. This result concurs with previous studies which demonstrated that FGF-
2 upregulates VEGF and vice versa [23, 24]. FGF-2 also acts in synergy with PDGF signaling 
to improve neovessels’ maturation and stability by pericytes [342]. In addition, SDF-1α can 
increase angiogenesis and myocardial repair by recruiting endothelial progenitor cells to the 
ischemic tissue and in response to VEGF signaling [31, 32]. TIMP-3 was also reported to 
increase VEGF levels from cardiac fibroblasts within the infarct area [88]. Moreover, increased 
expression of Shh, as found in this study due to the delivery group, has been shown to activate 
several signaling pathways and contribute to angiogenesis [343-345]. All these indications 
support our finding that spatiotemporal delivery of TIMP-3, FGF-2, and SDF-1α leads to the 
formation of new, mature, and stable blood vessels, necessary to the repair of MI injury. 
As MI causes the death of millions of cardiomyocytes and puts millions more at risk, it 
is an indispensable task to support the survival of cardiomyocytes after MI and prevent their 
 154 
apoptosis. Our delivery group showed remarkable ability to preserve the viability of the cardiac 
muscle, activate pro-survival molecular pathways ERK1/2 and Akt, inhibit apoptosis mediated 
by caspase-3, and increase expression of anti-apoptotic factor IGF-I. Many studies have proved 
the important role of activating the PI3K/Akt and Ras-Raf-MEK-ERK pathways to inhibit 
apoptosis and provide cardioprotection [76-78]. The complementary proteins in our system 
TIMP-3, FGF-2, and SDF-1α have all been reported to prevent cardiomyocyte apoptosis [85, 
88, 151, 346-350]. Moreover, our delivery group induced higher expression levels of IGF-I and 
Shh. IGF-I is a well-studied potent cardioprotective and anti-apoptotic factor that activates the 
PI3K/Akt pathway and prevents cardiomyocyte apoptosis [351-354]. Shh also reduces 
cardiomyocyte apoptosis through increased expression of pro-survival markers and reduced 
expression of apoptotic markers, as we and other groups have shown [86, 343, 344]. 
Stem cell recruitment to the infarct region is another important aspect of an effective 
therapy because of the potential of stem cells to ultimately differentiate into cardiac and 
vascular cells and/or support the repair by paracrine signaling, thereby supporting the survival 
of remaining cardiomyocytes and regeneration of a viable myocardium that replaces the lost 
damaged one. Our delivery group showed significant ability at homing stem cells to the 
borderzones of the infarct. This is likely due to the sustained bioavailability of SDF-1α provided 
by the coacervate within our composite. SDF-1α is a powerful chemoattractant that can 
mobilize different types of progenitor cells such as endothelial progenitor cells (EPCs), 
hematopoietic stem cells (HSC), mesenchymal stem cells (MSCs), and cardiac stem cells 
(CSCs) to the infarcted myocardium [85]. Our group has shown that tissue-engineered scaffolds 
coated with SDF-1α coacervates improved migration and infiltration of EPCs and MSCs [355]. 
The stem/progenitor cells, when recruited by SDF-1α to the heart, can enhance angiogenesis 
 155 
and cardiomyocyte survival and differentiation [117-119, 321, 330, 331]. FGF-2, present within 
our delivery system, and IGF-I, induced by our delivery combination, have been suggested to 
trigger differentiation of CSCs into functional cardiomyocytes [129, 130]. 
An excessive inflammatory response can have detrimental effects after MI. Large 
amounts of reactive oxygen species (ROS) produced by inflammatory cells invading the 
infarcted myocardium can cause massive cell death [55]. The spatiotemporal delivery approach 
employed in our study proved effective at reducing inflammation and promoting tissue repair. 
Our results revealed the reduction of non-M2 macrophages, which contain M1 macrophages 
that exacerbate inflammation and ECM degradation [59]. We also reported an increase in M2 
macrophages which contribute to reconstruction of the ECM and anti-inflammatory effects [59]. 
TIMP-3, provided by our delivery approach, can exert anti-inflammatory effects by inhibiting 
TNF-α which increases in heart failure and triggers infiltration of inflammatory cells into the 
myocardium [62-64, 177]. Our strategy reduced the potentially deleterious impact of excessive 
inflammation by preventing the infiltration of harmful macrophages into the infarcted 
myocardium or possibly forcing a change in the phenotype of present ones to become of M2 
phenotype involved in tissue repair. 
The unregulated and excessive collagen deposition in the infarct, and later non-infarct 
regions, leads to interstitial fibrosis that increases myocardial stiffness and risk of contractile 
dysfunction. Fibrosis arises as a result of an imbalance in ECM structure and increased 
production of collagen by different cells, mainly myofibroblasts. Myofibroblasts contribute to 
adverse remodeling and are heavily influenced by the signaling of pro-fibrotic factors such as 
TGF-β [160, 163, 164]. In this study, our findings demonstrated that the spatiotemporal delivery 
of TIMP-3, FGF-2, and SDF-1α prevented the development of interstitial fibrosis and the 
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expansion of scar and granulation tissue to a large extent. All of these 3 complementary proteins 
play important roles in reducing fibrosis in the heart after MI injury [88, 212, 241, 356-359]. 
Our delivery group proved very effective at decreasing the levels of TGF-β1, a main promoter 
of fibrosis post-infarction [164]. Therapies that aimed to antagonize TGF-β and reduce fibrosis 
proved beneficial for the heart recovery [171-174]. These results likely helped in the 
preservation of myocardial elasticity as witnessed in our delivery group. Therefore, the efficacy 
of our spatiotemporal delivery approach at preventing the excessive deposition of fibrillary 
collagen reduced the risk of stiffening the ventricular wall, its loss of contractile ability, and 
progression to heart failure. 
4.5 CONCLUSIONS 
We developed an optimized combination therapy for the repair of the infarcted myocardium 
using complementary proteins TIMP-3, FGF-2, and SDF-1α. This therapy utilizes a composite 
of fibrin gel and heparin-based coacervates, where complementary proteins are embedded 
differently for achieving spatiotemporal release. TIMP-3 was embedded in the fibrin gel 
achieving early release, while FGF-2 and SDF-1α were encapsulated within heparin-based 
coacervates and distributed in the same gel achieving sustained release. We found this refined 
spatiotemporal delivery approach to significantly improve cardiac function up to 8 weeks after 
MI in rats. In addition, we reported significant improvements in myocardial elasticity, 
cardiomyocyte survival, angiogenesis, stem cell homing, activation of survival pathways, and 
important protein signaling. We also reported significant reductions in ventricular dilation and 
wall thinning, inflammation, MMP activity, fibrosis, and cell apoptosis. Taken together, we 
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believe that the more comprehensive a treatment strategy is, where multiple crucial proteins are 
employed and delivered in a spatiotemporal manner, the more the therapy will be successful and 
effective at cardiac repair. Therefore, the spatiotemporal delivery approach of complementary 
proteins TIMP-3, FGF-2, and SDF-1α may serve as a new therapy to ameliorate MI injury and 
set the infarcted myocardium on a path to full repair, regeneration, and functional recovery. 
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5.0  SUMMARY AND FUTURE DIRECTIONS 
As our knowledge increases on the different roles and molecular pathways in which therapeutic 
proteins are involved, and the new developments in enabling spatiotemporal delivery of proteins 
through the design of effective controlled release systems, the enhanced options for treatment of 
myocardial infraction (MI) are expected to occur in the near future. In this dissertation, we 
demonstrated the strong potential of controlled delivery of different combinations of therapeutic 
proteins on the repair of the infarcted myocardium in a rat model.   
In chapter 2, we investigated the ability of our heparin-based coacervate technology to 
co-release VEGF and HGF and the effect of the dual delivery on angiogenic in vitro assays. We 
were able to demonstrate the coacervate’s high loading efficiency and sustained release of both 
factors for at least 3 weeks in vitro, and that coacervate-based dual delivery of VEGF and HGF 
triggered more profound angiogenic effects than free-form administration of the two factors and 
the controlled release of each one alone.  In chapter 3, we designed a composite of fibrin gel and 
coacervate to achieve sequential release of VEGF and PDGF for the purpose of therapeutic 
angiogenesis after MI in a rat model. With VEGF encapsulated directly in fibrin gel and PDGF 
encapsulated within coacervates distributed in the same gel, an early release of VEGF was 
achieved compared to a more sustained and delayed release of PDGF. We demonstrated the 
effectiveness of this sequential delivery approach on inducing a more robust angiogenesis 
process, which led to the formation of mature and stable neovasculature in the infarct 
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borderzone. Sequential delivery of VEGF and PDGF reflected positively on a functional level 
with improved cardiac contractility, and on a tissue level with improved cardiac muscle viability 
and angiogenesis and reduced fibrosis and macrophage presence 4 weeks after infarction. In 
chapter 4, we aimed for a potentially comprehensive strategy to treat MI by investigating the 
spatiotemporal delivery of 4 complementary proteins: TIMP-3, IL-10, FGF-2, and SDF-1α. 
TIMP-3 and IL-10 were embedded in the fibrin gel directly for early release to reduce ECM 
degradation and inflammation, respectively, while FGF-2 and SDF-1α were encapsulated within 
coacervates inside the gel for sustained release that is favorable for angiogenesis and stem cell 
homing as these processes require prolonged signaling. We optimized this combination using 
factorial design of experiments and found that TIMP-3, FGF-2, and SDF-1α had significant 
effects on improving cardiac function, while IL-10 did not, prompting IL-10’s removal from the 
combination. The optimized combination of TIMP-3, FGF-2, and SDF-1α delivered 
spatiotemporally by the fibrin-coacervate gel composite induced significant improvements in 
cardiac function, myocardial elasticity, cardiomyocyte survival, angiogenesis, stem cell homing, 
important protein signaling, and significant reductions in ventricular dilation, inflammation, 
fibrosis, MMP activity, apoptosis, and overall scar expansion. 
In this dissertation, we were able to develop a potentially comprehensive strategy to treat 
MI based on a carefully designed therapeutic approach that provided 3 complementary and 
crucial proteins spatiotemporally to prevent a number of pathologies triggered by MI and set the 
infarcted myocardium on a path to repair and recovery. To better understand the improvement 
in the design of our therapeutic strategies over time, here we directly compare some of the 
important functional data between our approaches in chapters 3 and 4. In chapter 3, we focused 
on therapeutic angiogenesis through the sequential delivery of VEGF and PDGF to the infarcted 
 160 
rat hearts. Using the echocardiography results, we estimated the functional improvement of this 
approach to be at 66% over untreated infarcted hearts at the terminal time point of 4 weeks after 
MI, showing a slight decline in function compared to the 68% improvement shown at 2 weeks. 
As for the other important functional assessment of ventricular dilation, we found no significant 
effect of the sequential delivery of VEGF and PDGF on dilation compared to untreated 
infarcted hearts with increasing dilation recorded throughout the period tested. In contrast, our 
potentially comprehensive approach, involving the spatiotemporal delivery of TIMP-3, FGF-2, 
and SDF-1α, developed in chapter 4 demonstrated significant advantages over the approach of 
chapter 3. At the functional level, we demonstrated our complementary approach preserved 
cardiac contractility significantly as early as 1 week after infarction with continuous 
improvement up to 8 weeks showing a 74% improvement over untreated infarcted rat hearts. 
This is an important advantage to see continuous improvement in function from 1 week to 8 
weeks compared to the slight decline that we started to observe after 2 weeks in our chapter 3 
approach. In regards to ventricular dilation, our results show significant reduction in LV dilation 
compared to untreated infarcted hearts up to 8 weeks. This is an additional advantage of the 
complementary approach in chapter 4 that we were not able to demonstrate with the previous 
approach of chapter 3, which showed no benefit on reducing dilation. We speculate that having 
TIMP-3 in our combination releasing early after MI helped preserve the structure of the heart 
and prevent ECM degradation, thereby significantly improving function and preventing dilation. 
In addition, having FGF-2 and SDF-1α, each with their unique roles in cardiac function, from 
angiogenesis, to stem cell homing, to supporting cardiomyocyte survival, and others drove the 
repair to a new level. Our results in chapter 4 indicate the advantage and improvement in our 
therapeutic strategy to repair the infarcted myocardium in a significantly more comprehensive 
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manner by addressing multiple MI pathologies through spatiotemporal delivery of multiple 
relevant proteins.  
Future directions for the research performed in this dissertation include testing the 
efficacy of our complementary approach in a large animal model, possible expansion of the 
therapeutic strategy to include other therapeutic proteins and/or combine with stem cells, and 
investigating the ability to deliver the composite gel through minimally invasive technology. 
We believe that the next logical step for this research is evaluating our complementary 
therapeutic approach in a large animal model. This would require the investigation of proper 
scalability of the fibrin gel-coacervate composite formulation parameters and the protein doses. 
A multimodal approach that combines multiple therapeutic proteins with promising cardiac 
stem cells, for instance, might be an attractive strategy, whereby therapeutic agents can act on 
co-delivered cells and the target tissue cells at the same time. This might not only increase the 
efficacy of the repair process, but also increase the possibility of generating a new viable 
myocardial tissue synchronized and electromechanically coupled with the rest of the heart. 
Although pursuing such multimodal approaches might result in a longer regulatory process and 
delays in clinical translation, the potential for a significant enhancement in treatment outcome 
should make these sophisticated approaches intriguing with serious consideration for future 
therapies. 
Localized therapy is very important to enhance efficacy in target tissues and reduce 
interaction with off-target tissues. It is also important to improve the translational potential of 
our therapy by enabling its delivery through minimally invasive approaches to reduce surgical 
time and costs, and patient morbidity. Therefore, we believe that to achieve localized delivery to 
the infarcted myocardium in a minimally invasive way, catheterization technology can be 
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utilized. However, catheter delivery of more advanced materials such as hydrogels is more 
challenging than the typical saline injections. Catheter-based access can be achieved through 
different routes such as intracoronary, intravenous, epicardial, transvascular, and endocardial. 
However, the retention of the cargo at the target tissue differs depending on the catheter 
approach. We believe that endocardial delivery might be the best approach to ensure high 
retention at the myocardial tissue. Endocardial delivery catheter devices would approach the 
myocardium from inside the ventricle with the help of support steerable designs and imaging 
systems to accurately target the infarct border zones. In order to ensure proper delivery of our 
gel-coacervate composite using catheter-based approaches, we need to optimize viscosity and 
gelation parameters so that gelation doesn’t occur while the injectable material is still in the 
catheter or too late after injection where the therapeutic cargo would diffuse away from the 
target site. We would want the gelation to occur rather quickly in situ once the composite has 
been injected. Having features such as shear-thinning and stimuli-responsiveness might be 
promising to facilitate injectability and gelation of the composite gel at the right place and time. 
A successful localized therapy using catheter-based systems, would be of great value to reduce 
surgical invasiveness, time, and burden, while capitalizing on the gains of increased retention, 
cytocompatibility, and spatiotemporal release kinetics of therapeutic formulations. The 
development of such systems would significantly aid the clinical translation of cardiac repair 
approaches. 
Because the heart physiology and pathology are inherently complex, it would be no 
surprise that more comprehensive therapeutic strategies with advanced delivery techniques, 
such as the one developed in this dissertation, may be needed to enable clinical translation of 
cardiac repair and regeneration therapies. As we expand our knowledge, decipher more 
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experimental data, and utilize more advanced technological tools, establishing a cure for 
ischemic heart disease could be within our reach in the foreseeable future. 
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APPENDIX A 
RELEASE PROFILE OF VEGF AND PDGF FROM COACERVATE 
Supplementary Figure S1. Release of VEGF and PDGF from the coacervate. The coacervate was formed by 
mixing 100ng of each GF together, then with heparin, then with PEAD polycation. Release of each GF was 
detected by ELISA. The coacervate released 57% of PDGF compared to 35% of VEGF by 3 weeks. Data are 
presented as means ± SD (n=3). 
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APPENDIX B 
MEASUREMENT OF ESV, EDV, AND EF USING MRI 
Supplementary Figure S2. MRI was performed with an average of 10 contiguous slices, at a thickness of 1.5 
mm covering the distance from heart apex at level 1 to mitral valve at level 10 in the representative images. 
End-systolic and end-diastolic phases were identified for each subject and the LV cavity manually traced to 
determine LV end-systolic (ESV) and end-diastolic (EDV) volumes. Ejection fraction (EF%) was calculated 
from ESV and EDV values. The infarct reduces the contractility of the heart as seen at levels 1 and 5. 
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APPENDIX C 
REGRESSION ANALYSIS OF FACTORIAL DESIGN MODEL 
Supplementary Figure S3. Regression analysis assumes the measurement and experimental errors in the 
data meet three assumptions: (1) the errors are normally distributed as seen in the straight line of the 
normal probability plot, (2) the errors are independent of time as seen in the random pattern of the residuals 
over the observation order, (3) the spread of the residuals is roughly equivalent regardless of the level of the 
EF% response. 
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APPENDIX D 
EFFECT OF DELIVERED COMPLEMENTARY PROTEINS ON CARDIOMYOCYTE 
SURVIVAL, ANGIOGENESIS, AND FIBROSIS AT 2 WEEKS AFTER MI 
D.1 CARIAC MUSCLE VIABILITY AT 2 WEEKS AFTER MI
Supplementary Figure S4. Representative images of the different groups showing staining of viable cardiac 
muscle by cardiac troponin I (cTnI) (green) at 2 weeks after MI. 
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D.2 ANGIOGENESIS AT 2 WEEKS AFTER MI 
Supplementary Figure S5. Representative images of the infarct groups showing co-staining of vWF (red), an 
endothelial marker, and α-SMA (green), a pericyte marker at 2 weeks after MI. 
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D.3 FIBROSIS AT 2 WEEKS AFTER MI 
 
Supplementary Figure S6. Representative picrosirius red staining images show the extent of collagen 
deposition in the different groups at 2 weeks after MI. 
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